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A B S T R A C T
Background
The World Health Organization (WHO) recommends treating all school children at regular intervals with deworming drugs in areas
where helminth infection is common. As the intervention is often claimed to have important health, nutrition, and societal effects
beyond the removal of worms, we critically evaluated the evidence on benefits.
Objectives
To summarize the effects of giving deworming drugs to children to treat soil-transmitted helminths on weight, haemoglobin, and
cognition; and the evidence of impact on physical well-being, school attendance, school performance, and mortality.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register (14 April 2015); Cochrane Central Register of Controlled
Trials (CENTRAL), published in the Cochrane Library (2015, Issue 4); MEDLINE (2000 to 14 April 2015); EMBASE (2000 to
14 April 2015); LILACS (2000 to 14 April 2015); the metaRegister of Controlled Trials (mRCT); and reference lists, and registers of
ongoing and completed trials up to 14 April 2015.
Selection criteria
We included randomized controlled trials (RCTs) and quasi-RCTs comparing deworming drugs for soil-transmitted helminths with
placebo or no treatment in children aged 16 years or less, reporting onweight, haemoglobin, and formal tests of intellectual development.
We also sought data on school attendance, school performance, and mortality. We included trials that combined health education with
deworming programmes.
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Data collection and analysis
At least two review authors independently assessed the trials, evaluated risk of bias, and extracted data. We analysed continuous data
using the mean difference (MD) with 95% confidence intervals (CIs). Where data were missing, we contacted trial authors. We used
outcomes at time of longest follow-up. The evidence quality was assessed using GRADE. This edition of the Cochrane Review adds
the DEVTA trial from India, and draws on an independent analytical replication of a trial from Kenya.
Main results
We identified 45 trials, including nine cluster-RCTs, that met the inclusion criteria. One trial evaluating mortality included over one
million children, and the remaining 44 trials included a total of 67,672 participants. Eight trials were in children known to be infected,
and 37 trials were carried out in endemic areas, including areas of high (15 trials), moderate (12 trials), and low prevalence (10 trials).
Treating children known to be infected
Treating children known to be infected with a single dose of deworming drugs (selected by screening, or living in areas where all children
are infected) may increase weight gain over the next one to six months (627 participants, five trials, low quality evidence). The effect
size varied across trials from an additional 0.2 kg gain to 1.3 kg. There is currently insufficient evidence to know whether treatment
has additional effects on haemoglobin (247 participants, two trials, very low quality evidence); school attendance (0 trials); cognitive
functioning (103 participants, two trials, very low quality evidence), or physical well-being (280 participants, three trials, very low quality
evidence).
Community deworming programmes
Treating all children living in endemic areas with a dose of deworming drugs probably has little or no effect on average weight gain
(MD 0.04 kg less, 95% CI 0.11 kg less to 0.04 kg more; trials 2719 participants, seven trials,moderate quality evidence), even in settings
with high prevalence of infection (290 participants, two trials). A single dose also probably has no effect on average haemoglobin (MD
0.06 g/dL, 95% CI -0.05 lower to 0.17 higher; 1005 participants, three trials, moderate quality evidence), or average cognition (1361
participants, two trials, low quality evidence).
Similiarly, regularly treating all children in endemic areas with deworming drugs, given every three to six months, may have little or no
effect on average weight gain (MD 0.08 kg, 95% CI 0.11 kg less to 0.27 kg more; 38,392 participants, 10 trials, low quality evidence).
The effects were variable across trials; one trial from a low prevalence setting carried out in 1995 found an increase in weight, but nine
trials carried out since then found no effect, including five from moderate and high prevalence areas.
There is also reasonable evidence that regular treatment probably has no effect on average height (MD0.02 cmhigher, 95%CI 0.14 lower
to 0.17 cm higher; 7057 participants, seven trials,moderate quality evidence); average haemoglobin (MD 0.02 g/dL lower; 95% CI 0.08
g/dL lower to 0.04 g/dL higher; 3595 participants, seven trials, low quality evidence); formal tests of cognition (32,486 participants, five
trials,moderate quality evidence); exam performance (32,659 participants, two trials,moderate quality evidence); or mortality (1,005,135
participants, three trials, low quality evidence). There is very limited evidence assessing an effect on school attendance and the findings
are inconsistent, and at risk of bias (mean attendance 2% higher, 95% CI 4% lower to 8% higher; 20,243 participants, two trials, very
low quality evidence).
In a sensitivity analysis that only included trials with adequate allocation concealment, there was no evidence of any effect for the main
outcomes.
Authors’ conclusions
Treating children known to have worm infection may have some nutritional benefits for the individual. However, in mass treatment
of all children in endemic areas, there is now substantial evidence that this does not improve average nutritional status, haemoglobin,
cognition, school performance, or survival.
P L A I N L A N G U A G E S U M M A R Y
Deworming school children in developing countries
In this Cochrane Review, Cochrane researchers examined the effects of deworming children in areas where intestinal worm infection is
common. After searching for relevant trials up to April 2015, we included 44 trials with a total of 67,672 participants, and an additional
trial of one million children.
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What is deworming and why might it be important
Soil-transmitted worms, including roundworms, hookworms, and whipworms, are common in tropical and subtropical areas, and par-
ticularly affect children in low-income areas where there is inadequate sanitation. Heavy worm infection is associated with malnutrition,
poor growth, and anaemia in children.
The World Health Organization currently recommends that school children in endemic areas are regularly treated with drugs which
kill these worms. The recommended drugs are effective at eliminating or greatly reducing worm infections, but the question remains
whether doing so will reduce anaemia and improve growth, and consequently improve school attendance, school performance, and
economic development, as has been claimed.
What the research says
In trials that treat only children known to be infected, deworming drugs may increase weight gain (low quality evidence), but we do not
know if there is an effect on cognitive functioning or physical well-being (very low quality evidence).
In trials treating all children living in an endemic area, deworming drugs have little or no effect on average weight gain (moderate quality
evidence), haemoglobin (low quality evidence), or cognition (moderate quality evidence).
Regular deworming treatment every three to six months may also have little or no effect on average weight gain (low quality evidence).
The effects were variable across trials: one trial from 1995 in a low prevalence setting found an increase in weight, but nine trials carried
out since then from moderate or high prevalence settings showed no effect.
There is good evidence that regular treatment probably has no effect on average height (moderate quality evidence), haemoglobin (low
quality evidence), formal tests of cognition (moderate quality evidence), or exam performance (moderate quality evidence). We do not
know if there is an effect on school attendance (very low quality evidence).
Authors conclusions
Treating children known to have worm infection may improve weight gain but there is limited evidence of other benefits. For routine
deworming of school children in endemic areas, there is quite substantial evidence that deworming programmes do not show benefit
in terms of average nutritional status, haemoglobin, cognition, school performance, or death.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
In communities where intestinal helminths are endemic, what is the effect of multiple doses of deworming drugs given to all children?
Patient or population: School-aged children
Settings: Areas endemic for intestinal helminths
Intervention: Multiple dose deworming drugs, longest follow-up
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Deworming drugs
(Multiple doses)
Weight (kg)
Follow-up: 6 months to 3
years
The mean change in
weight in the control arm
ranged from 1.2 kg to 4.
73 kg
The mean weight gain
in the intervention groups
was
0.08 kg more (0.11 kg
less to 0.27 kg more)
- 38,392
(10 trials1)
⊕⊕©©
low2,3
Due to risk of bias and
inconsistency
There may be little or no
effect on weight gain
Height (cm)
Follow-up: 6 months to 2
years
The mean gain in height in
the control groups ranged
from
2.39 to 16.4 cm
The mean gain in height
in the intervention groups
was
0.02 cm higher
(0.14 lower to 0.17
higher)
- 7057
(7 trials4)
⊕⊕⊕©
moderate5
Due to risk of bias
Probably little or no effect
on height
Haemoglobin (g/dL)
Follow-up: 6 months to 2
years
The mean change in hae-
moglobin in the control
groups ranged from
0.26 to 1.75 g/dL
The mean haemoglobin
in the intervention groups
was
0.02 g/dL lower
(0.08 lower to 0.04
higher)
- 3595
(7 trials6)
⊕⊕©©
low7,8
Due to risk of bias and
indirectness
There may be little or no
effect on haemoglobin
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Formal tests of cognition
Follow-up: 2 years
- None of the trials reported
a benefit of deworming
across multiple tests9
- 32,486
(5 trials10)
⊕⊕⊕©
moderate11
Due to risk of bias
Probably little or no effect
on cognition
Physical well-being - - - -
(0 trials)
- We don’t know if there is
an effect on physical well-
being
School attendance
Follow-up: 2 years
(longest follow-up)
The mean school at-
tendance in the control
groups ranged from 66%
to 90%
The mean school atten-
dance in the intervention
groups was
2% higher
(-4 lower to 8 higher)12
- 20,243
(2 trials13)
⊕©©©
very low14,15,16
Due to risk of bias and
indirectness
We don’t know if there is
an effect on school atten-
dance
School performance - No difference in exam
performances was de-
tected in either trial
- 32,659
(2 trials)
⊕⊕⊕©
moderate17,18
Probably little or no effect
on school performance
Death
(between ages 1 and 6
years)
27 per 1000 25 per 1000 RR 0.95
(0.89 to 1.92)
1,005,135
(3 trials)19
⊕⊕©©
low20,21
Due to risk of bias and
indirectness
May be little or no effect
on death
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Four cluster-RCTs (302 clusters) and six individually RCTs (2552 participants).
2Downgraded by 1 for risk of bias: trials had high or unclear risk of selection bias.
3Downgraded by 1 for inconsistency. One trial had a large effect and in a sensitivity analysis only including high quality trials the
heterogeneity was considerably reduced. This trial was from a low prevalence setting (Awasthi 1995 (Cluster); 0.98 kg). A subsequent
trial in the same trial area as Awasthi 1995 (Cluster) found no effect.5
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4Two cluster-RCTs (174 clusters) and five individually RCT (1861 participants).
5Downgraded by 1 for risk of bias: two trials were considered at high risk of selection bias (Awasthi 2000; Awasthi 1995 (Cluster)), and
in the remaining trials the risk was unclear.
6All individually RCTs. In a re-analysis of one large quasi-experimental design (Miguel 2004 (Cluster); Aiken 2015) no difference in
anaemia between deworming and control groups was reported.
7Downgraded by 1 for risk of bias: two trials (Awasthi 2000; Kirwan 2010) were considered at high risk of selection bias; in the remaining
trials the risk was low or unclear.
8Downgrade by 1 for indirectness: trials were conducted in low- and moderate-prevalence settings, where any putative effect may be
attenuated.
9Awasthi 2000, with a follow-up of two years, reported that there was no difference in development between treatment groups in terms of
proportion with ‘ ‘ normal’’ development. Ndibazza 2012 measured a range of cognitive tests with a follow-up post-treatment and found
no effect of deworming. Miguel 2004 (Cluster) measured a range of cognitive tests with a follow-up of two years, but no deworming
effect was demonstrated. Stoltzfus 2001, with a follow-up of 12 months, found that treatment had no significant effect on motor or
language development. Watkins 1996, with a follow-up of six months, found no difference on any of the tests between treatment groups.
10One cluster-RCT, and four individually RCTs.
11Downgraded by 1 for risk of bias: two trials were considered at high risk of selection bias (Awasthi 2000; Miguel 2004 (Cluster)), and
in the remaining trials the risk was low or unclear.
12These are the corrected effects from the Aitken replication on the 3ie website.
13One cluster-RCT (50 clusters (20,000 participants) and one individually RCT (226 participants). The meta-analysis includes the two
year follow-up for Miguel 2004 (Cluster). The trial has one-year follow-up on two other quasi-randomized comparisons. These results
are shown in Table 7. These demonstrate higher participation in both arms (9.3% and 5.4%) but these estimates are not independent
because the control group in one comparison becomes the intervention group in the subsequent year. One additional trial showed no
effect but did not provide measures of variance.
14Downgraded by 1 for risk of bias: Miguel 2004 (Cluster) had a high risk of bias for sequence generation, allocation concealment and
blinding.
15Downgraded by 1 for imprecision: CIs include 4% lower attendance with deworming to 8% higher.
16Downgraded by 1 for indirectness: the intervention included a comprehensive health education programme in schools, and it not
possible to determine which component of the complex intervention led to effects on attendance.
17Downgraded by 1 for risk of bias. A number of previously documented problems with the trial design.
18Neither trial demonstrates an effect, with narrow CIs.
19Two cluster-RCTs (122 clusters) and one individually RCT (1423 participants). DEVTA dwarfs the other trials, none of which were
adequately powered.
20Downgraded by 1 for risk of bias: none of the trials adequately described allocation concealment to be considered ‘ ‘ low risk of bias’’.
21Downgraded by 1 indirectness: DEVTA was conducted in a low prevalence area and the findings may not be generalizable to higher
prevalence areas.
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B A C K G R O U N D
Description of the condition
The three soil-transmitted helminth (STH) infections, ascariasis
(roundworm), trichuriasis (whipworm), and hookworm, are the
main intestinal helminth infections in humans (Bethony 2006; de
Silva 2003b). Specialists estimate that each type of infection causes
between 600 to 800 million cases worldwide each year (de Silva
2003b; Hotez 2009), with more than a quarter of the world’s pop-
ulation infected with one or more of the soil-transmitted intesti-
nal worms (Chan 1997). Estimates from 2003 suggest that global
prevalence of STH infections is declining, with marked improve-
ment in the Americas and Asia, but a static picture in sub-Saharan
Africa (de Silva 2003b). STH infections particularly affect chil-
dren living in poverty, where inadequate sanitation, overcrowding,
low levels of education, and lack of access to health care make
them particularly susceptible (Bethony 2006; de Silva 2003b). In
1993, the World Bank ranked STH infection as a greater cause of
ill health in children aged five to 15 years than any other infection
(World Bank 1993), but there has been considerable variation in
the quoted estimates of global burden (de Silva 2003b), which are
currently being updated.
Policy makers are concerned that the long-term effects of worm
infestation impair childhood nutritional status, school perfor-
mance, and long-term cognitive development (Bethony 2006). It
is thought that iron status may mediate these effects, since hook-
worm and whipworm disease are associated with iron-deficiency
anaemia (Crompton 2000; de Silva 2003a), and a fall in blood
haemoglobin levels is associated with increasing intensity of infec-
tion (Crompton 2003). Furthermore, hookworm-induced iron-
deficiency anaemia has been associated with decreased physical
activity and worker productivity (Crompton 2003).
Worms are associated with malnutrition, impaired growth, and
poor school performance. Roundworms obtain their nutrition
from gastrointestinal contents. The association with malnutrition
is possibly mediated through impaired fat digestion, reduced vi-
tamin absorption (particularly vitamin A), and temporary lactose
intolerance (WHO 2002). Whipworm infection has been associ-
ated with malnutrition, although the precise mechanism for this
is unclear (Cappello 2004). Some suggest that the effects on nu-
trition are through appetite suppression, increased nutrient loss,
and decreased nutrient absorption and utilization (de Silva 2003a;
Stephenson 2000).
Roundworm, hookworm, and whipworm disease have all been as-
sociated with impaired growth in school children (de Silva 2003a).
Observational trials have reported an association between worm
infection and lower scores on tests of school performance (Kvalsvig
2003; Sakti 1999). In a multiple-regression model based on cross-
sectional data, Sakti 1999 found that hookworm infection was
associated with worse scores in six out of 14 cognitive tests in
Indonesian school children. Severe whipworm (Trichuris dysen-
tery syndrome) was associated with low intelligence quotient (IQ),
school achievement, and cognitive function after a four-year fol-
low-up of a specific group of Jamaican children with severe infec-
tion (Callender 1998).
While these associations would suggest potential benefits of de-
worming, the associations could equally be caused by the con-
founding factor of poverty. Even with adjustment for known con-
founding factors, residual confounding could be a problem. Fur-
thermore, the causal link between chronic infection and impaired
childhood development is extrapolated from the recorded im-
provement in these features after deworming (Bethony 2006).
Hence, reliable randomized controlled trials (RCTs) are required
to assess whether policies are effective. These can examine the ef-
fectiveness of treating worm infection in an individual, as evidence
of efficacy, and treatment in schools or communities, as evidence
of the effectiveness of programmes. The latter trials are ideally
cluster-RCTs, and thus able to detect any externalities (benefits to
other children) accruing as a result of reduced transmission.
Description of the intervention
Public health interventions to reduce worm infection include im-
proved sanitation and hygiene and drug therapy for populations
or targeted groups in the community, often coupled with health
education. The work of the Rockefeller Sanitary Commission in
the early 1900s in the USA with a grant of USD 11 million in the
Southern States was combined with efforts to improve schooling.
This led to the belief that sanitary reform was needed alongside
chemotherapeutic approaches to eradicate hookworm to rid chil-
dren of lethargy and improve their health (Brown 1979; Horton
2003). In Japan, worms virtually disappeared over a 20-year pe-
riod after the Second World War; this has been credited to an in-
tegrated programme of sanitary reform combined with screening
and treatment of positive cases (Horton 2003; Savioli 2002). A
similar experience occurred in Korea (Savioli 2002). The current
global decline in worm prevalence has been credited to economic
development and deworming programmes (de Silva 2003b). The
impact of the chemotherapeutic element is difficult to assess. In
countries where an improvement in sanitation and hygiene has
occurred as a component of economic growth, a parallel decline
in the prevalence of soil-transmitted helminths has occurred: for
example, in Italy between 1965 and 1980, the trichuriasis preva-
lence dropped from 65% to less than 5% without control activity
(Savioli 2002).
The World Health Organization (WHO) recommends periodic
treatment with anthelminthic (deworming) medicines, without
previous individual diagnosis to almost all children living in en-
demic areas. The WHO does not recommend individual screen-
ing, since the cost of screening is four to 10 times that of the
treatment itself. Treatment is recommended once a year when the
prevalence of STH infections in the community is over 20%, and
twice a year when the prevalence of STH infections in the com-
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munity exceeds 50% (WHO 2015). The strategy is to target drug
treatment to at-risk groups: pre-school-age children (between one
and five years); school-age children (between six and 15 years);
and women of childbearing age. The strategy requires a popula-
tion survey for prevalence and intensity of infection to determine
the population worm burden. This determines the recommended
frequency of treatment, updated in a WHO field manual in 2006
(WHO 2006b).
The policy promotes the use of schools, maternal and child health
clinics, and vaccination campaigns to reach at-risk groups. The
WHO advocates school-based programmes in particular, as it is
easy to deliver medicines through teaching staff, with estimated
costs varying fromUSD 0.05 to 0.65 per child per year for annual
dosing (Savioli 2002; WHO 2002). In areas with a high preva-
lence, the current policy recommends treatment three times per
year (WHO 2006b), based on modelling and reinfection preva-
lence trials. Following drug treatment, worm populations tend to
return rapidly to pretreatment levels; with roundworm and whip-
worm this happens in less than a year (Anderson 1991). Anderson
1991 suggests that, in order to control morbidity in areas of en-
demic infection, targeted treatment should be repeated every three
to four months for roundworm and whipworm, with longer in-
tervals acceptable for longer-lived species such as hookworm. The
WHO recommends monitoring with a range of impact indica-
tors, including prevalence and intensity, incidence, morbidity, and
mortality (WHO 2010). The control programme is intended to
reduce the worm burden in the 10% to 15% of children who are
most heavily infected in a particular population and to keep it low
through repeated treatments.
It has been argued that treating individuals in communities reduces
transmission in the community as a whole (Anderson 1991), and
that this can lead to health and schooling benefits for the whole
population, including those who have not received deworming
treatment (Bundy 2009). These ’spill over’ effects, or externalities,
are not captured in individually RCTs, since any benefit in the
control group reduces the overall treatment effect. A cluster design
is therefore required to identify these additional putative effects.
This Cochrane Review does not cover deworming and pregnancy
(reviewed in Haider 2009).
How the intervention might work
The rationale for the effects of deworming programmes on popu-
lation development depend on the assumption that they improve
nutrition, haemoglobin, and cognition. As a result of these ben-
efits, children are thought to have increased physical well-being,
with improved intellect, and are better able to attend school. As
a result, performance at school is enhanced, over the long-term
this benefits society as a whole, and reduces poverty (WHO 2005,
WHO 2011). This is expressed in our conceptual framework (see
Figure 1). The figure provides the basis for this review: the primary
outcomes sought are themain effects (increased haemoglobin, nu-
trition, and improved cognition); measurable aspects of the medi-
ating pathways (school attendance and physical well-being); and
measurable aspects of impact (mortality and school performance).
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Figure 1.
In this review we include community trials that measure effects
after a single dose of deworming drugs (’efficacy’ measures in the
individual), as well as trials ofmultiple doses with longer follow-up
periods. Multiple dose, cluster randomized trials with long follow-
up periods are the best measure of policy effectiveness since they
are likely to detect externalities within schools and potential long
term benefits.
Why it is important to do this review
The intended impacts of deworming programmes are clearly
worthwhile goals and are heavily promoted by advocates in the
field such as the WHO (Montresor 2002; WHO 2002; WHO
2006b; WHO 2011; WHO 2015), theWorld Bank (World Bank
2011), and the Bill &Melinda Gates Foundation (Hawkes 2013).
Furthermore, deworming with albendazole was recently endorsed
in the 2012 Copenhagen consensus statement, as the fourth high-
est ranking solution to address “big issues facing the planet”
in terms of cost and benefit (Copenhagen Consensus Center
2012). The widely-cited cost-effectiveness estimates from the Dis-
ease Control Priorities in Developing Countries (DCP2) report
(Jamison 2006) state that deworming for STH infections was one
of the most cost-effective interventions for global health. How-
ever, the reliability of these estimates has been questioned by the
organization GiveWell, which suggests they have been overstated
by a factor of about 100 (GiveWell 2011).
Advocates point to the favourable cost-effectiveness estimates for
deworming programmes, with a focus on the putative effect on
schooling outcomes and productivity (Deworm theWorld 2012).
The evidentiary basis for this draws on a range of trial designs, in-
cluding historical econometric trials such as Bleakely 2004, which
analysed the Rockefeller Sanitary Commission’s campaign to erad-
icate hookworm in the Southern states of the USA. This showed
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an association between areas with higher levels of hookworm in-
fection prior to the campaign and greater increases in school atten-
dance and literacy after the intervention, and an association with
income gains in the longer term. Another influential trial isMiguel
2004 (Cluster), which is included in this Cochrane Review.
Current policies have become even more challenging to assess,
as global specialists conflate the evidence on different helminths.
The WHO, for example, describes the benefits of treating all
helminths, including schistosomiasis, filariasis, and STH infec-
tions. The WHO states that deworming treatment against schis-
tosomes and STH infections helps (1) eradicate extreme poverty
and hunger; (2) achieve universal primary education; (3) promote
gender equality and empower women; (4) reduce child mortality
and improvematernal health; and (5) combatHIV/AIDS,malaria,
and other diseases (WHO 2005; WHO 2011). The evidence for
the benefit of treating populations with schistosomiasis is fairly
clear (Danso-Appiah 2008), as the infection has a very substantive
effect on health.However, this does not mean that a different drug
treating a different helminth species is equally effective.
Despite the lack of rigour in considering the evidence for separate
components of these policies, many countries are moving forward
with large scale purchases of drugs. The current neglected tropi-
cal disease (NTD) policy focus has been on addressing ’polypar-
asitism’ by treating the parasites that cause ascariasis, trichuria-
sis, hookworm, lymphatic filariasis, onchocerciasis, schistosomi-
asis, and trachoma with ivermectin, albendazole, azithromycin,
and praziquantel (Hotez 2009). These four drugs are donated by
pharmaceutical companies, and the ’overlapping specificity’ would
meanmultiple pathogenswould be targeted (Hotez 2006b). Thus,
mass drug administration for NTDs is promoted as “one of the
lowest cost and cost-efficient mechanisms for both improving ma-
ternal child health and lifting the bottom billion out of poverty”
(Hotez 2011b). Significant resources are being invested in this
agenda, with the UK Department for International Development
committing GBP 50 million in 2008, and the US government
committing USD 65 million in 2010 as part of the US Global
Health Initiative (Hotez 2011a).
Given the amount of investment of public money in these pro-
grammes, it is important to be clear whether mass or targeted drug
administration is able to contribute to health and development
in such a substantive way. Indeed, international donors and de-
veloped country governments and tax payers are contributing to
the efforts to tackle STH infections in the belief that they will
improve the health of children in the way that the WHO claims
(WHO 2005). For example, Deworm theWorld has worked with
the Indian Government to treat 140 million children across India
in 2015 on the basis of the Copenhagen Consensus Statement
(Evidence Action 2015; Mudur 2015).
Thus, this systematic review of reliable evidence from RCTs will
help clarify whether existing evidence supports the conclusion that
there is an impact of these drugs in populations with STH infec-
tions (ascariasis, trichuriasis, and hookworm) and will evaluate the
strength of the evidence.
History of this Cochrane Review
Previous editions of this Cochrane Review (Dickson 2000a;
Dickson 2000b; Taylor-Robinson 2007; Taylor-Robinson 2012)
have generated considerable debate (Hawkes 2013; Hilton 2012;
Savioli 2000).
Early on the debate was around medical outcomes, such as
anaemia. More recently there has been a shift in focus from short-
term impacts of deworming to potential longer-term developmen-
tal impacts (Figure 1). Indeed, Givewell suggests that the most
compelling case for deworming as a cost-effective intervention
comes from “the possibility that deworming children has a sub-
tle, lasting impact on their [children’s] development, and thus on
their ability to be productive and successful throughout life”, but
further comments that “empirical evidence on this matter is very
limited” (Givewell 2014). There have been some recent observa-
tional analyses with long-term follow-up of dewormed children
which were considered during this update. None of these trials
met the inclusion criteria of this review (Baird 2011; Croke 2014;
Ozier 2011; described in the Characteristics of excluded studies
section).
Important new trials have been published. The DEVTA trial of
over one million children was completed in 2005 and published
in 2013 (Awasthi 2013 (Cluster). A second important trial with
a manuscript date of 2006 of over 2500 children remains unpub-
lished, but we have included it in this review (Hall 2006 (Cluster).
The development organization 3ie recently commissioned the
replication of the influential econometric trial fromKenya (Miguel
2004 (Cluster). We highlighted concerns about the quality of the
evidence for school attendance on the basis of this trial in the pre-
vious version of this Cochrane Review (Taylor-Robinson 2012).
The replication was published recently (Aiken 2014; Aiken 2015;
Davey 2015). The authors checked the data and corrected any
errors, and then carried out an analysis using exactly the methods
in the original publication. The replication highlights important
coding errors and this resulted in a number of changes to the re-
sults: the previously reported effect on anaemia disappeared; the
effect on school attendance was similar to the original analysis, al-
though the effect was seen in both children that received the drug
and those that did not; and the indirect effects (externalities) of
the intervention on adjacent schools disappeared (Aiken 2015).
The statistical replication suggested some impact of the complex
intervention (deworming and health promotion) on school atten-
dance, but this varied depending on the analysis strategy, and there
was a high risk of bias. The replication showed no effect on exam
performance (Davey 2015).
In the light of the publication of the DEVTA trial of over one
million children, the replication trials of the Kenya trial, the new
longer term follow-up trials, and four new RCTs, we updated
Taylor-Robinson 2012. We have added new trials and data, re-
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structured the analysis, and updated the GRADE assessment of
the quality of the evidence.
O B J E C T I V E S
To summarize the effects of giving deworming drugs to children to
treat soil-transmitted intestinal worms on weight, haemoglobin,
and cognition; and the evidence of impact on physical well-being,
school attendance, school performance, and mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs and quasi-RCTs. We included cluster-RCTs, provided more
than two clusters were allocated to each treatment arm.
Types of participants
Infected children identified by screening in community trials.
All children must have lived in endemic areas.
We defined children as aged under 16 years. We excluded trials of
sick children or children being treated for malnutrition.
Types of interventions
Intervention
Deworming drugs for soil-transmitted helminths, administered at
any location (including health facilities, schools, and communi-
ties). We included trials examining effects after a single dose and
after multiple doses.
The deworming drugs we included are those in the WHOModel
List of Essential Medicines for deworming drugs of soil-trans-
mitted helminths (WHO 2006a). This includes albendazole, lev-
amisole, mebendazole, pyrantel, and ivermectin. Other drugs used
are nitazoxanide, piperazine, tetrachlorethylene, and thiabenda-
zole.
We did not exclude trials that also provided some health pro-
motion activities supporting the deworming programmes. Studies
that provided additional interventions (eg growthmonitoring, mi-
cronutrient supplementation, malaria chemoprevention, or other
drugs) were included when the additional intervention was given
to both the control and intervention arm.
Control
Placebo or no treatment.
Types of outcome measures
Primary outcomes
• Weight;
• Haemoglobin;
• Formal tests of cognition.
Secondary outcomes
• Other nutritional indicators:
◦ Height
◦ Mid-upper arm circumference (MUAC)
◦ Skin fold thickness (including triceps and subscapular
skin fold)
◦ Body mass index;
• Measures of physical well-being (eg Harvard Step Test);
• School attendance:
◦ Days present at school
◦ Number of children dropping out;
• School performance (measured by examination results);
• Death.
Adverse events
• Serious adverse events (death, life-threatening events, or
events leading to hospitalization);
• Other adverse events.
Search methods for identification of studies
Electronic searches
The review authors and the Cochrane Infectious Diseases Group
(CIDG) Information Specialist, Vittoria Lutje, attempted to iden-
tify all relevant trials regardless of language or publication status
(published, unpublished, in press, and in progress). The date of
the last search was 14 April 2015.
The Information Specialist searched the following databases using
the search terms and strategy described in Table 1: CIDG Special-
ized Register (14 April 2015); Cochrane Central Register of Con-
trolled Trials (CENTRAL), published in the Cochrane Library
(2015, Issue 4); MEDLINE (2000 to 14 April 2015); EMBASE
(2000 to 14 April 2015); and LILACS (2000 to 14 April 2015);
and reference lists, and registers of ongoing and completed trials.
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We also searched the metaRegister of Controlled Trials (mRCT)
using ’helminth* OR anthelminth*’ (14 April 2015).
Data collection and analysis
Selection of studies
David Taylor-Robinson (DTR) checked the search results for po-
tentially relevant trials and retrieved full articles as required. DTR
and Paul Garner (PG) independently assessed the trial eligibility
using an eligibility form based on the inclusion criteria; where
there was uncertainty, all five review authors participated in the de-
cision about inclusion. We checked that trials with multiple pub-
lications were managed as one trial. We recorded reasons for the
exclusion of trials and we contacted authors of unpublished trials
for information on when they intended to publish their results.
Data extraction and management
Nicola Maayan (NM), DTR, Sarah Donegan (SD), and Karla
Soares-Weiser (KSW) independently extracted data using data ex-
traction forms. PG extracted and cross-checked the data from a
selection of papers. We resolved any differences in opinion by dis-
cussion. Where methods, data, or analyses were unclear or miss-
ing, we contacted trial authors for further details.
We extracted data on type of additional interventions (eg accompa-
nying health promotion programme including programmes about
hygiene and behaviour, water and sanitation; drug; or vitamin)
and how this was delivered (mass media, community, or one-to-
one); and whether these interventions were in both intervention
and control groups, or only in the intervention group.
For each treatment group of each trial, we extracted the number of
patients randomized. For each outcome of interest, we extracted
the number of participants analysed in each treatment group of
each trial.
RCTs that randomized individuals
For dichotomous outcomes, we planned to extract the number of
patients with the event. For continuous outcomes, we aimed to
extract means and standard deviations (SDs). Where these data
were not reported, we extracted medians and ranges or any other
summary statistics. Where change from baseline results were pre-
sented alongside results purely based on the end value, we only
extracted the change from baseline results.
RCTs that randomized clusters
For each cluster-RCT, we extracted the cluster unit, the number
of clusters in the trial, the average size of clusters, and the unit of
randomization (such as household or institution). Where possi-
ble, we extracted the statistical methods used to analyse the trial
along with details describing whether these methods adjusted for
clustering or other covariates.
Where a cluster-RCT adjusted for clustering in their analysis, we
extracted the cluster adjusted results. When the trial did not ac-
count for clustering in their analysis, we extracted the same data
as for trials that randomize individuals.
For the analysis of Awasthi 1995 (Cluster) we tookweight from the
publication by Awasthi in 2008; height data from INCLEN 1995
monograph (references contained in the main reference). Means
of cluster means were used in analysis; details of correspondence
fromprevious review suggest that trial was ongoing; data for 3-year
follow-up are provided from R. Dickson’s correspondence with
the author for the Dickson 2000a Cochrane Review, but the loss
to follow up is very high: only 24% analysed.
Replication
One included trial, Miguel 2004 (Cluster), has been the subject
of an independent re-analysis, with a full report published on the
3ie website (Aiken 2014), which also includes a response from the
authors (3ie 2014); and two subsequent academic papers (Aiken
2015; Davey 2015). In this edition of the Cochrane Review we
used new information on conduct of the trial, on the thorough
evaluation for potential biases, and also corrected data from the
replication, including the measure of variance for school atten-
dance (Aiken 2014).
Assessment of risk of bias in included studies
DTR, PG, NM, SD, and KSW independently assessed the risk of
bias (Higgins 2011b).We resolved any differences through discus-
sion. On occasion, we corresponded with trial investigators when
methods were unclear.
For RCTs that randomized individuals we addressed six compo-
nents: sequence generation; allocation concealment; blinding; in-
complete outcome data; selective outcome reporting; and other
biases. For cluster-RCTs, we addressed additional components:
recruitment bias; baseline imbalance; loss of clusters; incorrect
analysis; compatibility with RCTs randomized by individual. For
each component, we placed judgments of low, high, or unclear/
unknown risk of bias as described in Appendix 1. We displayed
the results in ’Risk of bias’ tables, a ’Risk of bias’ summary, and a
’Risk of bias’ graph.
Measures of treatment effect
We summarized continuous data (means and SDs) using themean
differences (MDs). We planned to use the risk ratio to compare
the treatment and control groups for dichotomous outcomes. All
treatment effects were presented with 95% confidence intervals
(CIs).
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Unit of analysis issues
For a particular cluster-RCT when the analyses had not been ad-
justed for clustering, we attempted to adjust the results for clus-
tering by estimating the design effect calculated as 1+(m-1)*ICC
where m is the average cluster size and ICC is the intra-cluster
correlation coefficient. To make the adjustment, we estimated a
treatment effect that did not adjust for clustering and then multi-
plied the standard errors of the estimate by the square root of the
design effect. When the true ICC was unknown, we estimated it
from other included cluster-RCTs.
Dealing with missing data
We aimed to conduct a complete-case analysis in this Cochrane
Review, such that all patients with a recorded outcome were in-
cluded in the analysis.
Assessment of heterogeneity
We inspected the forest plots to detect overlapping CIs, applied
the Chi² test with a P value of 0.10 used to indicate statistical
significance, and also implemented the I² statistic with values of
30 to 60%, 59 to 90%, and 75 to 100% used to denote moderate,
substantial, and considerable levels of heterogeneity, respectively.
Assessment of reporting biases
We decided not to construct funnel plots to look for evidence of
publication bias because there were a limited number of trials in
each analysis.
Data synthesis
DTR, NM, and SD analysed data with Review Manager 5.3. We
structured the analysis into four sections
1. Infected children-first dose.
2. Infected children-multiple dose.
3. All children living in an endemic area-first dose.
4. All children living in an endemic area-multiple doses,
longest follow up.
For trials involving children living in an endemic area, trials were
also grouped by prevalence and intensity (high/moderate/low).
High prevalence or high intensity areas are referred to as ’high
prevalence’; moderate prevalence and low intensity are referred to
as ’moderate prevalence’; and low prevalence with low intensity are
referred to as ’low prevalence’.We used theWHO technical guide-
lines classification (WHO 2002; Table 2), rather than the simpli-
fied prevalence based field guide categories that are now used to
determine treatment frequency (WHO 2006b; Table 2). In trials
where information on intensity was not provided, we estimated
the community category on the basis of quoted prevalence; it is
possible that the community category has been underestimated in
these trials.
When a trial reported data at multiple time points we included
data collected at the longest follow-up time in the analysis of ’after
multiple doses’, because long term outcomes of multiple doses
of deworming are of most relevance to policymakers, and short-
term effects are captured in the single dose results. This decision
was supported by findings from an exploratory meta-regression
analysis thatwas applied tofindoutwhether the intervention effect
was modified by the length of follow-up (see below).
We combined cluster-RCTs that adjusted for clustering and RCTs
that randomized individuals using meta-analysis. We used a fixed-
effect meta-analysis when the assessments of heterogeneity did
not reveal heterogeneity. In the presence of heterogeneity, we used
random-effects meta-analysis.
For continuous data, we combined change from baseline results
with end value results providing they were from distinct trials
(Cochrane Collaboration 2011; Higgins 2011a). Labels on the
meta-analyses indicate when end values were used.
We presented data that could not be meta-analysed in additional
tables and reported on these in each section, under the heading
’other data’.
Subgroup analysis and investigation of heterogeneity
In the presence of statistically significant heterogeneity, we planned
to explore the following potential sources using subgroup analyses:
age group (< five years vs ≥ five years); manufacturer; treatment
setting (community, school, health post, hospital). We did not
carry out these analyses because there were too few trials in the
analyses.
To find out whether the intervention effect was modified by the
length of follow-up, SD and DTR performed a random-effects
meta-regression for the outcome weight (in all children in an
endemic area after multiple doses), with length of follow-up in
months as a covariate using the ’metafor’ package in R. The co-
variate was centred at its mean.
We also sorted the forest plot for weight (in all children in an
endemic area after multiple doses) by year that the trial was carried
out to visually inspect whether the intervention effect changed
over time.
Sensitivity analysis
We carried out sensitivity analyses including only those trials with
a low risk of bias regarding allocation concealment.
’Summary of findings’ tables
We interpreted results using ’Summary of findings’ tables, which
provide key information about the quality of evidence for the in-
cluded trials in the comparison, the magnitude of effect of the in-
terventions examined, and the sum of available data on the main
outcomes. Using GRADE profiler (GRADEpro 2014), we im-
ported data from Review Manager 5.3; the GRADE display was
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based on a recent trial of what users prefer (Carrasco-Labra 2015).
We presented the primary outcomes for the review in the ’Sum-
mary of findings’ tables, and added height, school attendance, and
death for multiple dose trials.
R E S U L T S
Description of studies
We identified 45 trials reported in 64 articles that met the inclu-
sion criteria (see Figure 2, Characteristics of included studies and
Appendix 2). For a trial completed in 2006 but never published,
the trial authors provided a manuscript with data we were able
to use (Hall 2006 (Cluster)). For Alderman 2006 (Cluster), the
trial authors did not adjust the CIs to take into account clustering
for the primary outcome. For this Cochrane Review, we used the
corrected values supplied by the trial author.
Figure 2. Study flow diagram.
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We excluded 40 trials (see Characteristics of excluded studies), and
one trial is ongoing (see Characteristics of ongoing studies).
Location
The included trials were undertaken in 23 different countries:
Bangladesh (four trials); China (two trials); Ethiopia (two trials);
Haiti (two trials); India (five trials); Indonesia (four trials); Jamaica
(two trials); Kenya (five trials); Malaysia (two trials); Phillipines
(two trials); South Africa (two trials); Uganda (two trials); Vietnam
(three trials); Zanzibar (two trials); Benin, Botswana, Cameroon,
Guatemala, Nigeria, Sierra Leone, Tanzania, Zaire (one trial in
each); China, Philippines andKenya; China andMyanmar (multi-
centre trials).
Population
Children were recruited from school populations in 26 trials, com-
munities in 12 trials, and in health facilities or by health work-
ers in seven trials. One of these trials recruited children on dis-
charge from hospital (Donnen 1998) and another recruited chil-
dren whose mothers had participated in the pregnancy phase of
the trial (Ndibazza 2012). Olds 1999 and Wiria 2013 (Cluster)
also included adolescents 17 to 19 years old, but most participants
were under 16 years old.
Thirty-seven trials were based on mass targeted treatment of an
unscreened population. Eight trials studied children who were
screened and selected on the basis of their having high worm loads
and the purpose of three of these trials was to measure cognitive
outcomes. One trial of unscreened children, Stephenson 1993,
also studied an infected subgroup of the larger unscreened trial
population for cognitive and haemoglobin outcomes. Fifteen trials
were conducted in populations where worms were of high preva-
lence or intensity (community category 1), 12 in populations with
moderate prevalence and low intensity (category 2), and 10 in
populations with low prevalence and low intensity (category 3).
Interventions
Albendazole
Twenty-eight trials had albendazole only in one treatment arm; in
addition, some of these trials had arms with combinations with
albendazole and: praziquantel (Olds 1999); ivermectin (Beach
1999); and diethylcarbamazine (Fox 2005); the additional drugs
were also given to children in the control arms.
One trial included Giardia treatment, secnidazole, in both inter-
vention and control arms (Goto 2009).
One trial was a deworming programme that included deworming
drugs for STHs, praziquantel to treat schistosomiasis in schools
with > 30% prevalence, and health promotion interventions (
Miguel 2004 (Cluster)).
Other anthelminthic drugs
Seven trials used mebendazole; and two trials used mebenda-
zole in combination with pyrantel. Other deworming drugs used
included pyrantel pamoate, piperazine, piperazine citrate, tetra-
chloroethylene, and levamisole.
Accompanying health promotion activities
Nine trials reported on a range of child health activities (Table 3).
In eight trials, the accompanying activities appeared to be applied
to both intervention and control arms.
One trial had a comprehensive health promotion programme ac-
companying the deworming, including regular public health lec-
tures, teacher training, and health education targeted to avoid in-
testinal helminths and exposure to schistosomiasis (Miguel 2004
(Cluster).
Control groups
Most trials used placebo or no treatment as a control. Others used
vitamin A, vitamin C, or calcium powder.
There were 13 trials where both the treatment and control group
received nutritional supplementation: multi-nutrient, vitamin B,
iron, vitamin A, or child health packages, including growth mon-
itoring and health education (Table 3).
Trial design
Nine trials were cluster randomized, including one trial with quasi-
random allocation of the 75 clusters (Miguel 2004 (Cluster)). The
rest used the individual as the unit of randomization.
Six of the nine cluster-RCTs used an appropriate method to take
clustering into account. Awasthi 2001 (Cluster) and Awasthi 1995
(Cluster) used urban slums as the unit of randomization (50 and
124 respectively), and Awasthi 2013 (Cluster) used 72 rural ad-
ministrative blocks. These three trials were analysed at the cluster
level (mean of cluster mean values and associated SDs). Stoltzfus
1997 (Cluster) randomized 12 schools and adjusted for within-
school correlations using generalized estimating equations.Miguel
2004 (Cluster) adjusted for clustering in their regression estimates,
and presented robust standard errors. Wiria 2013 (Cluster) ran-
domized 954 households and used generalised linear mixed-effects
models that captured the data correlations induced by clustering
within households.
The three remaining cluster-RCTs did not adjust for clustering:
• Alderman 2006 (Cluster) had not adjusted the primary
outcome for clustering in this trial of 48 parishes containing
27,955 children in total. Upon request, the trial authors
provided the adjusted values which we have used in the analysis;
• Hall 2006 (Cluster) had 80 units of randomization
(schools) containing 2659 children in total. The report presents
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some regression modelling that adjusts for the cluster design, but
the outcomes by randomized comparison do not appear to have
been adjusted. We used the ICC calculated from the Alderman
2006 (Cluster) data to adjust the primary weight outcome for
inclusion in meta-analysis. As the average cluster size for Hall
2006 (Cluster) (ie 33 children) differed somewhat from that of
Alderman 2006 (Cluster) (ie 582 children), the true ICC for
Hall 2006 (Cluster) may be different to that of Alderman 2006
(Cluster), therefore the adjusted result for weight is merely an
approximation;
• Rousham 1994 (Cluster) had 13 units of randomization
(villages) containing 1476 children in total and had also not
adjusted for clustering, but no outcomes from this trial were
suitable for meta-analysis.
Four trials had a factorial design. Awasthi 2013 (Cluster) random-
ized clusters to usual care, six-monthly vitaminA, six-monthly 400
mgalbendazole, andboth vitaminA and albendazole. Kruger 1996
randomized individual participants to albendazole or placebo, and,
also, three of the five schools in the trial received soup fortifiedwith
vitamins and iron, and two received unfortified soup. Le Huong
2007 randomized individual participants to iron-fortified noodles
and mebendazole, noodles without iron fortification and meben-
dazole, iron-fortified noodles and placebo, noodles without iron
fortification and placebo, and iron supplementation and meben-
dazole. Stoltzfus 2001 randomized households to iron, with ran-
dom allocation of mebendazole by child, stratified by iron allo-
cation and age grouped households; disaggregated data for each
treatment allocation group was not provided for each outcome.
Follow-up periods for the trials that used a single dose ranged from
one to 21 months, while the follow-up periods for trials that used
multiple doses ranged from post-intervention to five years.
Miguel 2004 (Cluster) is an cluster quasi-randomized stepped-
wedge trial of a combined education and drug-treatment interven-
tion. The trial included 75 schools with a total of 30,000 pupils en-
rolled. In addition to helminth treatment, the phased complex in-
tervention included public health lectures, teacher education, and
child health education including handwashing, as noted above. In
addition, a number of schools in the trial were also mass treated
for schistosomiasis. In our previous update of the review we iden-
tified two potential quasi-randomized comparisons that provide
unbiased estimates, one in 1998 and one in 1999, in the stepped-
wedge design. Since our last review update this trial has been the
subject of an independent reanalysis, with a full report published
on the 3ie website (Aiken 2014), and two subsequent academic
papers (Aiken 2015; Davey 2015). In this review update we used
data from these sources to assess the methodological quality of the
trial. The results are primarily draw from the replication report,
Aiken 2014, which provides estimates corrected for coding errors
in the original paper.
Outcome measures
Nutritional status
Forty-six trials measured nutritional indicators. Some trials re-
ported absolute values, or changes in absolute values of weight
and height (or other anthropometric measures). Many trials pre-
sented anthropometric data in terms of z-scores or percentiles of
weight-for-age, weight-for-height, and height-for-age, and com-
pared the trial results to an external reference. Sometimes these
values were dichotomised and presented as the prevalence of un-
derweight, stunting or wasting (defined as -2 SD z-scores). The
external standard was usually quoted as the National Centre for
Health Statistics (NCHS) standard, but a variety of references were
quoted (including anthropometric computer packages or country
standards). These data have not been used in the meta-analyses as
the results were already incorporated in the values for weight and
height. Furthermore, in some trials, outcome data were not re-
ported or were incomplete and could not be used inmeta-analysis.
A number of reports did not provide summary outcome data for
each trial arm, and the results were reported in terms of regression
modelling outcomes or subgroup analyses. We have described the
results of these trials in Table 4.
Haemoglobin
Nineteen trials measured haemoglobin. Of these, two trials did
not report the measured haemoglobin results (Olds 1999; Solon
2003), two trials only measured this outcome in a subset of
the participants (Awasthi 2013 (Cluster); Miguel 2004 (Cluster))
and one trial did not report results by randomized comparisons
(Stephenson 1993).
Psychometric tests of cognition
Eleven trials measured intellectual development using formal tests
(Table 5).
Measures of physical well-being
Three trials measured physical well-being using the Harvard Step
Test, 10 m shuttle run and VO2 max, grip strength and standing
broad jump test (Stephenson 1989; Stephenson 1993; Yap 2014;
Table 6).
School attendance
Four trials measured school attendance (Table 7).
School performance
Hall 2006 (Cluster) and Miguel 2004 (Cluster) measured exam
performance (Table 8).
16Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school
performance (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Death
Ndibazza 2012 provided data on mortality. Awasthi 2013
(Cluster) also monitored mortality although these data are not yet
in the public domain so we are unable to report them.
Adverse events
Four trials provided information on adverse events (Fox 2005;
Michaelsen 1985; Wiria 2013 (Cluster); Yap 2014).
Risk of bias in included studies
See Figure 3 and Figure 4 for ’Risk of bias’ summaries and
Characteristics of included studies section for details of the risk of
bias and methods used in each trial.
Figure 3.
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Figure 4.
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Allocation
Sequence generation
In the 38 individually RCTs, the risk of bias was low in 13 trials (see
Figure 3 and Figure 4), high in five, and unclear in the other trials.
For the nine cluster-RCTs, the risk of bias was low in two trials
(Alderman 2006 (Cluster); Wiria 2013 (Cluster)), high in two
trials (Awasthi 1995 (Cluster);Miguel 2004 (Cluster)) and unclear
in five trials (Awasthi 2001 (Cluster), Awasthi 2013 (Cluster),
Hall 2006 (Cluster), Rousham 1994 (Cluster), Stoltzfus 1997
(Cluster).
Allocation concealment
For the 38 individually randomized trials, seven trials were at low
risk of bias regarding allocation concealment (Fox 2005; Garg
2002; Le Huong 2007; Nga 2009; Olds 1999; Stoltzfus 2001;
Sur 2005), high in two trials (Awasthi 2000; Kirwan 2010), and
unclear in the other trials.
The risk of bias was low in one of the eight cluster-RCTs (Hall
2006 (Cluster)), high in two trials (Awasthi 1995 (Cluster);Miguel
2004 (Cluster)), and unclear in the remaining six trials.
Blinding
Fifteen trials were double blinded and judged to be at low risk
of bias. Five trials were at high risk of bias as they did not use
blinding. Details of blinding were unclear in the remaining 26
trials.
Incomplete outcome data
Twenty nine trials appeared to have low risk of bias in relation
to outcome data. Overall, the percentage of randomized partici-
pants that were evaluable ranged from 4% to 100%, with 19 trials
including 90% or more of the randomized participants (low risk
cut-off ). The percentage was particularly low in three of the trials
measuring school performance and cognitive outcomes: 71% in
Ndibazza 2012; 73% in Nokes 1992; and 52% in Stoltzfus 2001;
and in one trial measuring haemoglobin: 26% in Kirwan 2010.
In Miguel 2004 (Cluster) for haemoglobin a sample of around
4% (778/20,000) of the quasi-randomized comparison of group
1 vs group 2 in 1998 was analysed. Weight and height data were
collected on all individuals in standards 3.8, 48% of the total com-
parison (9102/20000). For exam performance and cognitive tests,
34% of eligible children were included in the treatment school
(group 1) and 32% in the control school (group 2 and 3). Wiria
2013 (Cluster) did not report the number of children that were
randomized, so it was not possible to calculate the percentage
evaluable in this trial.
Selective reporting
Fourteen trials had evidence of selective reporting and were judged
to be at high risk of bias (Goto 2009; Greenberg 1981; Kirwan
2010; Koroma 1996; Nga 2009; Nokes 1992; Olds 1999; Simeon
1995; Solon 2003; Stoltzfus 1997 (Cluster); Stoltzfus 2001; Sur
2005; Willett 1979). The remaining trials did not show evidence
of selective reporting.
Other potential sources of bias
In general, quality of the design of the nine cluster-RCTswas good:
they were judged as low risk for recruitment bias (six trials), base-
line imbalance (nine trials), loss of clusters (nine trials), compat-
ibility with RCTs that randomized individuals (one trial).These
data are included in the “table of characteristics”).
There were problems with incorrect analysis noted above:
Alderman 2006 (Cluster) did not adjust for clustering in the pub-
lished trial, but gave us the adjusted data (see trial design above),
and we used this to adjust the analysis in Hall 2006 (Cluster).
One trial was potentially confounded by co-interventions noted
under “accompanying health promotion activities” under inter-
ventions (above).
Effects of interventions
See: Summary of findings for the main comparison Multiple
doses of deworming drugs given to all children, longest follow-
up; Summary of findings 2 Single dose of deworming drugs
given to infected children; Summary of findings 3 Single dose of
deworming drugs given to all children
The effects were grouped into trials in children known to be in-
fected, and trials of all children in endemic areas. In the trials
treating whole populations, we stratified the results by commu-
nity worm prevalence. We have detailed the prevalence strata in
Table 2 (high prevalence or high intensity areas (referred to as ’high
prevalence’); moderate prevalence and low intensity referred to as
(’moderate prevalence’); and low prevalence with low intensity re-
ferred to as ’low prevalence’). Within each section, we present the
results of the meta-analysis, and then report any other data from
trials that we could not include in the meta-analysis.
Comparison 1. Children with infection: single dose of
deworming drugs vs no intervention
These trials screened for infection, and then included only chil-
dren with proven infection; or were conducted in settings where
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all the children were known to be infected. None of these tri-
als provided data for the outcomes school attendance (number of
children dropping out), school performance, mortality, or adverse
events. No trials appeared to have potentially confounding health
promotion activities (Table 3). For single dose, see Summary of
findings 2.
Nutritional measures
Trials measured weight (n = 5), height (n = 5), MUAC (n = 4),
triceps (n = 3), subscapular skinfold (n = 2) and BMI (n = 1).
Large effects were seen in two trials for weight, MUAC, and skin-
fold, with an average weight gain of over one kg in both trials
(Stephenson 1989; Stephenson 1993). These trials were in a high
prevalence area of Kenya. The gain in weight in the deworming
group ranged from 0.2 kg to 1.3 kg more (627 participants, five
trials, Analysis 1.1), height gain (0.25 cm, 95% CI 0.01 to 0.49;
647 participants, five trials, Analysis 1.2), and gains in MUAC,
triceps and subscapular skinfold values (Analysis 1.3; Analysis 1.4;
Analysis 1.5). No difference in body mass index was detected after
a single dose (Analysis 1.6).
Nokes 1992 did not provide data for nutritional outcomes as nine
weeks was cited as too short a follow-up period to demonstrate a
change (Table 4).
Haemoglobin
There was no difference in overall mean haemoglobin at the end
of two trials with deworming (Analysis 1.7).
Psychometric tests of cognition
Two trials reported on formal tests (Table 5). Kvalsvig 1991a did
not clearly report change in cognitive scores; Nokes 1992 did not
report unadjusted data, but results ofmultiple regression suggested
an improvement in treated children in three of the 10 tests carried
out (fluency, digit span forwards, digit span backwards).
Measures of physical well-being
Two trials in the same high prevalence area of Kenya measured
performance on the Harvard Step Test in non-randomly selected
subgroups (Stephenson 1989; Stephenson 1993), and both indi-
cated benefit. Yap 2014 found no effect on any of the measures of
physical well-being (Table 6).
Other data
Three trials did not provide data in a form that we could use in
meta-analysis. We have collated these data in Table 4, and this
information is summarized below:
• Nokes 1992 measured growth but did not report the
results, as nine weeks was cited as too short a follow-up period to
demonstrate a change;
• Tee 2013 found no significant differences in median change
in weight and weight-for-height z-scores, and for mean change in
weight-for-age, and height-for-age z-scores at 12 month follow-
up;
• Yap 2014 found no significant differences in percentage
stunted and sum of skinfolds at six month follow-up.
Comparison 2. Children with infection: multiple
doses of deworming drugs vs no intervention
Nutritional measures
Stephenson 1993 demonstrated weight, MUAC, triceps, sub-
scapular and skinfold gains, but no improvements in height
(Analysis 2.1; Analysis 2.2; Analysis 2.5; Analysis 2.6; Analysis
2.7). For body mass index, Simeon 1995 did not demonstrate a
difference (Analysis 2.3). They also reported height for age z-score
and did not detect a difference (Table 4).
Psychometric tests of cognition
Simeon 1995 measured intellectual development using a wide
range achievement test in the main trial, and digit spans and ver-
bal fluency tests in subgroups. The trial authors reported that de-
worming had no effect on intellectual development scores, but did
not report the data (Table 5).
School attendance (days present at school)
Simeon 1995 found no demonstrable effect on school attendance
rates of children actively attending school (MD -2.00, 95% CI -
5.49 to 1.49; 407 participants, one trial, Analysis 2.4).
Comparison 3. All children living in endemic area:
single dose of deworming drugs
One trial had substantive health promotion activities accompany-
ing the deworming group (Table 3).
See Summary of findings 3.
No trials provided data for the outcomes school attendance, phys-
ical well-being, and mortality.
Nutritional measures
Trials measured weight in high (n = 2), moderate (n = 2), and
low (n = 3) prevalence areas. The trials demonstrated no effect on
weight (-0.04 kg, 95% CI -0.11 to 0.04; 2719 participants, seven
trials; Analysis 3.1), height (-0.12 cm, 95%CI -0.33 to 0.10; 1974
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participants, five trials; Analysis 3.2) or MUAC (0.04 cm, 95%
CI -0.19 to 0.26; 911 participants, three trials; Analysis 3.3).
Haemoglobin
Two trials were inmoderate prevalence areas, and one in low preva-
lence areas. No effect was demonstrable in individual trials or on
meta analysis (MD 0.06 g/dL, 95% CI -0.05 to 0.17; 1005 par-
ticipants, three trials; Analysis 3.4).
Psychometric tests of cognition
Solon 2003measured cognitive ability using a standardizedwritten
mental-abilities test, and reported that deworming had either no
effect or a negative effect on mental ability scores, but did not
report the data. Nga 2009 reported no effects on any cognitive
tests measured (Table 5).
Adverse events
Fox 2005 reported none in 46 patients given albendazole.
Michaelsen 1985 reported a number of adverse events with tetra-
chloroethylene, a drug no longer used (Table 4).
Other data
Some trials did not provide data in a form that we could use in
meta-analysis. We have collated these data in Table 4, and we have
summarized this information below:
• Beach 1999 did not detect a nutritional benefit of
treatment after four months for the entire trial population (no
figures provided);
• Fox 2005 only reported on subgroups infected with worms;
• Greenberg 1981 stated there was no significant difference
for all measured anthropometric variables for the total group and
for subgroups defined by severity of infection (no figures
provided);
• Kloetzel 1982 reported the proportion of treatment or
control group that improved, deteriorated, or experienced no
change, but it is not known what anthropological measures were
used;
• Koroma 1996 found significant increases in weight-for-
height, weight-for-age, and height-for-age z-scores recorded in
rural and urban treatment groups at six months;
• Michaelsen 1985 found no significant difference in change
in mean for haemoglobin or weight for height at five months;
• Nga 2009 found not significant difference in weight-for-
height, weight-for-age, and height-for-age z-scores at four
months.
• Wiria 2013 (Cluster) found no significant difference in
BMI at 21 months follow-up in children aged 19 years and less.
Sensitivity analysis
In the sensitivity analysis including only trials where the risk of
bias for allocation concealment was low, no difference between
treatment and control groups in weight, height, MUAC, or hae-
moglobin was evident (Analysis 5.1; Analysis 5.2; Analysis 5.3;
Analysis 5.4).
Comparison 4. All children living in endemic area:
multiple doses of deworming drugs, longest follow-up
See Summary of findings for the main comparison.
No trials provided data for adverse events.
Nutritional measures
Trials were in high (n = 2), moderate (n = 3), and low (n = 5)
prevalence areas. For weight, overall there was no evidence of an
effect (Analysis 4.1), although one trial (Awasthi 1995 (Cluster)
(low prevalence) showed a large weight gain of almost 1 kg in the
treatment groups. Notably two subsequent trials in the same area
as Awasthi 1995 (Cluster) did not demonstrate an effect (Awasthi
2000; Awasthi 2001 (Cluster)). Overall, the meta-analysis did not
demonstrate a difference in weight gain between intervention and
control (MD 0.08 kg, 95% CI -0.11 to 0.27; 36,038 partici-
pants from cluster trials and 2354 individually randomized par-
ticipants, 10 trials), but the heterogeneity was high (I² statistic
= 83%). When the trials were stratified by community category,
heterogeneity was explained for the high and moderate prevalence
trials, but not for the low prevalence trials. No significant effect
was apparent in any subgroup. For MUAC (two trials) and tri-
ceps skinfold (one trial), no overall effects were evident (Analysis
4.3; Analysis 4.4). No effect on height was demonstrated in any
of the trials measuring this (5384 participants from cluster trials
and 1673 participants from individually randomized, seven trials;
Analysis 4.2).
Haemoglobin
Seven trials reported this, with no difference between intervention
and control apparent (Analysis 4.5). In addition, the re-analysis
of Miguel and Kremer (Aiken 2015) reported no difference in the
prevalence of anaemia between the groups.
Psychometric tests of cognition
Five trials (30,000 participants from cluster trials and 2486 indi-
vidually randomized participants) measured this outcome (Table
5). Ndibazza 2012 measured a range of cognitive tests, Watkins
1996 measured reading and vocabulary, and Stoltzfus 2001 mea-
suredmotor and language development. All reported that no effect
was demonstrated.Miguel 2004 (Cluster) alsomeasured a range of
cognitive tests. The results were not reported, but the trial authors
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stated that no deworming effect was demonstrated. Awasthi 2000
measured developmental status using the Denver Questionnaire,
and did not demonstrate an effect of deworming.
School attendance (days present at school)
Three trials reported on this outcome (Kruger 1996;Miguel 2004
(Cluster); Watkins 1996; Table 7). Watkins reported attendance
rates of children actively attending school on the basis of school
registers, at baseline and after treatment, and no effect was demon-
strated. Miguel 2004 (Cluster) reported on end value differences
in attendance for girls under 13 years of age and all boys based on
direct observation.
For outcomes measures at the longest follow-up point we found
no difference in school attendance (MD 2%, 95% CI -4 to 8%;
Analysis 4.6; 20,000 participants in cluster trials and 243 partici-
pants from an individually RCT, two trials) ). This uses the longest
point of follow-up fromMiguel 2004 (Cluster) at two years (group
1 vs group 3), in line with our analytical plan.
School performance
Two trials measured this (Hall 2006 (Cluster); Miguel 2004
(Cluster); Table 8). Miguel 2004 (Cluster) measured exam score
performance (English, Mathematics, and Science-Agriculture ex-
ams in pupils in grades 3 to 8). Results showed no difference in
performance. This included the results in the original trial analysis,
Miguel 2004 (Cluster), in the analysis after coding errors had been
corrected, Aiken 2015), and in the statistical replication, Davey
2015. Hall 2006 (Cluster) found no difference in test scores at the
end of the trial.
Death
Deworming showed no effect in the DEVTA cluster trial of over
one million children (Awasthi 2013 (Cluster)) (MD in deaths per
child-care centre at ages 1.0 to 6.0 was 0.16 (SE 0.11); mortality
ratio 0.95, 95% CI 0.89 to 1.02). Ndibazza 2012 reported that
during the trial there were 16 deaths, eight in the placebo arm and
eight in the treatment arm. Awasthi 1995 (Cluster) reported 23
deaths during the trial, 13 of which were in the usual care arm,
and 10 were in the treatment arm.
Other data
Some trials did not provide data in a form that we could use in
meta-analysis. We have collated these data in Table 4 and Table 7,
and have summarized this information below:
• Goto 2009 reported no significant differences in mean z-
scores or prevalence of stunting, underweight or wasting between
the intervention groups, and the changes between intervals (ie
between weeks 0 to 12, 0 to 24, 0 to 36, 12 to 24, etc.) did not
differ significantly between groups;
• Hadju 1997 reported no significant differences detected
between treatment groups on basis of multivariate analyses;
• Hall 2006 (Cluster) reported no difference in final and
change in height;
• Kruger 1996 found that “the rates of absenteeism were
similar for all groups”, but no measures of variance were
provided;
• Lai 1995 found no difference in height or weight between
treatment and control group at the end of two-year follow-up;
• Le Huong 2007 reported no obvious trend in nutritional
variable;
• Miguel 2004 (Cluster) demonstrated no significant effect
on weight-for-age z-score, height-for-age z-score, and
haemoglobin;
• Rousham 1994 (Cluster) reported that ANOVAS of the
change in z-scores revealed no significant improvement with
treatment;
• Ndibazza 2012 found no significant differences in mean z-
scores for weight-for-height, weight-for-age, and height-for-age
z-scores at five years of age;
• Stoltzfus 2001 reported that mebendazole significantly
reduced the prevalence of mild wasting malnutrition in a
subgroup of children aged < 30 months;
• Stoltzfus 1997 (Cluster) reported that in a subgroup of
under 10 year olds, the twice-yearly treated group experienced
significantly greater weight gain (kg) compared to control (2.38
(SE 0.08) vs 2.11 (SE 0.08), P < 0.05);
• Willett 1979 reported no statistical difference in growth
rates in terms of height and weight between the two groups.
Comparisons 5 and 6. Sensitivity analysis
Including only trials with low risk of bias for allocation of con-
cealment, no significant difference between treatment and control
groups was detected in weight, height, or haemoglobin (Analysis
5.1; Analysis 5.2, Analysis 5.3, Analysis 5.4; Analysis 6.1, Analysis
6.2; Analysis 6.3).
Comparison 7. Exploring whether the intervention
effect changed over time
The MD in weight (between deworming drugs vs control in chil-
dren in an endemic area after multiple doses) did not differ by
length of follow-up (results not presented) or by publication year
(Analysis 7.1).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
In infected children, what is the effect of a single dose of deworming drugs?
Patient or population: Children known to be infected with soil-transmitted intestinal worms
Settings: Areas hyper-endemic for intestinal helminths, or children screened for infection
Intervention: Single dose deworming drugs
Control: No intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Deworming drugs
(Single dose)
Weight (kg)
Follow-up: 4 weeks to 6
months
The mean gain in weight
in the control groups
ranged from 0.54 to 2.2
kg
The gain in weight in
the intervention groups
ranged from 0.20 to 1.30
kg higher
Not pooled 627
(5 trials)
⊕⊕©©
low1,2
Due to risk of bias and
inconsistency
May increase average
weight gain
Haemoglobin (g/dL)
Follow-up: 9 weeks to 6
months
The mean change in hae-
moglobin in the control
groups ranged from
-0.6 to -0.9 g/dL
The mean change in hae-
moglobin in the interven-
tion groups was 0.10 g/
dL higher
(0.65 lower to 0.86
higher)
- 247
(2 trials)
⊕©©©
very low1,2,3
Due to risk of bias, incon-
sistency and indirectness
We don’t know if there
is an effect on average
haemoglobin
Formal tests of cognition - - Not pooled 103
(2 trials)
⊕©©©
very low4
Due to risk of bias and
indirectness
We don’t know if there is
an effect on cognition
Physical well-being - - Not pooled5 280
(3 trials)
⊕©©©
very low5,6
due to risk of bias and
indirectness
We don’t know if there is
an effect on physical well-
being
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School attendance - - - -
(0 trials)
- We don’t know if there is
an effect on school atten-
dance
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 1 for risk of bias: none of the trials adequately described allocation concealment.
2Downgraded by 1 for inconsistency: there is a high level of heterogeneity.
3Downgraded by 1 for indirectness: one of the trials showing large effects is from a highly endemic area in Kenya with intense worm
loads and conducted 20 years ago.
4Downgraded by 2 for risk of bias and 1 for indirectness: two trials measured cognitive functioning: i) Kvalsvig 1991a, with a follow-
up of one month, did not clearly report the changes in cognitive scores since ‘ ‘ the dose of mebendazole was inadequate to free
children from infection’’; and ii) Nokes 1992, with a follow-up of nine weeks, reported that results of a multiple regression suggest a
greater improvement in treated children in 3/10 tests (fluency, digit span forwards, digit span backwards). These two trials are not easily
generalized to other settings.
5 Downgraded by 1 for indirectness: Small differences in Harvard Step tests in two older trials in Kenya; no differences detected in VO2
and other parameters in a third trial with a small number of participants suggested no differences (Table 8).
6Downgraded by 2 for risk of bias: only one of the trials adequately described allocation concealment to be considered low risk of
selection bias. Two trials conducted Harvard step tests on small non-random samples of larger trials.
2
4
D
e
w
o
rm
in
g
d
ru
g
s
fo
r
so
il-tra
n
sm
itte
d
in
te
stin
a
l
w
o
rm
s
in
c
h
ild
re
n
:
e
ffe
c
ts
o
n
n
u
tritio
n
a
l
in
d
ic
a
to
rs,
h
a
e
m
o
g
lo
b
in
,
a
n
d
sc
h
o
o
l
p
e
rfo
rm
a
n
c
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
A
u
th
o
rs.
T
h
e
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
In communities where intestinal helminths are endemic, what is the effect of a single dose of deworming drugs given to all children?
Patient or population: All children
Settings: Areas endemic for intestinal helminths
Intervention: Single dose deworming drugs
Control: No intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Deworming drugs
(Single dose)
Weight (kg)
Follow-up: 7 weeks to 1
year
The mean weight gain in
the control groups ranged
from
0.45 kg to 1.19 kg
The mean weight gain
in the intervention groups
was
0.04 kg less
(0.11 kg less to 0.04 kg
more)
- 2719
(7 trials)
⊕⊕⊕©
moderate1
Due to risk of bias
Probably little or no effect
on average weight gain
Haemoglobin (g/dL)
Follow-up: 9 weeks to 6
months
The mean haemoglobin in
the control groups ranged
from
12.01 to 12.12 g/dL
The mean haemoglobin
in the intervention groups
was
0.06 g/dL higher
(0.05 lower to 0.17
higher)
- 1005
(3 trials)
⊕⊕⊕©
moderate1
Due to risk of bias
Probably little or no effect
on average haemoglobin
Formal tests of cognition - One trial reported that de-
worming had no effect,
and the other that de-
worming reduces cogni-
tive scores
Not pooled 1361
(2 trials)
⊕⊕©©
low1,2
due to risk of bias and
indirectness
There may be little or no
effect on cognition
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Physical well-being - - - -
(0 trials)
- We don’t know if there is
an effect on physical well-
being
School attendance - - - -
(0 trials)
- We don’t know if there is
an effect on school atten-
dance
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 1 for risk of bias: none of the trials were classified as having low risk of bias.
2Downgraded by 1 for indirectness: only two trials have assessed these outcomes and the results are not easily generalized to other
settings. In the Philippines Solon 2003 reported deworming either had no effect or a negative effect on cognitive test scores, and in
Vietnam Nga 2009 reported no difference detected. We could not combine data.
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D I S C U S S I O N
Summary of main results
We identified 45 trials, including nine cluster-RCTs, that met the
inclusion criteria. One trial that assessed mortality in addition
to other endpoints included over one million children, and the
remaining 44 trials included a total of 67,672 participants.
For infected children, deworming drugs may increase average
weight gain over one to six months, but we do not know if there
is an effect on haemoglobin or cognitive functioning.
In trials treating all children living in endemic areas of varying en-
demicity (15 in high prevalence areas, 12 in moderate prevalence,
and 10 in low prevalence areas), a single dose of deworming drugs
probably has little or no effect on average weight gain or average
haemoglobin, and may have little or no effect on cognition or
physical well-being. For multiple doses of deworming drugs over
six months to three years after the intervention started, there was
little or no effect on average weight gain, height, or haemoglobin,
and probably little or no effect on formal tests of cognition. We
do not know if there was an effect on school attendance, but there
is probably no effect on exam performance or death.
Overall completeness and applicability of
evidence
Since the previous version of this review, the DEVTA trial has
been published and is now included in this Cochrane Review. One
further trial (of 2660 children in Vietnam from 1999) remains
unpublished (Hall 2006 (Cluster)). In May 2015 we offered the
trial investigators an opportunity to present the trial as an annex
to this review, and await a response from them. Meanwhile, the
data from the unpublished manuscript are included in this review.
In children infected with worms, a single dose of deworming
medicine appears to result in some weight gain. This evidence
comes from trials conducted in a single school in Kenya more
than 20 years ago, where all of the children were infected-the ma-
jority with heavy worm loads of both hookworm and Trichuris
(Stephenson 1989; Stephenson 1993). However, when the inter-
vention is used in the way the WHO currently recommends -
giving treatment to whole school populations - an overall aver-
age effect is not evident. An effect on average weight was seen in
one cluster-RCT assessing long-term multiple dosing in a low-
burden community undertaken in 1995 in India (Awasthi 1995
(Cluster)). Trials conducted subsequently, some in the same area,
including large cluster-RCTs, have not demonstrated effects.
Some policy arguments point out that deworming programmes
will not provide a detectable average effect on nutritional status,
but actually will provide a substantial effect in a proportion of
children with heavy worm load infections. Even if this were the
case, there should be an effect on average values, and in this review
treating children known to be infected may have some effect on
weight gain (driven mainly by data from Kenya from a highly
endemic area conducted over twenty years ago) but not other
variables. If policy makers feel this is credible even in the absence
of differences in average effect, then further trials are needed to
evaluate this.
Ten trials measured intellectual development using formal tests.
Only one of these trials demonstrated an effect on cognitive out-
comes in 3/10 of the outcomes measured (Nokes 1992; Table 5).
The trials used a range of cognitive tests, which seems to reflect the
difficulty inherent in choosing appropriate cognitive performance
tests since there is no accepted test battery that can be applied
across cultures and settings, and, asMiguel 2004 (Cluster) pointed
out, the mechanisms for any putative effects are unknown.
For school attendance, one quasi-RCT reported an effect, which
was apparent in only one of the two comparisons in up to a year of
follow-up, and not apparent in the one comparison after one year
(Miguel 2004 (Cluster)). Miguel 2004 (Cluster) measured atten-
dance outcomes directly, unlike the other two trials (Simeon 1995;
Watkins 1996) which measured attendance using school registers,
which may be inaccurate in some settings. Two large cluster-RCTs
measured school performance and neither demonstrated an effect
of deworming (Hall 2006 (Cluster); Miguel 2004 (Cluster)).
For children living in endemic areas, in terms of the logic frame-
work (Figure 1) evidence on the desired impacts (child mortality
and school performance) is absent. The evidence for school atten-
dance is limited, and there is no evidence of effects on physical
well-being. In terms of the main effects there may be no effect on
weight, and there is fairly good evidence of no impact on haemo-
globin, cognition, and school performance.
Long-term outcomes
There have been some recent trials on long-term follow-up, none
of which met the quality criteria needed in order to be included
in this review (Baird 2011; Croke 2014; Ozier 2011; described in
Characteristics of excluded studies). Baird 2011 and Ozier 2011
are follow-up trials of the Miguel 2004 (Cluster) trial. Ozier 2011
studied children in the vicinity of the Miguel 2004 (Cluster) to
assess long-term impacts of the externalities (impacts on untreated
children). However, in the replication trials (Aiken 2014; Aiken
2015; Davey 2015), these spill-over effects were no longer present,
raising questions about the validity of a long-term follow-up. Baird
2011 compared children who received two years more deworming
to those who received less in the Miguel 2004 (Cluster) analysis.
Croke 2014 is a follow-up of the Alderman 2006 (Cluster), but
assessed only 3% (1097/37,165) of the original randomized par-
ticipants, and furthermore all children were offered treatment af-
ter the original follow-up period in the Alderman 2006 (Cluster)
trial.
Overall, given the growing evidence of a lack of short-term effects,
arguments for long-term population impacts appear implausible
in our view.
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Externalities
There have been previous claims that deworming benefits not only
the individuals, but also those around them. Whilst not ignoring
this, we tried to establish first that there was a benefit to indi-
viduals; as this seems debatable, examining for externalities seems
less important. Miguel 2004 (Cluster), in their original analysis,
stated their analysis demonstrated externalities. After correction
of coding errors, the pure replication failed to find any evidence
of externalities (Aiken 2015).
Completeness of the analysis
Critics of a previous version of this review, Dickson 2000a, stated
that the impactmust be considered stratified by the intensity of the
infection (Cooper 2000; Savioli 2000).We have done this compre-
hensively in this edition and no clear pattern of effect has emerged.
Other criticisms were that trials of short-term treatment cannot
assess the long-term benefits of regular treatment (Bundy 2000).
However, this analysis clearly examines long-term outcomes from
trials conducted over the last 10 years.
Extrapolating evidence on selective deworming to
targeted deworming
Advocates of deworming argue that the evidence of benefit seen in
selective deworming provides an evidential base for targeted de-
worming, because the latter reduces costs due to diagnostic screen-
ing. The argument is that population treatment benefits those in-
fected, but this benefit is simply not detectable. Even among those
children known to be infected, this Cochrane Review does not
clearly demonstrate a consistent benefit on weight: there are two
trials from 20 years ago in which all the children were heavily in-
fected and had large weight gain, but this was not consistent across
all trials (Summary of findings 2).
Choking
The WHO has raised concerns about the prevalence of choking
in young children (aged between one to three years), with several
pages of recommendations in a newsletter about how to administer
albendazole in tablet form without children choking. Although
common sense might suggest this is a rare occurrence, nevertheless
some might argue there is a lack of evidence on the safety of
administering deworming drugs to young children in tablet form
in a community setting.
Polyparasitism
Individuals and communities are often infected with more than
one helminth infection (Molyneux 2005) and the WHO is cur-
rently promoting the large-scale use of ’preventive chemotherapy’.
This involves use of multiple anthelminthic drugs to treat a range
of diseases, including STHs, schistosomiasis, and filariasis. Engels
2009 comments on the need for a comprehensive assessment of
the impact of deworming. In the absence of such evidence, there
is a need to demonstrate that a drug is effective against a particular
parasite and to quantify its effects on people before combining all
the drugs into a basket treatment for all helminth infections, and
assuming that all components are effective.
Secular trends in worm burden
Evidence of the benefit of deworming on nutrition appears to
depend on three trials, all conducted more than 15 years ago,
with two from the same area of Kenya where nearly all children
were infected with worms and worm burdens were high. Later and
much larger trials have failed to demonstrate the same effects. It
may be that over time the intensity of infection has declined, and
that the results from these few trials are simply not applicable to
contemporary populations with lighter worm burdens.
Quality of the evidence
Conducting field trials to test this intervention is complex and
challenging, and researchers have worked hard to generate this
body of research evidence. There is now a reasonable amount of
evidence from trials in a range of settings, including high, moder-
ate, and low burden areas. There have also been ten trials (Analysis
4.1) that have assessed the effects of multiple doses of deworming,
four of which were cluster-RCTs. These are particularly important
because they can detect the ’real life’ community level effects of
treatment that include possible effects from a reduction in worm
transmission (Bundy 2009).
Potential biases in the review process
Statistical errors in analysis
Of the eight cluster-RCTs, three did not take adequate account
of cluster randomization (Alderman 2006 (Cluster); Hall 2006
(Cluster); Rousham 1994 (Cluster)). This has the potential sub-
stantive impact on the interpretation of the trials. For example,
the significant difference between intervention and control quoted
on the cover of the BMJ for Alderman 2006 (Cluster) assumed
27,995 children had been individually randomized.Whenwe clar-
ified this with the trial authors, they provided the BMJwith a cor-
rection, which showed that no significant difference was detected
in weight gain between intervention and control groups; this cor-
rected result has been used in the meta-analysis in this trial.
School attendance
Advocates of deworming have emphasised the potential impacts
on school attendance, on the basis of the influential econometric
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trialMiguel 2004 (Cluster). The recent replication trials ofMiguel
2004 (Cluster) substantiate our concerns in the previous version
of this Cochrane Review about the high risk of bias in this trial
(Aiken 2015; Davey 2015). In particular the replication trials raise
concerns about the validity of combining the school attendance
data across years, since this involves a non-randomized before and
after comparison. We have thus presented the corrected separate
year estimates in this review, and present the longest follow-up
time point in line with our a priori analysis strategy.
Miguel 2004 (Cluster) also reported data on school attendance at
one year of follow-up, in two groups: group 1 versus group 2+3;
and group 2 versus group 3. As outlined in the previous edition
of the review, it is methodologically incorrect to combine these
in meta-analysis as they are not independent (Taylor-Robinson
2012). The analysis in the previous edition presents each com-
parison separately (Analysis 4.7 in Taylor-Robinson 2012), both
with modest effects, and both non-significant in the meta-analysis
(including Watkins 1996) and this is not repeated in this edition.
Nutritional outcomes
The included trials reported a range of nutritional status outcomes.
For meta-analysis, we did not use nutritional data expressed as
z-scores or percentile scores calculated on the basis of reference
standards, or dichotomised z- or percentile scores (eg proportion
stunted with height-for-age z-score < -2). As these data were de-
rived from the absolute values, we used these values for evidence
of benefit. We knew the nutritional data would be captured in the
absolute values and wanted to reduce selective reporting through
collection of multiple variables from papers that are all derived
from the same basic outcomes measured in the trial. We noted
that in some trials there was a discrepancy between what was mea-
sured and what was reported; eg Nokes 1992 recorded but did not
report anthropometric data. This is a concern as it may indicate
selective reporting. However, we have systematically reported all
relevant outcomes not included in meta-analysis in Table 4.
Subgroup analyses
Some trials presented data from subgroups, selected on the basis of
factors such as infection status (Beach 1999; Fox 2005; Greenberg
1981), location (Koroma 1996), age (Stoltzfus 2001), frequency
of treatment (Stoltzfus 1997 (Cluster)), and sex (Lai 1995). These
comparisons were not randomized and have not been included in
meta-analysis. Two trials, one of which one was a cluster-RCT,
demonstrated improvements in nutritional outcomes in subgroup
analyses (Stoltzfus 1997 (Cluster); Stoltzfus 2001). We have re-
ported these data in Table 4.
Agreements and disagreements with other
studies or reviews
A review and meta-analysis by Hall 2008, funded by the World
Bank, presented evidence in favour of an effect of deworming on
weight gain (MD 0.21 kg, 95% CI 0.17 to 0.26, 11 trials). This
analysis differs from our analyses of weight gain in a number of
respects: it was not a protocol-driven systematic review; the review
excluded trials in lower prevalence areas (< 50%); pooled results
were presented without exploration of significant heterogeneity;
it combined trials that included both screened and unscreened
children; it included trials excluded fromour review on the basis of
methodological quality; it included data from subgroup analyses;
and included data unadjusted for cluster randomization.
The narrative review, Albonico 2008, explored the evidence for the
impact of deworming on pre-school age children, and concluded
that deworming has been shown to improve growth. Their analysis
differed from our analyses in a number of ways: a different pop-
ulation was considered, although our review considers data from
this subgroup; it was not a protocol-driven systematic review; it
included trials excluded from our review; it was a narrative sum-
mary rather than meta-analysis of data; it reported results from
subgroup analyses; it reported point estimates without taking into
account statistical significance; and it included data unadjusted for
cluster randomization. The authors state: “A few trials have failed
to show any impact of deworming on growth”. This is at odds
with our interpretation of the reliable randomized comparisons
of nutritional outcomes in this review, which suggests that most
trials have failed to show an effect on nutrition.
Gulani 2007 undertook a systematic review of the effects of de-
worming on haemoglobin, and reported a marginal increase in
mean values that could translate into small reduction (5% to 10%)
in anaemia in a population with a high prevalence of intestinal
helminths. This systematic review differs from our analysis of hae-
moglobin in a number of respects: it included trials in adults and
pregnant women and it included trials excluded from our review
on the basis of methodological quality.
Other advocates of deworming, such as Bundy 2009, have ar-
gued that many of the underlying trials of deworming suffer from
three critical methodological problems: treatment externalities in
dynamic infection systems, inadequate measurement of cognitive
outcomes and school attendance, and sample attrition. We agree
with these points. However, externalities will be detected by large
cluster-RCTs and there are now nine trials such as this included
in this review, and the externalities previously reported in Miguel
2004 (Cluster) were not found in the replication analysis after
various coding and classification errors had been corrected (Aiken
2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is good medical practice that children known to be infected
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with worms should receive treatment. This is obvious and not the
subject of this Cochrane Review.
There is now good evidence to show that routine, repeated de-
worming public health programmes at a large scale have little or no
benefit on average biomedical parameters or school performance.
Current evidence does not support large public health programmes
of deworming in developing countries.
Implications for research
The replication of theMiguel andKremer trial highlighted a num-
ber of errors in the original analysis which have been corrected.
This demonstrates the value of replication in trials that are con-
troversial and where there is a lack of clarity over methods and the
analysis.
The quality of evidence is graded as moderate on most of the
outcomes, in relation to demonstrating little or no effect of com-
munity deworming. This means that research could possibly have
important impact on the confidence of the results and alter the
effect. Therefore, further research may be useful, but this needs to
be balanced against the declining worm burdens worldwide and
the absence of any good evidence of an effect given the current
research.
Authors of trials, whether they are small or large, should publish
the results of the trials promptly irrespective of the findings, in line
with the basic principles of research integrity (Garner 2013). We
encourage the authors of the Vietnam trial to publish their results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alderman 2006 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: Not adjusted
Cluster unit: parish
Average cluster size: 560
ICCs: not reported but calculated from adjusted and unadjusted figures to be 0.01
Length of follow-up: 3 years
Participants All children living in endemic area
Number analysed for primary outcome: 48 parishes randomized containing 27,995
children
Age range: 1 to 7 years
Inclusion criteria: children aged 1 to 7 in 50 parishes in Uganda selected by the govern-
ment on the basis that around 60% of children aged 5 to 10 years in these parishes were
infected with intestinal nematodes
Exclusion criteria: sick children
Interventions Multiple dose vs no treatment
1. Albendazole: 400 mg tablet (Zentel, GSK) every 6 months, although in the event
a year elapsed between the first and second treatment round; given in conjunction with
a child health package including vaccinations, vitamin A, and health promotion;
2. Child health package including vaccinations, vitamin A, and health promotion.
Outcomes 1. Mean change in weight post-treatment.
Notes Location: Uganda
Community category: 2
Weight gain data taking into account the effects of cluster randomization provided by
the author
Source of funding: the nutrition and early child development project, government of
Uganda, the Institute of Public Health and the research committee of the World Bank
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Coin toss “The randomization was done
by a member of the research team (HA)
by assigning numbers to all of the parishes
and converting these to base two and then
determining which of the parishes were to
be in the treatment by coin flips”
Allocation concealment (selection bias) Unclear risk No details reported.
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Alderman 2006 (Cluster) (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk None. “It was not possible for us to carry
out a double blind trial because of the scale
of the programme and because we aimed
to assess the effectiveness of giving albenda-
zole […] during standard child health days
without any trial specific inputs”
Incomplete outcome data (attrition bias)
All outcomes
High risk 75% (27,995/37,165) of randomized par-
ticipants were evaluated
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: low risk
Baseline imbalance: characteristics similar
(low risk)
Loss of clusters: nil (low risk)
Incorrect analysis: primary outcome in pa-
per not adjusted for clustering (personal
communication Harold Alderman), but
Cochrane Review adjusts this (low risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Awasthi 1995 (Cluster)
Methods Cluster-quasi-RCT
Method to adjust for clustering: cluster used as unit of analysis
Cluster unit: urban slum
Average cluster size: 74
ICCs: not reported.
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 50 slums randomized containing 3712 children
Age range: 1 to 4 years
Inclusion criteria: children aged 1 to 4 from 50 urban slums in Lucknow selected on the
basis of geographic convenience
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
1. Albendazole plus placebo: 400 mg albendazole plus 2 mL vitamin A every 6
months;
2. Placebo: 2 mL vitamin A every 6 months.
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
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Awasthi 1995 (Cluster) (Continued)
Notes Location: Lucknow, India
Community category: 3
Trial carried out in 1995 and published in 2008.
Source of funding: Clinical Trial Service Unit (CTSU), University of Oxford, United
Kingdom, and co-funded by the International Clinical Epidemiology Network Inc.
, Philadelphia, United States of America. Albendazole was donated by SmithKline
Beecham (now GlaxoSmithKline)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized: “Random allocation
was done by SA, listing the anganwadi cen-
ters of each slumarea serially in alphabetical
order, numbering them from 1 to 50, and
then generating a single random number
by computer that allocated either all odd or
all even numbers to a specific intervention
type”
Allocation concealment (selection bias) High risk Not concealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Cluster-RCT with health staff and partic-
ipants knowing which group they were al-
located to
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1852/1968 children in the treatment group
completed all follow-up visits; 1860/1967
children in the usual care group completed
all follow-up visits. Inclusionof all random-
ized participants (number evaluable/num-
ber randomized): 94% (3712/3935)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: unclear (Not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: unclear
Loss of clusters: low (none reported)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
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Awasthi 2000
Methods Quasi-RCT
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 1045
Age range: 1.5 to 3.5 years
Inclusion criteria: children living in 32 randomly selected urban slums; registered with
an Anganwadi worker (health worker); between 1.5 to 3.5 years of age
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
1. Albendazole powder: 600 mg every 6 months for 2 years;
2. Placebo: calcium powder
Outcomes 1. Mean weight post-treatment;
2. Mean change in weight post-treatment;
3. Mean height post-treatment;
4. Mean change in height post-treatment;
5. Developmental status (Denver Questionnaire): reported as proportion with
normal development;
6. Haemoglobin.
Not included in review: prevalence of underweight and stunting over 2 years as defined by
z-scores, haemoglobin (visual colour estimation), stool examination (non-concentration
method), incidence of illness, and death
Notes Location: Lucknow, India
Community category: 3
Source of funding: International Clinical Epidemiology Network (INCLEN), Philadel-
phia, USA grant #2002-94-623 under the Clinical Economics Small Grants Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk 32 Anganwadi centres randomly selected,
and then children allocated to a serial num-
ber; those with odd or non-zero ending
numbers were assigned to placebo
Allocation concealment (selection bias) High risk Not concealed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/610 children in the albendazole group and
7/451 in the placebo group were lost to fol-
low-up
Inclusion of all randomized participants
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Awasthi 2000 (Continued)
(number evaluable/number randomized):
98% (1045/1061)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Awasthi 2001 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: cluster used as unit of analysis
Cluster unit: urban slums
Average cluster size: 13.5
ICCs: not reported.
Length of follow-up: 1.5 years
Participants All children living in endemic area
Number analysed for primary outcome: 124 slums randomized containing 1672 children
Age range/ mean age: 0.8 years
Inclusion criteria: clusters selected if they had functional community workers in slum
areas of Lucknow; within each cluster, children recruited if aged between 0.5 and 1 year,
on basis of survey register held by each worker of their particular area
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
1. Albendazole plus placebo: albendazole suspension (concentration not stated)
(Zentel, SZB) every 6 months and 100,000 units of vitamin A every 6 months
2. Placebo: 100,000 units of vitamin A every 6 months
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment (not used due to question over quoted
standard error)
Not included in review: stool smear for Ascaris prevalence on a subsample of the group;
death rates
Notes Location: Lucknow, India
Community category: 3
Means of cluster means used in analysis. The results (weight gain) in the abstract differ
from the text
Source of funding: International Clinical Epidemiological Network (INCLEN) Inc,
USA and Clinical Trials Unit (CTSU), Oxford, UK
Risk of bias
Bias Authors’ judgement Support for judgement
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Awasthi 2001 (Cluster) (Continued)
Random sequence generation (selection
bias)
Unclear risk Cluster-randomized trial, no further de-
tails.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat (ITT) analysis; 13.9%
lost to follow-up in albendazole group
and 16.2% in the placebo group. Inclu-
sion of all randomized participants (num-
ber evaluable/number randomized): 83%
(1672/2010)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: unclear (Not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: characteristics similar
(low risk)
Loss of clusters: no loss reported (low risk)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: low
Awasthi 2013 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: cluster used as unit of analysis (’means of block-specific
numbers of deaths per AWC’)
Cluster unit: a block of 10,000 to 20,000 children
Average cluster size: 9259 approximately (under-5 population 1 million/108 clusters)
ICCs: not reported
Length of follow-up: 5 years
Participants All children living in endemic area
Number analysed for primary outcome: total population of 1 million children at any
one time, with a total of 2 million children ever in the trial
Age range: 1 to 6 years
Inclusion criteria: all preschool children then aged 1 to 6.0 years in 72 participating
blocks near Lucknow that were considered to have a well-functioning ICDS system
with willing district and block directors and with paid workers in most of the block’s
anganwadi centres
Exclusion criteria: severe anaemia (haemoglobin < 75 g/L)
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Awasthi 2013 (Cluster) (Continued)
Interventions Multiple doses vs placebo
Factorial design in four arms:
1. Usual care - no placebo;
2. 6-monthly vitamin A [for 5 years];
3. 6-monthly 400 mg albendazole;
4. Both 6-monthly vitamin A and 6-monthly 400 mg albendazole.
Outcomes 1. Mortality
Not included in review: A subset of 5165 children were assessed for other outcomes
(height, weight, BMI, haemoglobin, prevalence of illness in past 4 weeks)
Notes Location: Lucknow, India
Community category: 3
Annually about 30 non-randomly selected preschool children were surveyed for growth,
nutritional and morbidity outcomes from one randomly selected AWC per block (10,
000 to 20,000 children in about 120 AWCs per block)
Source of funding: UKMedical Research Council, USAIDOMNI project,World Bank.
Albendazole (Zentel) was donated by SmithKlineBeecham
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly allocated”; “Randomisation (in
Oxford) was stratified in groups of 4 neigh-
bouring blocks, where possible in the same
district.”
Allocation concealment (selection bias) Unclear risk See above.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk All cause mortality is the outcome.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89 AWCs (2%) in the albendazole block
lost to follow-up, 86 AWCs (2%) in the
placebo block lost to follow-up. “Loss to
follow-up is defined by having only 1-6
follow-up visits (mean only 3, as against
12 in the included AWCs), and was gener-
ally because the AWC had ceased to func-
tion.” Inclusion of all randomized partici-
pants (number evaluable/number random-
ized): Denominator for mortality was all
children. A subset of 5165 non-randomly
selected children were assessed for other
outcomes
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Awasthi 2013 (Cluster) (Continued)
Selective reporting (reporting bias) Low risk Mortality is the single outcome for this
trial.
Other bias Low risk Recruitment bias: unclear
Baseline imbalance: unclear
Loss of clusters: unclear
Incorrect analysis: Cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Beach 1999
Methods RCT
Length of follow-up: 4 months
Participants All children living in endemic area
Number analysed for primary outcome: 853
Age range/ mean age: 5 to 11 years
Inclusion criteria: all children attending 5 schools (grades 1 to 4)
Exclusion criteria: haematocrit < 22%
Interventions Single dose vs placebo
1. Albendazole: 400 mg (SmithKlineBeecham, Philadelphia or generic BeltaPharm,
Milan);
2. Ivermectin: 200 to 400 µg/kg (mean 282.7 µg/kg) (Merck, West Point, PA);
3. Albendazole plus ivermectin;
4. Placebo: 250 mg vitamin C.
Outcomes 1. Height
2. Weight
3. Stool examination for helminth prevalence and intensity (geometric mean)
4. Haematocrit
Notes Location: Haiti
Community category: 3
Results presented in a stratified analysis as per individual infection: disaggregated results
not presented; measures of error not given in tables
Source of funding: USAID.
Invermectin provided byPhilippeGaxotte (Merck, Inc.) and albendazole by JohnHorton
(SmithKline Beecham)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
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Beach 1999 (Continued)
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, provider, and assessors were blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 29/229 were lost to follow-up in the placebo
group and 25/244 were lost to follow-up in
the albendazole group. Inclusion of all ran-
domized participants (number evaluable/num-
ber randomized): 88.4% (853/965)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Donnen 1998
Methods RCT
Length of follow-up: 1 year
Participants All children living in endemic area
Number analysed for primary outcome: 222
Age range: 0 to 72 months
Inclusion criteria: children aged 0 to 72months eligible on discharge fromhospital where
primary cause for admission is malnutrition
Exclusion criteria: none stated
Interventions Multiple doses vs placebo and no treatment
1. Mebendazole: 500 mg at start and every 3 months;
2. Placebo: 60 mg vitamin A at start and 3 months;
3. No treatment.
Outcomes 1. Mean weight post-treatment;
2. Mean change in weight post-treatment;
3. Mean height post-treatment;
4. Mean change in height post-treatment;
5. Mean MUAC;
6. Mean change in MUAC.
Not included in review: vitamin A levels; z-scores for height-for-age, weight-for-age,
weight-for-height (NCHS reference); egg counts (eggs/g: Kato Katz method)
Notes Location: Zaire
Community category: 3
Unadjusted data not provided in original paper; results of multiple-regression models
presented on basis of stratifications into vitamin A status and sex; results in meta-anal-
ysis from R Dickson’s correspondence with author when preparing the Dickson 2000a
Cochrane Review.
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Donnen 1998 (Continued)
Source of funding: Fonds de la Recherche Scientifique et Medicale (FRSM), contract 3.
4505.94 and the David and Alice Van Buuren Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized”. No further details reported.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 6% of children were lost to follow-up, with
approximately equal proportions from each group.
During the follow-up period, 25 children died. The
final sample included 311 children Inclusion of all
randomized participants (number evaluable/num-
ber randomized): 86% (311/358)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Dossa 2001
Methods RCT
Length of follow-up: 10 months
Participants All children living in endemic area
Number analysed for primary outcome: 65
Age range: 3 to 5 years
Inclusion criteria: children aged 3 to 5 years; not acutely unwell
Exclusion criteria: none stated
Interventions Multiple doses vs placebo:
1. Albendazole plus iron: 200 mg albendazole per day for 3 consecutive days
repeated 1 month later plus iron;
2. Placebo plus iron;
3. Albendazole: 200 mg per day for 3 consecutive days repeated 1 month later plus
iron placebo;
4. Placebo plus placebo.
Outcomes 1. Mean change in weight post-treatment;
2. Mean change in height post-treatment;
3. Mean change in MUAC;
48Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school
performance (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Dossa 2001 (Continued)
4. Mean change in triceps skinfold thickness;
5. Mean haemoglobin post-treatment.
Not included in review: weight-for-height z-score and height-for-age z-score at 3 and 10
months (both after 2 doses)
Measured but not reported: z-scores for weight-for-height, height for age using NCHS
reference data; egg count (arithmetic and geometric mean); prevalence, intensity; food
intake over 3 days in subset at end of trial (not at baseline)
Notes Location: Benin
Community category: 2
Source of funding: TheNestle Foundation (Lausanne, Switzerland).Smithkline Beecham
provided the deworming and placebo tablets
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”. No further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind”. No further details provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk 175/177 children finished the trial, but 140
were included in the final analysis: “One child
was treated for severe worm infection and 34
children received other pills during the trial
period (iron, vitamins/minerals or deworming
pills that were not provided by our research
team).” Inclusion of all randomized partici-
pants (number evaluable/number randomized)
: 79% (140/177)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias High risk No obvious other source of bias.
Fox 2005
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 626
Age range: 5 to 11 years
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Fox 2005 (Continued)
Inclusion criteria: children aged 5 to 11 years attending any of 12 primary schools in
Haiti where no other deworming activity was taking place
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Albendazole 400 mg plus placebo (250 mg vitamin C tablet);
2. 6 mg/kg diethylcarbamazine (DEC) plus placebo (250 mg vitamin C tablet);
3. Albendazole 400 mg plus single dose of 6 mg/kg diethylcarbamazine (DEC);
4. Placebo plus placebo (2 x 250 mg vitamin C tablets).
Outcomes 1. Weight: final and change in weight;
2. Height: final and change in height;
3. Adverse effects.
Not included in review: worm intensity and prevalence; microfilarial density
Notes Location: Haiti
Community category: 2
Weight and height outcomes are only presented for a subgroup of children infected with
Trichuris
Source of funding: Emerging Infections Program of the Centers for Disease Control
and Prevention (CDC) and an Institutional Strengthening Grant from the WHO to the
Hopital Sainte Croix
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table.
Allocation concealment (selection bias) Low risk Centrally-coded allocation system broken after
baseline measures taken
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind”. Laboratory personnel, mea-
surement teams and personnel evaluating stu-
dents for adverse reactions were all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 626/646 participants analysed for the primary
outcome. Reasons for loss to follow-up unclear
Inclusion of all randomized participants (num-
ber evaluable/number randomized): 97% (626/
646)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
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Freij 1979a
Methods Quasi-RCT
Length of follow-up: 28 days
Participants Infected children identified by screening
Number analysed for primary outcome: 13
Age range: 1.5 to 5 years
Inclusion criteria: boys attending mother and child clinic with Ascaris on stool smear;
aged 1.5 to 5 years with no history of diarrhoea for preceding 2 weeks; no fever; no
respiratory symptoms; no signs of severe disease
Exclusion criteria: children diagnosed with other parasites; excluded girls to eliminate
the contamination of samples with urine
Interventions Single dose vs placebo
1. Piperazine: 3 g single dose;
2. Placebo syrup: single dose.
Outcomes 1. Weight;
2. MUAC;
3. Triceps skinfold thickness.
Not included in review: Ascaris worm count
Notes Location: Ethiopia
Community category: N/A
The trial authors mention that boys were matched in pairs so that if there were drop outs
they could be replaced. They do not indicate if there were any drop outs. SDs calculated
from individual data
Freij 1979a and Freij 1979ai were reported in the same article.
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research
Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-RCT: boys matched into pairs of
equal age and nutritional status
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind, no further de-
tails reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 100% (13/13) of enrolled participants were
evaluated. The authors mention that boys
were matched in pairs so that if there were
drop outs they could be replaced. They do
not indicate if there were any drop outs.
Inclusion of all randomized participants
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Freij 1979a (Continued)
(number evaluable/number randomized):
100% (13/13)
Selective reporting (reporting bias) Low risk Authors had intended tomeasure bicep and
tricep skinfolds, but staff were unable to
take these measurements
Other bias Low risk No obvious other source of bias.
Freij 1979b
Methods Quasi-RCT
Length of follow-up: 34 days
Participants Infected children identified by screening
Number analysed for primary outcome: 44
Age range: 1 to 5 years
Inclusion criteria: 92 children 1 to 5 years from a community morbidity trial
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Piperazine: 3 g/day for 2 days;
2. Placebo: for 2 days.
Outcomes 1. MUAC;
2. Morbidity.
Not included in review: weight in % of Harvard standard; authors had intended to
measure bicep and tricep skinfolds, but staff were unable to take these measurements
Notes Location: Ethiopia
Community category: 3
Freij 1979a and Freij 1979ai were reported in the same article.
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research
Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-RCT: childrenmatched into pairs of
equal age and nutritional status
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind, no further de-
tails reported.
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Freij 1979b (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% (44/44) of enrolled participants were
evaluated. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): 100% (44/44)
Selective reporting (reporting bias) Low risk Trial authors had intended tomeasure bicep
and tricep skinfolds, but staff were unable
to take these measurements
Other bias Low risk No obvious other source of bias.
Garg 2002
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 347
Age range: 2 to 4 years
Inclusion criteria: sick children 2 to 4 years old presenting to 3 government health centres
in Bungamo district, without palmar pallor
Exclusion criteria: children with palmar pallor
Interventions Single dose vs placebo
1. Mebendazole: 500 mg (Vermox, Janssen, Belgium);
2. Placebo: sucrose starch capsule.
Outcomes 1. Mean weight post-treatment;
2. Mean change in weight post-treatment;
3. Mean height post-treatment;
4. Mean change in height post-treatment;
5. Mean haemoglobin post-treatment;
6. Mean change in haemoglobin post-treatment.
Not included in review: z-scores for weight-for-age, height-for-age, and weight-for-
height; egg count (formol-ethyl acetate concentration method) in categories of intensity
Notes Location: Kenya
Community category: 3
Source of funding: the CDC, Atlanta, USA.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random numbers.
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Garg 2002 (Continued)
Allocation concealment (selection bias) Low risk Drugs kept in envelope until after baseline as-
sessment.
Blinding (performance bias and detection
bias)
All outcomes
High risk “the trial was not double-blinded”. Assessors
were blinded; participants unclear; provider not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93%(347/370) of randomizedparticipantswere
evaluated, loss to follow-up balanced across
groups. Inclusion of all randomized participants
(number evaluable/number randomized): 93%
(347/370)
Selective reporting (reporting bias) Low risk All stated outcomes included.
Other bias Low risk No obvious other source of bias.
Goto 2009
Methods RCT
Length of follow-up: 36 weeks
Participants All children living in endemic area
Number analysed for primary outcome: 410
Age range: 0 to 11 months
Inclusion criteria: infants under 11 months of age in the local area
Exclusion criteria: not stated
Interventions Multiple doses vs placebo
1. Anti-Giardia (secnidazole every 4 weeks) and anthelminthic (albendazole every 12
weeks);
2. Anti-Giardia treatment only (secnidazole every 4 weeks) and placebo;
3. Placebo and placebo.
Secnidazole: a 70 mg/mL suspension with about 0.5 g of sweetener was made up, and
0.5 mL per kg body weight was given by spoon. If the infant was sick immediately,
secnidazole was re-administrated
Albendazole: a 200 mg (5 mL) suspension given by spoon.
Outcomes 1. Haemoglobin (g/L) (endpoint week 36).
Not included in review:
1. Height-for-age z-score (endpoint week 36);
2. Weight-for-age z-score (endpoint week 36);
3. Weight-for-height z-score (endpoint week 36);
4. Plasma albumin (g/L) (endpoint week 36);
5. IgG (g/L) (endpoint week 36);
6. Alpha-1-acid glycoprotein (g/L) (endpoint week 36);
7. Giardia-specific IgM titre (endpoint week 36);
8. Lactulose/mannitol ratio (endpoint week 36);
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Goto 2009 (Continued)
9. Prevalence ofGiardia-specific IgM titre, % (week 0, 12, 24, 36);
10. Prevalence of Giardia cysts, % (week 0, 12, 24, 36);
11. Prevalence of Ascaris/Trichuris, % (week 0, 12, 24, 36);
12. Prevalence of Intestinal mucosal damage, % (week 0, 12, 24, 36);
13. Prevalence of Anaemia,% (week 0, 12, 24, 36).
Notes Location: Dhamrai Upazila, located 40 km northwest of Dhaka, Bangladesh
Community category: 3. “Prevalences and intensities of geohelminths were consistently
low throughout the intervention”
Drug source: Dhaka, Bangladesh (Essential Drugs Company Ltd for secnidazole; Square
Pharmaceuticals Ltd for the secnidazole placebo; Opsonin Chemical Industries Ltd for
albendazole; and UniMed and UniHealthManufacturing Ltd for albendazole placebo)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated.
Randomized on the basis of their age, sex, height-
for-age, weight-for-age and weight-for-height z-
scores, socio-demographic and economic data
and presence of any parasitic infection
Allocation concealment (selection bias) Unclear risk Unclear whether the allocation was concealed
since patients were randomized by their charac-
teristics
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind.
“Bottles containing the two medications and
placebo suspensions were labelled with different
colours corresponding to the three intervention
groups, but the assistants did not know the re-
lationship between the colour codings and the
contents of the bottles.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 394/410 (96.10%) of randomized participants
were evaluated.
“A total of 16 infants were excluded from the
trial, as they had eithermoved away from the trial
area (n = 12), or were absent during the trial pe-
riod (n = 2) or the parents subsequently refused
to participate (n = 2). Of the infants who com-
pleted the trial (n = 394), data on 96 infants was
incomplete (ie they did not provide information
for all the ten z-scores and four intestinal perme-
abilities, serological variables and prevalences of
parasite infections), and severe anaemic infants
were also omitted from the trial”. Inclusion of
all randomized participants (number evaluable/
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Goto 2009 (Continued)
number randomized): 96% (394/410)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Greenberg 1981
Methods RCT
Length of follow-up: 11 months
Participants All children living in endemic area
Number analysed for primary outcome: 152 aged 1.5 to 8 years
Age range: 1.5 to 8 years
Inclusion criteria: children aged 1.5 to 8 years living in Nandipara, Bangladesh; 50%
entered into trial; only those who provided stool sample and had anthropometric mea-
surements taken at first visit entered
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Piperazine citrate: 80 mg/kg added to flavoured syrup; 2 doses in 2-week period;
2. Placebo: syrup only.
Outcomes 1. Cure rates;
2. Reinfection rates;
3. Weight-for-height;
4. Height-for-age (NCHS reference);
5. Weight-for-age (graphically);
6. Other measured parameters not reported: weight; height; triceps skinfold
thickness; MUAC; chest circumference; abdominal girth; egg counts (Dunn’s method);
prevalence; triceps skinfold for age; MUAC for age (Tanner reference charts).
Notes Location: Bangladesh
Community category: 1
Groups stratified by intensity of Ascaris infection
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”, no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details reported.
56Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school
performance (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Greenberg 1981 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind”. Participants blinded both
placebo and treatment given as a flavoured
syrup, no information about provider and as-
sessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 82% (152/185) of randomized participants
were evaluated. Reasons for leaving the trial
early not reported. Inclusion of all randomized
participants (number evaluable/number ran-
domized): 82% (152/185)
Selective reporting (reporting bias) High risk Not all stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Hadju 1996
Methods Quasi-RCT
Length of follow-up: 1.75 months (7 weeks)
Participants All children living in endemic area
Number analysed for primary outcome: 64
Age range: 6 to 10 years
Inclusion criteria: boys aged 6 to 10 years attending second grade at 3 primary schools;
completed assessment and provided a stool sample; randomized by descending hook-
worm count (all treated)
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Pyrantel pamoate: 10 mg/kg;
2. Placebo.
Outcomes 1. Mean weight post-treatment;
2. Appetite: consumption test (mL porridge) and self assessment.
Not included in review: egg counts arithmetic and geometric means (Kato-Katz); weight-
for-age (NCHS reference)
Notes Location: Indonesia
Community category: 1
Large drops in geometric mean egg counts in placebo noted
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Hadju 1996 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomized: ”Randomly assigned“ by de-
scending A. lubricoides egg count”
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Double-blind”. Participants blinded both
placebo and treatment identical round
white tablets, no information about
provider and assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85% (64/75) of randomized participants
were evaluated. Reasons for loss to fol-
low-up included: moved away, refused to
be examined, did not return a stool sam-
ple, absent during examination. Not clear
how many lost from each treatment group.
Inclusion of all randomized participants
(number evaluable/number randomized):
85% (64/75)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Hadju 1997
Methods RCT
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 330; mean age 8.3 years
Inclusion criteria: all primary school children in grades 1, 2, and 3 in 2 schools in slum
areas in Indonesia; randomized according to Ascaris egg count and age
Exclusion criteria: children > 11; signs of puberty; signs of severe protein energy malnu-
trition
Interventions Multiple doses vs placebo
1. Pyrantel pamoate: 10 mg/kg;
2. Pyrantel pamoate: 10 mg/kg repeated at 6 months;
3. Albendazole: 400 mg;
4. Albendazole: 400 mg repeated at 6 months;
5. Placebo.
Outcomes 1. Stool (Kato-Katz) prevalence and intensity;
2. Weight;
3. Height;
4. MUAC;
5. z-scores: weight-for-age, height for age, weight-for-height, and MUAC.
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Hadju 1997 (Continued)
Results of multivariate analysis using z-scores presented and could not be used in meta-
analysis; unadjusted results not reported
Notes Location: Indonesia
Community category: 1
Placebo group showed an unexplained drop in egg counts at the 3-month exam
Source of funding: Directorate of Higher Education, Department of Education and
Culture, Government of Indonesia through Hibah Bersaing Project I & II. Albendazole
and placebo provided by Smithkline Beecham Pharmaceuticals Indonesia.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned “by sex and egg count”.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 65% (330/507) of randomized participants
were evaluated, number lost from each treat-
ment group not reported. Inclusion of all ran-
domizedparticipants (number evaluable/num-
ber randomized): 65% (330/507)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Hall 2006 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: not adjusted (review authors adjusted using the ICC
from Alderman 2006)
Cluster unit: school
Average cluster size: 33
ICCs: not reported
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 80 schools randomized containing 2659 children
in class 3
Mean age: 104.5 months
Inclusion criteria: children from class 3 and born in 1990 of 80/81 schools in the Red
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Hall 2006 (Cluster) (Continued)
River delta of north Vietnam
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
1. Albendazole (GlaxoSmithKline): 400 mg every 6 months and 200,000 IU retinol
after first 6 months only;
2. Retinol: 200,000 IU after first 6 months followed by inert placebo every 6
months.
Outcomes Measured:
1. Hookworm, Trichuris, and Ascaris prevalence;
2. Eggs/g faeces;
3. Weight and height;
4. Mathematics test score, Vietnamese test score.
Notes Location: Vietnam
Community category: 1
It is unclear what is meant by “randomization was adjusted so that there were equal
numbers of schools in each district of the trial group”. It is also appears as if the analysis
has not taken into account the effects of cluster randomization
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomization was adjusted so that there
were equal numbers of schools in each dis-
trict of the trial group” (unclear what this
means)
Allocation concealment (selection bias) Low risk Central allocation. “...using a list provided
by the Ministry of Education”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Placebo was used, blinding not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions. 80 schools containing 56,444 pupils
randomized, and those from class 3 used
in trial. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): unclear; 80 schools containing
56,444 pupils randomized, and those from
class 3 used in trial
Selective reporting (reporting bias) Low risk All stated outcomes reported.
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Hall 2006 (Cluster) (Continued)
Other bias Low risk Although not adjusted for clustering, we
used estimates to adjust in the review
Recruitment bias: low (schools)
Baseline imbalance: low (characteristics
similar)
Loss of clusters: low (no loss reported)
Incorrect analysis: not cluster adjusted
(high risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Kirwan 2010
Methods RCT
Length of follow-up: 14 months
Participants All children living in endemic area
Number analysed for primary outcome: 320
Age range: 12 to 59 months
Inclusion criteria: pre-school children aged 12 to 59 months, either sex
Exclusion criteria: severe anaemia < 5 g/dL, severe malaria
Interventions Multiple doses vs placebo
1. Albendazole;
2. Placebo.
Treatment strategy: 200 mg (one tablet) albendazole was given to children aged 1 year,
400 mg (two tablets) albendazole was given to children aged 2, 3, and 4 years. Children
who were in the placebo group were given one or two (1 year) placebo (2 to 4 years)
tablets. Treatment or placebo was given at baseline, 4, 8, and 12 months and then
followed up for the last time at 14 months. Children in the placebo group were treated
with albendazole at 14 months
Outcomes 1. Haemoglobin, measured at baseline and 4, 8, 12, and 14 months.
Unable to use: nutritional status and anthropometric measures, at baseline and 14
months, no data was reported for these outcomes
Not included in review: infection with STHs, measured at baseline and 4, 8, 12, and
14 months (eggs or worms in stool sample). Incidence of malaria and malaria attacks,
measured at baseline and 4, 8, 12, and 14 months. Adverse events not fully reported for
albendazole treatment vs placebo
Notes Location: 4 semi-urban villages, Osun State, Nigeria
Community category: 3
No adverse events reported in the albendazole treatment group. Not reported for control
group
Source of funding: Health Research Board (HRB) (Ireland). GlaxoSmithKline sponsored
the drug albendazole which was used in the trial
Risk of bias
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Kirwan 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized, “During the first assess-
ment each alternate child was assigned tablet
B”
Allocation concealment (selection bias) High risk Alternation, one of the investigators “placed
the albendazole and placebo tablets in contain-
ers labelled either A or B” later “The treatment
coordinator [...] oversaw the allocation of treat-
ments to the children”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were blinded.
“Experienced physicians […] enrolled all par-
ticipants, measured all trial endpoints, and
were kept masked to treatment allocation of
children. Field workers involved in data col-
lection and mothers of participating children
were also masked to the treatment allocation.”
“Albendazole and placebo tablets were identi-
cal”.
Incomplete outcome data (attrition bias)
All outcomes
High risk 320 children (out of 1228, 26.1%) complied
with all the follow-up assessments and were
included in the analyses. Inclusion of all ran-
domizedparticipants (number evaluable/num-
ber randomized): 26% (320/1228)
Selective reporting (reporting bias) High risk Nutritional status and anthropometric mea-
sures not reported.Main paper states these out-
comes are reported in the companion paper; no
data reported for these outcomes in the com-
panion paper
Other bias Low risk No obvious other source of bias.
Kloetzel 1982
Methods RCT
Length of follow-up: 10 months
Participants All children living in endemic area
Number analysed for primary outcome: 337; unclear how many randomized
Age range: 1 to 8 years old
Inclusion criteria: enlisted from 9 rural communities in Pariquera-Acu state of Sao Paulo
Exclusion criteria: none stated
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Kloetzel 1982 (Continued)
Interventions Single dose vs placebo
1. Mebendazole: 100 mg twice per day for 3 days;
2. Placebo.
Outcomes 1. Weight;
2. Height;
3. Head, chest, and mid-arm circumference;
4. Triceps skinfold;
5. Stool egg counts (Kato-Katz).
Notes Location: Cameroon
Community category: 1
Results reported as changes in nutritional status grouped into 3 categories: improved,
deteriorated, no change (unclear onbasis ofwhich parameter), andproportions compared
Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”, no further details provided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind, no details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details about losses to follow-up reported;
“the present report only deals with those 337
that could be followed throughout the entire
10 months”. Inclusion of all randomized par-
ticipants (number evaluable/number random-
ized): unclear (337 analysed)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other sources of bias.
Koroma 1996
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 187
Age range: 6 to 10 years
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Koroma 1996 (Continued)
Inclusion criteria: selected (unclear how) urban and rural school primary children aged
6 to 10 years
Exclusion criteria: not stated
Interventions Single dose vs placebo
1. Albendazole: 400 mg;
2. Placebo.
Outcomes 1. Prevalence and intensity (arithmetic mean eggs/g);
2. z-scores (no reference category stated): weight-for-height, weight-for-age, and
height-for-age.
Notes Location: Sierra Leone
Community category: 2
Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”, no further details provided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 76%(187/247) of randomizedparticipantswere
evaluated. Reasons for loss to follow-up not re-
ported. Inclusion of all randomized participants
(number evaluable/number randomized): 76%
(187/247)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other sources of bias.
Kruger 1996
Methods RCT
Length of follow-up: 11 months
Participants All children living in endemic area
Number analysed for primary outcome: 74
Age range: 6 to 8 years
Inclusion criteria: 65 pupils in first year of school randomly selected from each of 5
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Kruger 1996 (Continued)
primary schools; schools included in a feeding scheme
Exclusion criteria: age > 9 years; current use of iron supplements; inclusion in an iron
fortification trial; infection (raised white cell count)
Interventions Multiple doses vs placebo
1. Albendazole: 2 x 200 mg repeated at 4 months, daily unfortified soup;
2. Placebo: daily unfortified soup.
Also: whole population
3/5 schools also allocated soup fortified with 20 mg elemental iron per day, and 100 mg
vitamin C for 6 months; unclear whether this intervention was cluster randomized. All
schools taking part in feeding programme providing bread, soup, and peanut butter to
all pupils
Outcomes 1. Mean change in weight post-treatment;
2. Mean change in height post-treatment;
3. Mean change in haemoglobin post-treatment;
4. School attendance.
Not included in review: other iron indices; stool egg counts (Visser filter method); z-
scores for weight-for-age, height for age, and weight-for-height
Notes Location: South Africa
Community category: 3
In the Dickson 2000a Cochrane Review, the data were combined irrespective of the pos-
sible confounding effects of iron allocation; data extracted for albendazole-iron placebo
vs placebo-placebo groups only for this review
Data stratified by baseline iron stores into 2 groups that were combined for meta-analysis
Source of funding: Fortified and unfortified soup provided by Funa Foods, Zentel and
placebo provided by SmithKline Beecham Pharmaceuticals (Pty) Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”, no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 72% (179/247) of randomized participants
were evaluated. Reasons for loss to follow-up
not reported. Inclusion of all randomized par-
ticipants (number evaluable/number random-
ized): 72% (179/247)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
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Kruger 1996 (Continued)
Other bias Low risk No obvious other source of bias.
Kvalsvig 1991a
Methods RCT
Length of follow-up: 1 month
Participants Infected children identified by screening
Number analysed for primary outcome: unclear
Age range: unclear
Inclusion criteria: most severely infected 100 children in a primary school
Exclusion criteria: children with schistosomiasis
Interventions Single dose vs placebo
1. Mebendazole: 500 mg;
2. Placebo.
Outcomes 1. Cognition tests: card sorting task (coloured cards; cancellation task - striking out
of letter ’s’ in text, number done in a period)
Not included in review: height; weight at baseline; standardized using NCHS standards;
stool examination (intensity index designed for this trial); no nutritional outcomes re-
ported that can be used in the review
Notes Location: South Africa
Community category: 1
No data used in meta-analysis since SDs not provided.
Source of funding: Janssen Pharmaceutica, South African Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assigned randomly”, no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “A ’blind’ procedure was adopted; the research
assistant did not know whether a particular child
had received drug or placebo”. No further details
provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details reported. Inclusion of all random-
ized participants (number evaluable/number ran-
domized): unclear
Selective reporting (reporting bias) Low risk All stated outcomes reported.
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Kvalsvig 1991a (Continued)
Other bias Low risk No obvious other source of bias.
Lai 1995
Methods Quasi-RCT
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 314
Mean age: 8 years
Inclusion criteria: school children aged 8 who provided a stool sample
Exclusion criteria: concurrent illness; anthelminth treatment in previous 3 months
Interventions Multiple doses vs placebo
1. Mebendazole plus pyrantel: 100 mg mebendazole and 200 mg pyrantel every 3
months for 2 years;
2. Placebo: every 3 months for 2 years.
Outcomes Measured:
1. Hookworm, Trichuris, and Ascaris prevalence;
2. Eggs/g faeces;
3. Weight and height.
Notes Location: Malaysia
Community category: 1
No data used in meta-analysis since SDs not provided
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized: block assignment de-
sign by school, then by sex, then by presence
of worms as none, light, or moderate/heavy,
and then by rank order of body weight in
the group; used odd and even numbers; in
urban area the odd numbered children were
assigned to treatment; in the peri-urban area
the even numbered children were assigned
to the treatment group
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were blinded; trial staff not
blinded to group assignment
67Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school
performance (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Lai 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89% (314/353) of randomized participants
were evaluated.
Inclusion of all randomized participants
(number evaluable/number randomized):
89% (314/353)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other sources of bias.
Le Huong 2007
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area (children screened for anaemia then randomized and
all children treated)
Number analysed for primary outcome: 510 randomized
Mean age: ~7.3 years
Inclusion criteria: children in Grades 1 to 3 with haemoglobin < 110 g/L but not < 70
g/L
Exclusion criteria: haemoglobin concentrations < 70 g/L
Interventions Multiple dose vs placebo
Factorial design
Mebendazole 500 mg at 0 and 3 months
1. Iron-fortified noodles and mebendazole 500 mg;
2. Noodles without iron fortificant and mebendazole 500 mg;
3. Iron-fortified noodles and placebo;
4. Noodles without iron fortificant and placebo; and
5. Iron supplementation and mebendazole 500 mg.
Outcomes 1. Haemoglobin - change;
2. Prevalence of underweight, stunting and wasting (defined as -2SD for weight-for-
height, height-for-age and weight-for- age using WHO/NCHS reference data).
Not included in review: Ferritin; serum transferrin; worm prevalence; CRP
Notes Location: Vietnam
Community category: 2
Source of funding: Neys-van Hoogstraten Foundation, Ellison Medical Foundation and
the Ministry of Education and Training, Vietnam
Risk of bias
Bias Authors’ judgement Support for judgement
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Le Huong 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomized, no further details.
Allocation concealment (selection bias) Low risk Central allocation. “Randomization was carried
out by a researcher [...] who did not know the
children and could not introduce bias in the ran-
domization”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel blinded. “Chil-
dren, teachers and researchers were blinded to
the treatment”
Placebo identical to intervention drug.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 409/425 participants were evaluated. Reason for
drop-out: refusal (n = 16, intervention: 4.7%,
placebo: 2.3%). Inclusionof all randomizedpar-
ticipants (number evaluable/number random-
ized): 96% (409/425)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other sources of bias.
Michaelsen 1985
Methods RCT
Length of follow-up: 5 months
Participants All children living in endemic area
Number analysed for primary outcome: 121 for nutritional outcomes
Age range: 5 to 14 years
Inclusion criteria: children from a school identified as having high prevalence of hook-
worm on the basis of a previous survey
Exclusion criteria: children with height above 137 cm girls and 145 cm for boys since
these were the upper limits in the reference ranges
Interventions Single dose vs placebo
1. Tetrachloroethylene: 0.1 mL/kg (max 5 mL dose);
2. Placebo: children’s cough medicine.
Outcomes Measured:
1. Stool: prevalence in subgroup;
2. Haemoglobin;
3. Weight;
4. Height;
5. Weight-for-height (WHO reference median 1983).
Reported:
1. Stool prevalence (graph) with 95% CIs;
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Michaelsen 1985 (Continued)
2. Haemoglobin mean and difference (no SD);
3. Weight-for-height %, mean and difference (no SD).
Notes Location: Botswana
Community category: 1
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Random sample of half the children” were give
the treatment and the remaining the placebo; no
further details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 53%(121/228) of randomizedparticipantswere
evaluated. Inclusion of all randomized partici-
pants (number evaluable/number randomized):
53% (121/228)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other sources of bias.
Miguel 2004 (Cluster)
Methods Cluster quasi-randomized stepped-wedge trial
Method to adjust for clustering: CIs adjusted for clustering in regression modelling,
robust standard errors presented (confirmed in correspondence with authors)
Cluster unit: schools
Average cluster size: 400
ICCs: not reported
Length of follow-up: one year for phased quasi-randomized comparisons for health
outcomes. Two years for school attendance
Participants All children living in endemic area
Number analysed for primary outcomes: 75 primary schools randomized containing 778
children analysed for haemoglobin. 9102 children analysed for weight and height, 32%
and 34% of eligible population analysed for exam performance and cognitive tests, and
100% of eligible population analysed for school attendance
Age range/mean age: school children 12 years or under
Inclusion criteria: children from 75 primary schools in the trial area
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Miguel 2004 (Cluster) (Continued)
Exclusion criteria: girls > 13 years old
Interventions Deworming package of interventions vs no treatment
1. Albendazole 600 mg (Zentel, SZB) every 6 months in 1998 intervention, and
albendazole 400 mg (Zentel, SZB) in 1999; plus a) worm prevention education b)
schools with schistosomiasis prevalence over 30% were mass treated with praziquantel
(40 mg/kg Bayer) annually; 6/25 schools treated with praziquantel in 1998, and 16/50
treated with praziquantel in 1990;
2. No treatment.
Outcomes 1. Weight-for-age z-score - change;
2. Haemoglobin - change;
3. Exam score performance (ICS administered English, Mathematics and Science-
Agriculture exams in pupils in grades 3 to 8);
4. Cognitive tests including picture search, Raven matrix, verbal fluency, digit span,
Spanish learning, and a dynamic test using syllogisms;
5. Height-for-age z-score - change;
6. School participation rate based on external NGO assessment at unannounced
visit.
Not included in review: worm prevalence and intensity, self reported sickness, worm
prevention behaviours: proportion “clean” as per health worker observation, proportion
wearing shoes as per health worker observation, self-reported contact with fresh-water
in past week, access to home latrine, malaria/fever
Notes Location: Kenya
Community category: 1
Source of funding: Sponsored by the World Bank and the Partnership for Child Devel-
opment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Schools in a deworming project were strat-
ified by zone, their involvement with other
NGO programmes, and then listed alpha-
betically and every third school assigned to
start the programme in 1998, to start it in
1999, or to be a control
Allocation concealment (selection bias) High risk Not concealed (see above).
Blinding (performance bias and detection
bias)
All outcomes
High risk Pragmatic cluster implementation trial
with no blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk For haemoglobin, weight and height the
outcomes have beenmeasured on a random
sub-sample of the quasi-randomized pop-
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Miguel 2004 (Cluster) (Continued)
ulation
Selective reporting (reporting bias) Low risk Outcome data not reported for cognitive
tests, though authors state: Deworming
treatment effects are not significantly dif-
ferent than zero for any component of
the cognitive exam (results available on re-
quest)
Other bias High risk Recruitment bias: low (no asymmetric mi-
gration between schools)
Baseline imbalance: low
Loss of clusters: low (none reported)
Incorrect analysis: low (correctly adjusted
for clustering).
Comparability with RCTs randomizing in-
dividuals: low
Other sources of bias: high for confounding
due to a co-intervention. The drug inter-
vention is accompanied by intensive health
promotion that could account for some of
the effectswith key outcomes such as school
attendance
Ndibazza 2012
Methods RCT
Length of follow-up: 5 years
Participants All children living in endemic area
Number analysed for primary outcome: 1423
Mean age: 15 months (randomized at 1.5 years)
Inclusion criteria: 15 month old children whose mothers participated in the pregnancy
phase of the trial (pregnant healthy women from the area, planning to deliver at Entebbe
Hospital)
Exclusion criteria: none stated
Interventions Multiple dose vs placebo
Factorial designa
1. Albendazole: 200 mg quarterly from age 15 to 21 months; 400 mg quarterly from
age 2 to 5 years;
2. Matching placebo.
aMothers when pregnant had been randomized in a 1:1:1:1 ratio to receive single-dose
albendazole (400 mg) + praziquantel (40 mcg/kg), albendazole + praziquantel placebo,
albendazole placebo + praziquantel, or albendazole placebo + praziquantel placebo
Outcomes 1. Weight-for-age z-score;
2. Height-for-age z-score;
3. Weight-for-height z-score;
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Ndibazza 2012 (Continued)
4. Haemoglobin;
5. Cognitive tests including Block design, Picture vocabulary scale, Sentence
repetition, Verbal fluency, Counting span, Running memory, Picture search,
Wisconsin card sort test, Tap once tap twice task, Shapes task, Tower of London;
6. Serious adverse events;
7. Death.
Not included in review: immune response at age 5 years to BCG and tetanus immuni-
sation, incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis, measures
of fine motor function and gross motor function
Notes Location: Entebbe, Uganda
Community category: 3
Source of funding: Wellcome Trust
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization code generated by statistician us-
ing Stata version 7
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and provider blinded.Not reported for
assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Inclusion of all randomized participants (num-
ber evaluable/number randomized): 71% (1423/
2016) of randomized participants
Selective reporting (reporting bias) High risk Serious adverse events not reported.
Other bias Low risk No other obvious source of bias.
Nga 2009
Methods RCT
Length of follow-up: 4 months
Participants All children living in endemic area
Number analysed for primary outcome: 510 randomized
Age range: 6 to 8 years
Inclusion criteria: school children aged 6 to 8 years and written informed consent from
parents/caregivers
Exclusion criteria: haemoglobin concentrations < 80 g/L, chronic illness, congenital
abnormalities, mental or severe physical handicap, severe malnutrition ([z-scores for
weight-for-height (WHZ) < -3.0 SD), obesity (BMI ≥ 25 or z-scores for WHZ > +2
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Nga 2009 (Continued)
SD), or receiving deworming within the previous 6 months
Interventions Single dose vs placebo
1. Non-fortified biscuit plus placebo deworming-treatment (placebo);
2. Multi-micronutrient-fortified biscuit plus placebo deworming-treatment;
3. Non- fortified biscuit plus deworming treatment with albendazole (400 mg);
4. Multi-micronutrient-fortified biscuits plus deworming treatment with
Albendazole (400 mg).
Outcomes 1. Haemoglobin;
2. Mean MUAC;
3. Cognitive function;
4. Change in weight-for-age (WAZ), height-for-age (HAZ), and WHZ, using the
EpiInfo program (version 6.0, CDC) and the National Center for Health Statistics/
WHO nutritional reference data.
Not included in review: changes in zinc, iodine, and ferritin concentration; worm preva-
lence
Measured but not reported: weight and height recorded at baseline and end point but
only baseline data reported. Skin fold thickness recorded at baseline and end point, but
no data reported
Notes Location: Vietnam
Community category: 2
This trial was supported by the Neys-van Hoogstraten Foundation, The Netherlands,
and the Ellison Medical Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. “pupils were allocated to
1 of the 4 intervention groups based on a com-
puter generated list, matched on age (12-mo age
groups) and sex, and using a block size of 8 by
one of the researchers not involved in the field
work”
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were blinded.
“All investigators, field assistants, teachers, and
children did not know the codes of the trial
groups”
Placebo identical to treatment (orange chewable
tablet).
Incomplete outcome data (attrition bias)
All outcomes
Low risk 482/510 randomized participants were evalu-
ated. Reasons for drop-out: moved (n =12),
surgery (n = 2), refusal to participate (n = 14)
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Nga 2009 (Continued)
, balanced across intervention groups. Inclusion
of all randomized participants (number evalu-
able/number randomized): 94.5% (482/510)
Selective reporting (reporting bias) High risk Three outcomes (weight, height and skin fold
thickness) not reported adequately
Other bias Low risk No obvious other source of bias.
Nokes 1992
Methods RCT
Length of follow-up: 2.25 months (9 weeks)
Participants Infected children identified by screening
Number analysed for primary outcome: 103
Age range: 9 to 12 years
Inclusion criteria: children from 3 schools in Mandeville; Trichuris egg counts > 1900,
but low hookworm counts on 2 occasions before the trial separated by 3 months
Exclusion criteria: twins; severe illness; physical handicaps; neurological disorders
Interventions Single dose vs placebo
1. Albendazole: 400 mg daily for 3 days (SmithKlineBeecham);
2. Placebo: identical.
Outcomes Cognitive tests: digit span forwards/backwards; arithmetic and coding from Wechsler
Intelligence Scale for Children; fluency and listening comprehension from the Clinical
Evaluation of Language functions; and matching familiar figures test
Not included in review: stool egg counts at baseline and 10 days (prevalence and arith-
metic mean); height and weight (expressed as % NCHS standard) iron status; school
attendance; IQ; socioeconomic status; educational opportunity measures at baseline
Outcomes not reported: nutritional outcomes at 9 weeks cited as too short a follow-up
period to demonstrate a change;school attendance only measured at baseline
Notes Location: Jamaica
Community category: 1
There was an infected placebo group and an “uninfected control group”
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”; no further details re-
ported.
Allocation concealment (selection bias) Unclear risk No details reported.
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Nokes 1992 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 73%(103/140) of randomizedparticipants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 73% (103/140)
Selective reporting (reporting bias) Unclear risk Pyschometric tests reported; other out-
comes such as nutrition not reported
Other bias Low risk No obvious other source of bias.
Olds 1999
Methods RCT
Length of follow-up: 6 months for randomized comparison
Participants All children living in endemic area
Number analysed for primary outcome: 1518 randomized, 90% followed up at 6months
Age range/mean age: 10.5 years
Inclusion criteria: school age children
Exclusion criteria: failure to submit 2 stool specimens prior to the initial treatment,
known allergy to either drug, treatment with either drug within 6 months, lack of
consent, and marriage or possible pregnancy
Interventions Single dose vs placebo
Albendazole (400 mg) plus praziquantel (40 mg/kg)
Praziquantel plus an albendazole placebo
Albendazole plus a praziquantel placebo
Both placebos
Outcomes No useable data.
Not included in review: ultrasound, physical examination and history findings, duplicate
stool and urine measurements of egg counts
Measured but not reported: weight, height, skinfold thickness (subscapular, triceps, and
abdominal) and haemoglobin recorded at baseline and end point but only baseline data
reported; data for side effects not useable in review
Notes Location: China, Philippines and Kenya
Community category: 1 randomized comparison up to 6 months at which point all
infected children were treated as needed, and followed up until one year
There was no difference between the side effect rate from albendazole or the double
placebo
Result text: “No statistically significant improvement was seen in haemoglobin after al-
bendazole treatment. In the trial population as awhole, no significant differences between
treatment groups were seen in any of the growth and anthropometric measurements.”
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Olds 1999 (Continued)
Source of funding: Tropical Disease Research of the WHO.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. “Randomization lists
were prepared byWHO/TDR using a ran-
domized block design with a block size of
80”
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, key personnel, and outcome
assessment was blinded. “The randomiza-
tion code was not broken until after the 6-
month results were tabulated and submit-
ted to WHO”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1518 participants, 90% at 6 months fol-
low-up, 83% at one year, no further de-
tails. Inclusion of all randomized partici-
pants (number evaluable/number random-
ized): 90% (1366/1518)
Selective reporting (reporting bias) High risk Weight, height, skinfold thickness, and
haemoglobin recorded at baseline and end
point but only baseline data reported
Other bias Low risk No obvious other source of bias.
Palupi 1997
Methods RCT
Length of follow-up: 9 weeks (2.25 months)
Participants All children living in endemic area
Number analysed for primary outcome: 191
Age range: 2 to 5 years
Inclusion criteria: children ages 2 to 5 years registered at village health centres
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Albendazole: 400 mg plus 30 mg elemental iron weekly;
2. Elemental iron: 30 mg weekly.
Outcomes 1. Mean change in weight post-treatment;
2. Mean change in height post-treatment;
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Palupi 1997 (Continued)
3. Mean change in haemoglobin post-treatment;
4. Mean haemoglobin post-treatment.
Not included in review: z-scores for height-for-age, weight-for-age, andweight-for-height
(NCHS reference)
Notes Location: Java, Indonesia
Community category: 2
Source of funding: Kimia Farma Indonesia.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The children were randomly divided into
three, equal-sized treatment groups”. No
further details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double blind. Participants
were blinded, unclearwhether provider and
assessor were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97% (289/299) of enrolled participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 97% (289/299)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other source of bias.
Rousham 1994 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: not adjusted
Cluster unit: village
Average cluster size: 114
ICCs: not reported
Length of follow-up: 18 months
Participants All children living in endemic area
Number analysed for primary outcome: 13 villages randomized containing 1402 children
Age range: 2 to 6 years
Inclusion criteria: children ages 2 to 6 years from 13 villages surrounding a mother and
child health centre; subgroup living in 8 villages within waking distance of health centre
analysed for additional outcomes
Exclusion criteria: none stated
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Rousham 1994 (Cluster) (Continued)
Interventions Multiple doses vs placebo
1. Mebendazole: 500 mg (Janssen) every 2 months;
2. Placebo;
3. Pyrantel pamoate and mebendazole: initial dose of 10 mg/kg pyrantel pamoate
(Combantrin, Pfizer, UK) then mebendazole 500 mg bimonthly for 8 months (4
doses).
Outcomes 1. ANOVAs for change in z-scores for z-scores for height-for-age, weight-for-age,
and weight-for-height (NCHS reference);
2. Change in MUAC at 6, 12, and 18 months (no SD);
3. Other outcomes measured but not reported: height; weight; stool examination for
prevalence and intensity in subgroup (eggs/g: modified sedimentation technique);
subgroup also analysed for intestinal permeability, albumin, alpha-1-antichymotrypsin,
total protein every 2 months.
Notes Location: Bangladesh
Community category: 1
No adjustment made for cluster randomization
Source of funding: the Overseas Development Administration and the University of
Cambridge Maintenance Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial was described as randomized, no
further details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and field
workers were blinded, unclear if assessment
was blinded. “The treatment and placebo
tablets were given in a double-blind man-
ner; neither the fieldworkers nor the par-
ents were aware of the group to which they
belonged”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94% (1402/1476) of enrolled participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 94% (1402/1476)
Selective reporting (reporting bias) Low risk Not all pre-specified outcomes reported.
Other bias Low risk Recruitment bias: unclear (not known if
children shift clinics in the light of the in-
tervention)
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Rousham 1994 (Cluster) (Continued)
Baseline imbalance: low (no differences ap-
parent)
Loss of clusters: low (none reported)
Incorrect analysis: not adjusted (high risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Sarkar 2002
Methods RCT
Length of follow-up: 4 months (16 weeks)
Participants Infected children identified by screening
Number analysed for primary outcome: 81
Age range: 2 to 12 years
Inclusion criteria: children ages 2 to 12 living in Mirpur slum infected with Ascaris
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Pyrantel pamoate: 11 mg/kg (Combantrin, Pfizer, Bangladesh);
2. Placebo.
Outcomes 1. Mean change in weight post-treatment;
2. Mean weight post-treatment;
3. Mean change in height post-treatment;
4. Mean height post-treatment.
Not included in review: median % weight-for-age, weight-for-height, and height-for-
age
Notes Location: Bangladesh
Community category: 1
Source of funding: research grant from theWorldBank andwas fundedby theBangladesh
National Nutrition Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random table”.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind”; “The syrups were identi-
cal in appearance and flavor and were pack-
aged in identical containers. Randomized
patient numbers were labeled on the bot-
tles to maintain the double blind design”
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Sarkar 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94% (81/85) of randomized participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 94% (81/85)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other source of bias.
Simeon 1995
Methods RCT
Length of follow-up: 6.5 months (26 weeks)
Participants Infected children identified by screening
Number analysed for primary outcome: 392
Age range: 6 to 12 years
Inclusion criteria: children in grades 2 to 5 of 14 schools in Jamaica with intensities of
Trichura > 1200 eggs/g
Exclusion criteria: children with mental handicaps identified by their teachers
Interventions Multiple doses vs placebo
1. Albendazole: 800 mg (400 mg in each of 2 days), repeated at 3 months and 6
months;
2. Identical placebo.
Outcomes 1. Main trial (264 children)
Wide range achievement test: reading, arithmetic, and spelling subtests; school atten-
dance from children with class registers pre- and post-intervention, height-for-age z-
score, body mass index pre- and post-intervention
2. Subgroup 1 (189 infected children from original population)
Digit span; verbal fluency test; visual search; number choice; French vocabulary learning
3. Subgroup 2 (97 children from grade 5)
French learning; digit spans (forward and backward); Corsi block span; verbal fluency;
picture search; silly sentences
Other outcomes measured but not reported: stool at baseline and at 8 weeks after sec-
ond treatment round (Kato): prevalence and intensity, weight, height, z-scores (NCHS
standard)
Notes Location: Jamaica
Community category: 1
Source of funding: grant from the James S. McDonnell Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
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Simeon 1995 (Continued)
Random sequence generation (selection
bias)
Low risk Random-numbers table.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Paricipants blinded; unclear whether asses-
sors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96%(392/407) of randomizedparticipants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 96% (392/407)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Solon 2003
Methods RCT
Length of follow-up: 16 weeks
Participants All children living in endemic area
Number analysed for primary outcome: 808/851
Age range/ mean age: 10 years
Inclusion criteria: Children in grades 1 to 6
Exclusion criteria: Children with Haemoglobin < 8 g/dL
Interventions Single dose vs placebo
1. Fortified beverage (multivitamin and iron) twice per day for 16 weeks with
anthelmintic therapy (Albendazole 400 mg);
2. Fortified beverage with placebo anthelmintic therapy;
3. Non-fortified beverage with anthelmintic therapy (400 mg);
4. Non-fortified beverage with placebo anthelmintic therapy.
Outcomes No useable data
Not included in review: urine iodine, stool egg count.
Measured but not reported: weight, height, haemoglobin, physical fitness (Harvard step
test), heart rate, cognitive ability measured by the Primary Mental Abilities Test for
Filipino Children. The test measures verbal, non verbal and quantitative skills
Notes Location: Philippines
Community category: 2
Narrative results:
No significant difference in change in weight. Deworming improved the iron status of a
subgroup ofmoderately to severely subjects. Deworming had either no effect or a negative
effect on fitness scores, and the effect on heart rate was inconclusive. Deworming had
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Solon 2003 (Continued)
either no effect or a negative effect on mental ability scores
Sources of support: The Nutrition Center of the Philippines, The Procter & Gamble Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization at individual level, no further de-
tails.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind trial. “Both the researchers and the
trial participants were blinded to the treatment
assignment of each child”
“Placebo beverage and placebo anthelmintic pills
were indistinguishable from their counterparts
in appearance, smell and taste”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 808/851 (95%) enrolled participants were eval-
uated, no reasons for withdrawal reported. In-
clusion of all randomized participants (number
evaluable/number randomized): 95% (808/851)
Selective reporting (reporting bias) High risk Nutritional andhaemoglobin outcomes not fully
reported.
Other bias Low risk No obvious other source of bias.
Stephenson 1989
Methods RCT
Length of follow-up: 6 months
Participants Infected children (all children in the school were known to be infected)
Number analysed for primary outcome: 150
Age range/mean age: 8.5 years
Inclusion criteria: all available children in lower grades (standards 1 and 2) in Mvindeni
Primary School, Kwale district (unscreened); subgroup of 36 boys chosen; haemoglobin
> 8 g/dL; willing to co-operate in physical tests; pre-pubertal
Exclusion criteria: haemoglobin < 8 g/dL
Interventions Single dose vs placebo
1. Albendazole: 2 x 200 mg (SmithKline and French);
2. Placebo: identical.
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Stephenson 1989 (Continued)
Outcomes 1. Mean weight post-treatment;
2. Mean change in weight post-treatment;
3. Mean height post-treatment;
4. Mean change in height post-treatment;
5. Mean MUAC;
6. Mean change in MUAC;
7. Mean triceps skinfold thickness;
8. Mean change in triceps skinfold thickness;
9. Mean subscapular skinfold thickness;
10. Mean change in subscapular skinfold thickness;
11. Harvard step test.
Not included in review: all above converted to % median for sex and age; prevalence
and mean egg counts (arithmetic and geometric means) Test heart rates and score for
subgroup
Notes Location: Kenya
Community category: 1
Source of funding: Smith Kline & French Laboratories, Ltd., and the Edna McConnell
Clark Foundation, grant 284-0120
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “allocated at random within sex”, no further de-
tails reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, tablets identical for treat-
ment andplacebo; “Both examinationswere car-
ried out with the same team of workers, each
doing the same procedures, and were done in a
blind fashion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88%(150/171) of randomizedparticipantswere
evaluated, reasons for losses to follow-up not re-
ported. Inclusion of all randomized participants
(number evaluable/number randomized): 88%
(150/171)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported.
Other bias Low risk No obvious other source of bias.
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Stephenson 1993
Methods RCT
Length of follow-up: 3.6 months (subgroup) and 8.2 months (main trial)
Participants Infected children (all children in the school were known to be infected)
Number analysed for primary outcome: 284
Age range/ mean age: 7 to 13 years
Inclusion criteria: all school children (unscreened) in grades 1 to 5 in Mvindeni Primary
School
Subgroup (53 analysed) of 60 boys chosen because haemoglobin > 80 g/L, willing to
cooperate in physical tests and appetite tests, pre-pubertal, infected with at least 1 of
helminths (screened), hookworm < 20,000 eggs/g; hookworm or Trichuris count > 1000
eggs/g or Ascaris > 4000 eggs/g
Exclusion criteria: Severe anaemia (haemoglobin < 75 g/L)
Interventions Multiple doses vs placebo
1. Albendazole (single dose) plus placebo: 600 mg (3 x 200 mg) SmithKline
Beecham at outset, identical placebo at 3.6 months;
2. Albendazole (multiple doses): single dose 600 mg repeated at 3.6 months;
3. Placebo: identical placebo.
Outcomes 1. Mean weight post-treatment;
2. Mean change in weight post-treatment;
3. Mean height post-treatment;
4. Mean change in height post-treatment;
5. Mean MUAC;
6. Mean change in MUAC;
7. Mean triceps skinfold thickness;
8. Mean change in triceps skinfold thickness;
9. Mean subscapular skinfold thickness;
10. Mean change in subscapular skinfold thickness;
11. Mean haemoglobin post-treatment;
12. Mean change in haemoglobin post treatment;
13. Harvard step test.
Not included in review: prevalence, eggs/g: geometric and arithmetic mean; converted
to percentage of median for age and sex using NCHS references; % weight-for-age, %
height for age; % weight-for-height; % arm circumference for age; % triceps for age; %
subscapular for age; appetite (self-rating and snack consumed intake in kJ)
Notes Location: Kwale, Kenya
Community category: 1
Source of funding: supported in part by Thrasher Research Fund and SmithKline
Beecham, Ltd.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “at randomwithin sex by descending hook-
worm egg count”.
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Stephenson 1993 (Continued)
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, tablets identical for
treatment and placebo; “Both examina-
tions were conducted by the same team,
each doing the same procedures, and were
done in a blind fashion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 86%(284/328) of randomizedparticipants
were evaluated, reasons for losses to follow-
up not reported. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 86% (284/328)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk No obvious other source of bias
Stoltzfus 1997 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: generalised estimating equations
Cluster unit: school
Average cluster size: 255
ICCs: not reported
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 12 schools randomized containing 3063 children
Mean age: 10.5 years
Inclusion criteria: children in grades 1 to 5 from 12 randomly selected schools on Pemba
island; only grades 1 to 4 included in evaluation of nutritional effect
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
1. Mebendazole: 500 mg twice yearly;
2. Mebendazole: 500 mg 3 times a year;
3. Placebo.
Outcomes 1. Weight gain;
2. Height gain;
3. Change in haemoglobin at 12 months.
Estimates are provided from multiple regression models taking into account various
baseline differences for 2 subgroups above and below 10 years old. Unadjusted outcomes
not presented. (These 2 groups were combined in the Dickson 2000a Cochrane Review.
)
Other outcomes measured but not reported: micronutrient status (blood) for protopor-
phyrin and serum ferritin; stool egg count (Kato-Katz); z-scores for height-for-age and
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Stoltzfus 1997 (Cluster) (Continued)
weight-for-height; body mass index
Notes Location: Zanzibar, Tanzania
Community category: 1
Appropriate adjustment made for cluster randomization using general estimating equa-
tion
Source of funding: funded through cooperative agreement DAN-5116-1-00-8051-00
between The Johns Hopkins University and the Office of Health and Nutrition, United
States Agency for International Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 3 schools randomly selected from each of
the 4 districts, and then allocated
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84% (3063/3605) of randomized partici-
pants were evaluated, reasons for losses to
follow-upnot reported. Inclusionof all ran-
domized participants (number evaluable/
number randomized): 84% (3063/3605)
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported ad-
equately.
Other bias Low risk Recruitment bias: low (Unlikely to change
schools)
Baseline imbalance: low (no differences ap-
parent)
Loss of clusters: low (none reported)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
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Stoltzfus 2001
Methods RCT (factorial design)
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 359 in Mebendazole arm aged 6 to 59 months
Age range: 3 to 56 months
Inclusion criteria: all children in Kengeja village, with age reported as 3 to 56 months
by parents; 3 months before planned start of trial (pre-school children)
Exclusion criteria: severe anaemia (< 70 g/L)
Interventions Multiple doses vs placebo
1. Mebendazole: 500 mg given every 3 months at home visits;
2. Placebo: identical.
Treatment strategy: randomized and treated all children
Both groups also received: 0.5 mL ferrous sulfate (20 mg/mL); 10 mg iron daily for 1
year or placebo as per factorial design
Outcomes 1. Cognitive outcomes: motor and language development by parents reporting gross
motor and language milestones using scoring system developed specifically for the trial;
2. Anthropometric measures presented in a stratified manner: (< 30 months, > 30
months), and presented as proportion of children with small arm circumference, mild
wasting, and stunting;
3. Proportion of children with poor appetite, and proportion with severe anaemia
are presented for the whole group;
4. Iron indices (not disaggregated, independent of the iron randomization).
Not included in review: prevalence and egg counts (no SD/SEM); motor and language
scores (results of multiple regression and correlations; raw data not reported) haemoglo-
bin (results not reported by randomized comparisons)
Others measured but not reported: stool (Kato-Katz); weight; height; malaria film; fer-
ritin; appetite as reported by mothers
Notes Location: Zanzibar, Tanzania
Community category: 2
Factorial design, with households randomized to iron, random allocation of mebenda-
zole by child, stratified by iron allocation and age grouped households. An iron with
mebendazole treatment term was tested in all regression models, but it did not reach
significance
Source of funding: Thrasher Research Fund between The Johns Hopkins University and
the United States Agency for International Development, AL Pharma, Baltimore, MD,
and Pharmamed, Malta
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized by “blocks of 4”, no further
details reported.
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Stoltzfus 2001 (Continued)
Allocation concealment (selection bias) Low risk Pills in bottles with unique treatment
codes, assignedby 1 investigator, codes kept
in sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and provider were blinded; un-
clear whether assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 52% (359/684) enrolled participants were
evaluated. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): 52% (359/684 = 52%)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported.
Other bias High risk No obvious other source of bias.
Sur 2005
Methods RCT
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 683
Age range: 2 to 5 years
Inclusion criteria: all children aged 2 to 5 in slum area of Tiljala identified and enrolled
Exclusion criteria: major illnesses; birth defects; and unwillingness to participate
Interventions Multiple doses vs placebo
1. Albendazole: 400 mg in a vitamin B complex base liquid; repeated at 6 months;
2. Placebo: vitamin B complex base.
Outcomes 1. Mean weight post-treatment (presented graphically).
Other outcomes measured but not reported: stool samples from random sample of 30%
(formalin concentration technique) for prevalence of Ascaris; weight-for-age; diarrhoeal
episodes
Notes Location: India
Community category: 2
Source of funding: Indian Council of Medical Research, New Delhi, India
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers se-
quence.
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Sur 2005 (Continued)
Allocation concealment (selection bias) Low risk Identical coded bottles.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97% (683/702) of enrolled participants were
evaluated. Inclusion of all randomized partici-
pants (number evaluable/number randomized)
: 97% (683/702)
Selective reporting (reporting bias) High risk Incomplete reporting of some outcomes
(prevalence of Ascaris in stools; weight-for-age;
diarrhoeal episodes).
Other bias Low risk No obvious other source of bias.
Tee 2013
Methods RCT
Length of follow-up: 12 months
Participants Infected children identified by screening
Mean age: 7.3 years
Number analysed for primary outcome: 33
Inclusion criteria: children with confirmed Trichus trichiura in a rural school
Exclusion criteria: none reported
Interventions Single dose vs placebo
1. Albendazole: 2 x 400 mg doses on 2 consecutive days;
2. Placebo.
Outcomes 1. Mean change in height;
2. Median change in weight;
3. Weight-for-age z-score;
4. Height-forage z-score;
5. Weight-for-height z-score.
Not included in review: urinary TNF-alpha levels
Notes Location: Sekolah Rendah Kebangsaan Tawang, Kelantan, Malaysia
Community category: NA
Source of funding: Universiti Sains Malaysia Short Term Grant
Risk of bias
Bias Authors’ judgement Support for judgement
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Tee 2013 (Continued)
Random sequence generation (selection
bias)
Low risk Randomization software was used.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk For participants and assessors, no details were
reported. “
Both the active drug and placebo were repack-
aged by a pharmacist blinded to the trial
groups”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 33/37 participants analysed for the primary
outcome; reasons for loss to follow-up unclear
Inclusion of all randomized participants (num-
ber evaluable/number randomized): 89% (33/
37)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Watkins 1996
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 226 for nutritional outcomes, reduced for cog-
nitive outcomes
Age range: 7 to 12 years
Inclusion criteria: children attending grades 1 to 4 in primary schools in the Guatemalan
highlands
Exclusion criteria: > 12 years; deworming medicine in last year
Interventions Multiple doses vs placebo
1. Albendazole: 2 x 200 mg at baseline and 12 weeks;
2. Placebo: identical at baseline and 12 weeks.
Outcomes 1. Mean weight post-treatment;
2. Mean change in weight post-treatment;
3. Mean height post-treatment;
4. Mean change in height post-treatment;
5. School performance: attendance rates of children actively attending school
measured using attendance books, dropout rates;
6. Mean MUAC;
7. Mean change in MUAC;
8. Cognitive tests: Interamerican vocabulary test, Interamerican reading test,
Peabody picture vocabulary test.
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Watkins 1996 (Continued)
Not included in review: egg counts (Kato-Katz: arithmetic and geometric mean); z-scores
(NCHS-CDC-WHO reference) for weight-for-age, change in weight-for-age, height,
change inheight, height-for-age, change inheight-for-age, weight-for-height, and change
in height-for-age
Notes Location: Guatemala
Community category: 1
Source of funding: Pew Charitable Trusts, the US Agency for International Develop-
ment University Development and Linkage Program, the Children’s Miracle Network
Telethon, and the ARCS Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “stratified by gender and age and then randomly
assigned”.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The children and field workers were unaware
of treatment group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 90%(226/250) of randomizedparticipantswere
evaluated. “No differences were detected in
treatment group assignment, initial age, anthro-
pometry, SES, andworm status between the 228
children who remained in the trial and the 18
who dropped out.” Sample size for nutritional
data is smaller due to missing data. Inclusion of
all randomized participants (number evaluable/
number randomized): 90% (226/250)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported.
Other bias Low risk No other obvious source of bias.
Willett 1979
Methods RCT
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 268
Age range: 6 to 91 months
Inclusion criteria: pre-school children from Ubiri village who attended clinic and pro-
duced a stool sample
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Willett 1979 (Continued)
Exclusion criteria: none stated
Interventions Multiple doses
1. Levamisole syrup: 2.5 mg/kg every 3 months;
2. Flavoured sucrose syrup: every 3 months.
Outcomes 1. Growth rates in both groups, and subgroup of those infected; these have been
corrected for various factors using analysis of covariance (unadjusted data are not
reported and the growth rates are not presented with any measure of variance).
Measured but not reported: height; length; stool egg count in subgroup (Kato method)
; growth rates using least square method
Notes Location: Tanzania
Community category: 3
Source of funding: Research and Publications Committee, University of Dar es Salaam.
Analysis was supported by a training grant (HL 05998-04) from the National Heart,
Lung and Blood Institute, NIH, DHEW Bethesda, MD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-numbers table.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “children were weighed and measured as be-
fore by a person unaware of their treatment sta-
tus”; placebo and treatment given as a flavoured
syrup
Incomplete outcome data (attrition bias)
All outcomes
High risk 78% (268/341) of randomized participants
were evaluated; inclusion of all randomized
participants (number evaluable/number ran-
domized): 78% (268/341)
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported.
Other bias Low risk No obvious other source of bias.
93Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school
performance (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Wiria 2013 (Cluster)
Methods Cluster RCT
Method to adjust for clustering: primary outcome of BMI was not adjusted for clustering
Cluster unit: household
Average cluster size: 4
ICCs: not reported
Length of follow-up: 21 months
Participants All children living in endemic area
Number analysed for primary outcome: 954 households containing 855 participants
Age range/mean age: Children aged 19 years and less
Inclusion criteria: all household in members except those < 2 years old or pregnant
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Albendazole: 3 x 400 mg for 3 consecutive days;
2. Matching placebo.
Outcomes 1. BMIa ;
2. Adverse events.
aBMI measured in children aged 19 years and less.
Not included in review: Malaria-like symptoms questionnaire, finger prick blood test
for malaria, skin prick tests, symptoms of asthma and atopic dermatitis, stool sample for
Tichuris and hookworms.
Notes Location: Ende district of Flores Island, Indonesia
Community category: 1
Source of funding: The Royal Netherlands Academy of Arts and Science (KNAW),
European, Prof. Dr. P.C. Flu Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random Allocation software” used.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and personnel blinded. “The
treatment code was concealed from trial in-
vestigators and participants. The un-blind-
ing of treatment codes occurred after all
laboratory results had been entered into the
database.”
Not reported whether the assessors for
height and weight were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of children randomized was not
reported.
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Wiria 2013 (Cluster) (Continued)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: low (unlikely to change
households)
Baseline imbalance: low (no differences ap-
parent)
Loss of clusters: low (ITT analysis done; in
the albendazole arm 61 people moved to
a house that was assigned to placebo while
in the placebo arm 62 people moved to a
house that was assigned to albendazole)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Yap 2014
Methods RCTRCT
Length of follow-up: 6 months
Participants Infected children identified by screening
Number analysed for primary outcome: 194
Age range: 9 to 12 years
Inclusion criteria: children aged 9 to 12 years from 5 primary schools, with at least one
type of STH infection
Exclusion criteria: deworming treatment within 6 months before the current trial
Interventions Single dose vs placebo
1. Albendazole: 3 x 400 mg for 3 consecutive days;
2. Matching placebo.
Outcomes 1. Physical fitness (10 m shuttle run and VO2 max);
2. Physical strength (grip strength and standing broad jump test);
3. Height;
4. Weight;
5. Triceps and subscapular skinfold thickness;
6. Haemoglobin.
Not included in review: parasitological examination.
Notes Location: Bulanghsam township bordering Myanmar, a sub-division of Menghai county
in Xishuangbanna Dai autonomous prefecture, situated in Yunnan province, P.R. China
Community category: N/A
Source of funding: Swiss Tropical and Public Health Institute in Basel, Switzerland and
the National Institute of Parasitic Diseases, Chinese Center of Diseases Control and
Prevention in Shanghai, P.R. China
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Yap 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The treatment allocation sequence was
generated by a statistician using block ran-
domization with randomly varying block
sizes of 2, 4, and 6.”
Allocation concealment (selection bias) Low risk “Albendazole and placebo tablets were
packaged by staff not involved in the field
work into sealed envelopes marked with
unique identifiers.”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and personnel blinded.
Not reported whether the assessors for
height and weight were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomized participants
(number evaluable/number randomized):
92% (194/211)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious risk of bias.
CI: confidence interval; Community category: a measure of the prevalence and intensity of infection (see Table 1); NCHS: National
Center for Health Statistics; SD: standard deviation; SEM: standard error of the mean.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Araujo 1987 Not a RCT.
Baird 2011 Not a comparison of deworming with placebo or no treatment.
Beasley 1999 Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schisto-
somiasis vs placebo
Bhargava 2003 Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schisto-
somiasis vs placebo
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(Continued)
Bhutta 2009 Population with significant comorbidity - 6 to 24 month old children with severe anaemia (<70 g/L). In
population with severe anaemia
Boivin 1993 Factorial-designed RCT with children allocated to deworming and iron supplementation, and in which the
analysis compares the results for the levamisole and iron group against all the other groups combined. Thus
the analysis is confounded by the iron co-intervention (Included in the Dickson 2000a Cochrane Review).
Cooper 2006 Trial of allergy with no outcomes of interest.
Cowden 2000 Not a RCT.
Croke 2014 3% (1097/37,165) of randomized participants were evaluated in 46% (22/48) of the original parishes from the
initial Alderman 2006 (Cluster) trial. All children were offered treatment after the initial trial, and therefore
potentially all of these children received treatment for deworming
Diouf 2002 Intervention comprised mebendazole, vitamin A, and iron supplementation and metronidazole as a combined
intervention vs placebo
Evans 1986 Treatments randomized, but some placebo groups accessed treatment. Analysis was by the treatment received,
and randomization was ignored (included in the Dickson 2000a Cochrane Review).
Fernando 1983 2 villages allocated to treatment or no treatment on the basis of a coin toss. Essentially a cluster-RCT with 2
large clusters (Included in the Dickson 2000a Cochrane Review, which reported that no conclusions could be
drawn from the results due to selective reporting)
Forrester 1998 Treatment regimen comprised of 3 days of albendazole vs 1 day of albendazole and 2 days of placebo vs 1 day
of pyrantel and 2 days of placebo
Friis 2003 Combined treatment regimen albendazole for soil-transmitted helminths and praziquantel for Schistosoma
mansoni vs placebo.
Gilgen 2001 Population consisted of adults.
Gupta 1982 Only two units of allocation for relevant comparison. Children randomly divided into 4 groups, “taking care
that age distribution was similar in each group”. The 4 groups were then allocated 1 of 4 different single
treatment regimens; no details given
Hadidjaja 1998 Cluster-RCT with 2 units of allocation to mebendazole and placebo. Trial authors stated that there were
differences in environmental sanitary conditions in the clusters (Included in the Dickson 2000a Cochrane
Review, but it was noted that the groups were not comparable and there was high loss to follow-up)
Hathirat 1992 Treatment regimen comprised of albendazole for soil-transmitted helminths and iron vs placebo
Jalal 1998 No relevant outcomes.
Jinabhai 2001a Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schisto-
somiasis vs placebo
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(Continued)
Jinabhai 2001b Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schisto-
somiasis vs placebo
Karyadi 1996 Not a RCT.
Krubwa 1974 Not a RCT.
Kvalsvig 1991b The researchers were unable to collect outcome data after treatment due to major floods in the area
Latham 1990 Population with schistosomiasis treated with praziquantel.
Marinho 1991 Treatment regimen comprised of mebendazole and metronidazole vs placebo
Mwaniki 2002 Treatment regimen albendazole for soil-transmitted helminths and praziquantel for schistosomiasis vs placebo
Ozier 2011 Not a comparison of deworming with placebo or no treatment.
Pollitt 1991 Not described as randomized; conference proceedings.
Rohner 2010 Treatment regimen albendazole for soil-transmitted helminths and praziquantel for schistosomiasis vs placebo
Steinmann 2008 No relevant outcomes.
Stephenson 1980 Treatment consisted of levamisole with no untreated controls
Stephenson 1985 Treatment regimen metrifonate used to treat Schistosoma haematobium vs placebo.
Tanumihardjo 1996 No relevant outcomes.
Tanumihardjo 2004 The only randomization is the timing of the deworming medicine
Taylor 2001 Treatment regimen albendazole for soil-transmitted helminths and praziquantel for S. haematobium vs placebo.
Thein-Hlaing 1991 3/21 intervention villages were not randomly allocated, and unclear how intervention and control villages
were allocated as there was a large imbalance (8 intervention and 13 non-intervention villages)
Uscátegui 2009 Trial in population with malaria.
Wright 2009 No relevant outcomes.
Yang 2003 Did not consider nutritional or cognitive outcome measures.
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Characteristics of ongoing studies [ordered by study ID]
Alam 2006
Trial name or title Relative efficacy of two regimens of ante-helminthic treatment
Methods Clinical trial
Participants Total enrolment: 200
Inclusion criteria: age 2 to 5 years; not suffering from serious chronic illness; stool test positive for STHs; not
taken any anthelminthic drug in previous 6 months; parents/guardian agree their child’s participation
Exclusion criteria: age < 2 years and > 5 years; stool test negative for any intestinal helminth; suffering from
serious chronic illness; parents/guardian not willing to give consent for their child’s participation; if he/she
receives any anthelminthic drug after survey but before the trial interventions
Interventions 1. Conventional treatment of 400 mg of albendazole in a single dose at 6-month interval;
2. Intervention group: 400 mg of albendazole in a single-dose treatment at 3-month interval.
Outcomes Primary
• To determine the relative efficacy of de-worming at every 3 months vs every 6 month single dose of
albendazole treatment.
Secondary
• To compare additional morbidity information such as diarrhoeal diseases, respiratory tract infections,
nutritional status and E. histolytica associated morbidity between 2 groups.
Starting date Not yet recruiting
Contact information Mohammad M AlamMBBS, Principal Investigator, ICDDR,B: Centre for Health and Population Research,
masud icddrb@yahoo.com
Notes ClinicalTrials.gov identifier: NCT00367627
Sources of support: International Centre for Diarrhoeal Disease Research, Bangladesh (sponsor)
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D A T A A N D A N A L Y S E S
Comparison 1. Infected children - Single dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 5 627 Mean Difference (IV, Random, 95% CI) 0.75 [0.24, 1.26]
2 Height (cm) 5 647 Mean Difference (IV, Random, 95% CI) 0.25 [0.01, 0.49]
3 Mid-upper arm circumference
(cm)
4 396 Mean Difference (IV, Fixed, 95% CI) 0.49 [0.39, 0.58]
4 Triceps skin fold thickness (mm) 3 352 Mean Difference (IV, Random, 95% CI) 1.34 [0.72, 1.97]
5 Subscapular skin fold thickness
(mm)
2 339 Mean Difference (IV, Fixed, 95% CI) 1.29 [1.13, 1.44]
6 Body mass index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Haemoglobin (g/dL) 2 247 Mean Difference (IV, Random, 95% CI) 0.10 [-0.65, 0.86]
Comparison 2. Infected children - Multiple dose, longest follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 1 Mean Difference (Fixed, 95% CI) Totals not selected
2 Height (cm) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Body mass index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 School attendance (days present
at school)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Mid-upper arm circumference
(cm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Triceps skin fold thickness (mm) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Subscapular skin fold thickness
(mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. All children living in endemic area - first dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 7 2719 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.11, 0.04]
1.1 High prevalence 2 290 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.15, 0.18]
1.2 Moderate prevalence 2 873 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.10, 0.27]
1.3 Low prevalence 3 1556 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.19, 0.01]
2 Height (cm) 5 1974 Mean Difference (IV, Random, 95% CI) -0.12 [-0.33, 0.10]
2.1 High prevalence 1 227 Mean Difference (IV, Random, 95% CI) 0.06 [-0.08, 0.20]
2.2 Moderate prevalence 1 191 Mean Difference (IV, Random, 95% CI) -0.20 [-0.47, 0.07]
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2.3 Low prevalence 3 1556 Mean Difference (IV, Random, 95% CI) -0.26 [-0.74, 0.21]
3 Mid-upper arm circumference
(cm)
3 911 Mean Difference (IV, Random, 95% CI) 0.04 [-0.19, 0.26]
3.1 High prevalence 1 207 Mean Difference (IV, Random, 95% CI) 0.09 [-0.03, 0.21]
3.2 Moderate prevalence 1 482 Mean Difference (IV, Random, 95% CI) 0.19 [-0.01, 0.40]
3.3 Low prevalence 1 222 Mean Difference (IV, Random, 95% CI) -0.3 [-0.52, -0.08]
4 Haemoglobin (g/dL) 3 1005 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.05, 0.17]
4.1 Moderate prevalence 2 658 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.06, 0.17]
4.2 Low prevalence 1 347 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.24, 0.36]
Comparison 4. All children living in endemic area - Multiple dose, longest follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 10 2656 Mean Difference (Random, 95% CI) 0.08 [-0.11, 0.27]
1.1 High prevalence 2 306 Mean Difference (Random, 95% CI) 0.04 [-0.08, 0.16]
1.2 Moderate prevalence 3 859 Mean Difference (Random, 95% CI) 0.11 [-0.03, 0.25]
1.3 Low prevalence 5 1491 Mean Difference (Random, 95% CI) 0.06 [-0.46, 0.57]
2 Height (cm) 7 1847 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.14, 0.17]
2.1 High prevalence 1 227 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.13, 0.25]
2.2 Moderate prevalence 1 129 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.46, 0.66]
2.3 Low prevalence 5 1491 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.46, 0.18]
3 Mid-upper arm circumference
(cm)
3 534 Mean Difference (IV, Random, 95% CI) -0.03 [-0.25, 0.18]
3.1 High prevalence 1 207 Mean Difference (IV, Random, 95% CI) 0.08 [-0.06, 0.22]
3.2 Moderate prevalence 1 129 Mean Difference (IV, Random, 95% CI) 0.06 [-0.22, 0.33]
3.3 Low prevalence 1 198 Mean Difference (IV, Random, 95% CI) -0.35 [-0.65, -0.05]
4 Triceps skin fold thickness (mm) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Moderate prevalence 1 130 Mean Difference (IV, Random, 95% CI) -0.30 [-1.28, 0.68]
5 Haemoglobin (g/dL) 7 3595 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.08, 0.04]
5.1 Moderate prevalence 2 464 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.15, 0.19]
5.2 Low prevalence 5 3131 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.09, 0.04]
6 School attendance (days present
at school)
2 293 Mean Difference (Random, 95% CI) 0.02 [-0.04, 0.08]
6.1 High prevalence 2 293 Mean Difference (Random, 95% CI) 0.02 [-0.04, 0.08]
Comparison 5. All children living in endemic area - Single dose (low risk of bias for allocation concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 2 1029 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.11, 0.19]
1.1 Moderate prevalence 1 682 Mean Difference (IV, Fixed, 95% CI) 0.5 [-0.28, 1.28]
1.2 Low prevalence 1 347 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.13, 0.17]
2 Height (cm) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Low prevalence 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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3 Mid-upper arm circumference
(cm)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Moderate prevalence 1 482 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.01, 0.40]
4 Haemoglobin (g/dL) 2 814 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.07, 0.17]
4.1 Moderate prevalence 1 467 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.08, 0.17]
4.2 Low prevalence 1 347 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.24, 0.36]
Comparison 6. All children living in endemic area - Multiple dose (low risk of bias for allocation concealment),
longest follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 2 Mean Difference (Fixed, 95% CI) 0.01 [-0.13, 0.15]
1.1 High prevalence 1 Mean Difference (Fixed, 95% CI) 0.0 [-0.14, 0.14]
1.2 Moderate prevalence 1 Mean Difference (Fixed, 95% CI) 0.5 [-0.42, 1.42]
2 Height (cm) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Low prevalence 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Haemoglobin (g/dL) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Moderate prevalence 1 326 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.21, 0.16]
Comparison 7. All children living in endemic area - All multiple ordered by year
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 10 Mean Difference (Random, 95% CI) 0.09 [-0.10, 0.28]
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Analysis 1.1. Comparison 1 Infected children - Single dose, Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 1 Infected children - Single dose
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Freij 1979a (1) 6 12.3 (2.91) 7 12.1 (2.29) 2.8 % 0.20 [ -2.68, 3.08 ]
Stephenson 1989 78 2.1 (0.79) 72 0.8 (0.85) 25.3 % 1.30 [ 1.04, 1.56 ]
Stephenson 1993 96 3.3 (1.76) 93 2.2 (1.16) 22.9 % 1.10 [ 0.68, 1.52 ]
Sarkar 2002 40 0.92 (0.84) 41 0.54 (0.45) 24.9 % 0.38 [ 0.09, 0.67 ]
Yap 2014 99 2.2 (1.2435) 95 1.9 (1.2435) 24.1 % 0.30 [ -0.05, 0.65 ]
Total (95% CI) 319 308 100.0 % 0.75 [ 0.24, 1.26 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 31.60, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours deworming
(1) End value data
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Analysis 1.2. Comparison 1 Infected children - Single dose, Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 1 Infected children - Single dose
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sarkar 2002 40 1.2 (1.5) 41 1.1 (0.7) 14.2 % 0.10 [ -0.41, 0.61 ]
Stephenson 1989 78 2.8 (0.79) 72 2.2 (0.85) 27.3 % 0.60 [ 0.34, 0.86 ]
Stephenson 1993 96 3.8 (1.18) 93 3.7 (1.16) 22.8 % 0.10 [ -0.23, 0.43 ]
Tee 2013 15 6.2 (1.2) 18 6.3 (1.1) 7.5 % -0.10 [ -0.89, 0.69 ]
Yap 2014 99 3.5 (0.8881) 95 3.3 (0.8881) 28.2 % 0.20 [ -0.05, 0.45 ]
Total (95% CI) 328 319 100.0 % 0.25 [ 0.01, 0.49 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.53, df = 4 (P = 0.07); I2 =53%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours control Favours deworming
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Analysis 1.3. Comparison 1 Infected children - Single dose, Outcome 3 Mid-upper arm circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 1 Infected children - Single dose
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Freij 1979a (1) 6 14.5 (1.13) 7 14.8 (1.44) 0.5 % -0.30 [ -1.70, 1.10 ]
Freij 1979b (2) 24 14.6 (1.2) 20 14.5 (1.1) 2.0 % 0.10 [ -0.58, 0.78 ]
Stephenson 1989 78 0.7 (0.44) 72 0.2 (0.51) 39.4 % 0.50 [ 0.35, 0.65 ]
Stephenson 1993 96 0.8 (0.49) 93 0.3 (0.39) 58.1 % 0.50 [ 0.37, 0.63 ]
Total (95% CI) 204 192 100.0 % 0.49 [ 0.39, 0.58 ]
Heterogeneity: Chi2 = 2.53, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 9.96 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours control Favours deworming
(1) End value data
(2) End value data
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Analysis 1.4. Comparison 1 Infected children - Single dose, Outcome 4 Triceps skin fold thickness (mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 1 Infected children - Single dose
Outcome: 4 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Freij 1979a (1) 6 9.8 (1.51) 7 10.6 (2.59) 6.6 % -0.80 [ -3.07, 1.47 ]
Stephenson 1989 78 1 (0.71) 72 -0.2 (0.68) 47.3 % 1.20 [ 0.98, 1.42 ]
Stephenson 1993 96 2 (1.08) 93 0.2 (0.77) 46.1 % 1.80 [ 1.53, 2.07 ]
Total (95% CI) 180 172 100.0 % 1.34 [ 0.72, 1.97 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 15.21, df = 2 (P = 0.00050); I2 =87%
Test for overall effect: Z = 4.20 (P = 0.000027)
Test for subgroup differences: Not applicable
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(1) End value data
Analysis 1.5. Comparison 1 Infected children - Single dose, Outcome 5 Subscapular skin fold thickness
(mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 1 Infected children - Single dose
Outcome: 5 Subscapular skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stephenson 1989 78 0.9 (0.62) 72 -0.3 (0.68) 56.0 % 1.20 [ 0.99, 1.41 ]
Stephenson 1993 96 1.8 (0.88) 93 0.4 (0.77) 44.0 % 1.40 [ 1.16, 1.64 ]
Total (95% CI) 174 165 100.0 % 1.29 [ 1.13, 1.44 ]
Heterogeneity: Chi2 = 1.55, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 16.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Infected children - Single dose, Outcome 6 Body mass index.
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 1 Infected children - Single dose
Outcome: 6 Body mass index
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simeon 1995 (1) 206 15.6 (1.3) 201 15.8 (1.4) -0.20 [ -0.46, 0.06 ]
-0.5 -0.25 0 0.25 0.5
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Analysis 1.7. Comparison 1 Infected children - Single dose, Outcome 7 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 1 Infected children - Single dose
Outcome: 7 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Stephenson 1993 27 -0.2 (0.6) 26 -0.6 (0.5) 62.9 % 0.40 [ 0.10, 0.70 ]
Yap 2014 99 -1.3 (3.01959) 95 -0.9 (3.01959) 37.1 % -0.40 [ -1.25, 0.45 ]
Total (95% CI) 126 121 100.0 % 0.10 [ -0.65, 0.86 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 3.03, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Infected children - Multiple dose, longest follow-up, Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 2 Infected children - Multiple dose, longest follow-up
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Stephenson 1993 (1) 0.9 (0.1842) 0.90 [ 0.54, 1.26 ]
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Analysis 2.2. Comparison 2 Infected children - Multiple dose, longest follow-up, Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 2 Infected children - Multiple dose, longest follow-up
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stephenson 1993 95 3.6 (1.07) 93 3.7 (1.16) -0.10 [ -0.42, 0.22 ]
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Analysis 2.3. Comparison 2 Infected children - Multiple dose, longest follow-up, Outcome 3 Body mass
index.
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 2 Infected children - Multiple dose, longest follow-up
Outcome: 3 Body mass index
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simeon 1995 (1) 206 15.6 (1.3) 201 15.8 (1.4) -0.20 [ -0.46, 0.06 ]
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Analysis 2.4. Comparison 2 Infected children - Multiple dose, longest follow-up, Outcome 4 School
attendance (days present at school).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 2 Infected children - Multiple dose, longest follow-up
Outcome: 4 School attendance (days present at school)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Simeon 1995 206 67.3 (18.4) 201 69.3 (17.5) -2.00 [ -5.49, 1.49 ]
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Analysis 2.5. Comparison 2 Infected children - Multiple dose, longest follow-up, Outcome 5 Mid-upper arm
circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 2 Infected children - Multiple dose, longest follow-up
Outcome: 5 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stephenson 1993 95 0.7 (0.49) 93 0.3 (0.39) 0.40 [ 0.27, 0.53 ]
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Analysis 2.6. Comparison 2 Infected children - Multiple dose, longest follow-up, Outcome 6 Triceps skin fold
thickness (mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 2 Infected children - Multiple dose, longest follow-up
Outcome: 6 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stephenson 1993 95 2 (1.17) 93 0.2 (0.77) 1.80 [ 1.52, 2.08 ]
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Analysis 2.7. Comparison 2 Infected children - Multiple dose, longest follow-up, Outcome 7 Subscapular
skin fold thickness (mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 2 Infected children - Multiple dose, longest follow-up
Outcome: 7 Subscapular skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stephenson 1993 95 1.9 (1.07) 93 0.4 (0.77) 1.50 [ 1.23, 1.77 ]
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Analysis 3.1. Comparison 3 All children living in endemic area - first dose, Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 3 All children living in endemic area - first dose
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Watkins 1996 116 0.99 (0.65) 110 0.98 (0.63) 20.6 % 0.01 [ -0.16, 0.18 ]
Hadju 1996 (1) 34 20.3 (3.2) 30 19.9 (2.2) 0.3 % 0.40 [ -0.93, 1.73 ]
Subtotal (95% CI) 150 140 20.9 % 0.02 [ -0.15, 0.18 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Moderate prevalence
Palupi 1997 95 0.51 (0.73) 96 0.45 (0.58) 16.3 % 0.06 [ -0.13, 0.25 ]
Sur 2005 (2) 342 12.6 (5.73) 340 12.1 (4.61) 0.9 % 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 437 436 17.3 % 0.08 [ -0.10, 0.27 ]
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.90 (P = 0.37)
3 Low prevalence
Donnen 1998 112 0.44 (0.72) 110 0.59 (0.74) 15.5 % -0.15 [ -0.34, 0.04 ]
Awasthi 2000 592 0.54 (1.34) 395 0.71 (1.23) 21.7 % -0.17 [ -0.33, -0.01 ]
Garg 2002 166 1.21 (0.77) 181 1.19 (0.67) 24.6 % 0.02 [ -0.13, 0.17 ]
Subtotal (95% CI) 870 686 61.8 % -0.09 [ -0.19, 0.01 ]
Heterogeneity: Chi2 = 3.31, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 1.82 (P = 0.069)
Total (95% CI) 1457 1262 100.0 % -0.04 [ -0.11, 0.04 ]
Heterogeneity: Chi2 = 8.01, df = 6 (P = 0.24); I2 =25%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 3.23, df = 2 (P = 0.20), I2 =38%
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Analysis 3.2. Comparison 3 All children living in endemic area - first dose, Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 3 All children living in endemic area - first dose
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Watkins 1996 116 1.44 (0.54) 111 1.38 (0.53) 33.3 % 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 116 111 33.3 % 0.06 [ -0.08, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 Moderate prevalence
Palupi 1997 95 1.2 (0.9) 96 1.4 (1) 24.1 % -0.20 [ -0.47, 0.07 ]
Subtotal (95% CI) 95 96 24.1 % -0.20 [ -0.47, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
3 Low prevalence
Awasthi 2000 592 4.19 (5.08) 395 4.59 (5.25) 8.4 % -0.40 [ -1.06, 0.26 ]
Donnen 1998 112 1.96 (1.99) 110 2.58 (2.05) 11.5 % -0.62 [ -1.15, -0.09 ]
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 22.6 % 0.08 [ -0.21, 0.37 ]
Subtotal (95% CI) 870 686 42.5 % -0.26 [ -0.74, 0.21 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 5.89, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 1081 893 100.0 % -0.12 [ -0.33, 0.10 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 9.60, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Chi2 = 3.96, df = 2 (P = 0.14), I2 =49%
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Analysis 3.3. Comparison 3 All children living in endemic area - first dose, Outcome 3 Mid-upper arm
circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 3 All children living in endemic area - first dose
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Watkins 1996 106 0.39 (0.51) 101 0.3 (0.4) 30.8 % 0.09 [ -0.03, 0.21 ]
Subtotal (95% CI) 106 101 30.8 % 0.09 [ -0.03, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
2 Moderate prevalence
Nga 2009 (1) 122 15.5 (1.1) 118 15.4 (1.1) 22.4 % 0.10 [ -0.18, 0.38 ]
Nga 2009 (2) 120 15.6 (1.2) 122 15.3 (1.2) 21.2 % 0.30 [ 0.00, 0.60 ]
Subtotal (95% CI) 242 240 43.6 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
3 Low prevalence
Donnen 1998 112 0.11 (0.84) 110 0.41 (0.84) 25.6 % -0.30 [ -0.52, -0.08 ]
Subtotal (95% CI) 112 110 25.6 % -0.30 [ -0.52, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
Total (95% CI) 460 451 100.0 % 0.04 [ -0.19, 0.26 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 12.73, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 11.82, df = 2 (P = 0.00), I2 =83%
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Analysis 3.4. Comparison 3 All children living in endemic area - first dose, Outcome 4 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 3 All children living in endemic area - first dose
Outcome: 4 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Nga 2009 (1) 118 12.22 (0.62) 114 12.12 (0.73) 39.2 % 0.10 [ -0.07, 0.27 ]
Nga 2009 (2) 117 11.99 (0.7) 118 12.01 (0.8) 32.3 % -0.02 [ -0.21, 0.17 ]
Palupi 1997 95 0.75 (0.88) 96 0.64 (1.06) 15.6 % 0.11 [ -0.17, 0.39 ]
Subtotal (95% CI) 330 328 87.1 % 0.06 [ -0.06, 0.17 ]
Heterogeneity: Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Low prevalence
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 12.9 % 0.06 [ -0.24, 0.36 ]
Subtotal (95% CI) 166 181 12.9 % 0.06 [ -0.24, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 496 509 100.0 % 0.06 [ -0.05, 0.17 ]
Heterogeneity: Chi2 = 0.99, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 4.1. Comparison 4 All children living in endemic area - Multiple dose, longest follow-up, Outcome
1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 4 All children living in endemic area - Multiple dose, longest follow-up
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Hall 2006 (Cluster) (1) 40 40 0 (0.071) 12.2 % 0.0 [ -0.14, 0.14 ]
Watkins 1996 116 110 0.13 (0.1059) 11.3 % 0.13 [ -0.08, 0.34 ]
Subtotal (95% CI) 156 150 23.5 % 0.04 [ -0.08, 0.16 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Moderate prevalence
Dossa 2001 37 28 0 (0.265) 6.7 % 0.0 [ -0.52, 0.52 ]
Dossa 2001 31 33 0 (0.1385) 10.4 % 0.0 [ -0.27, 0.27 ]
Sur 2005 (2) 342 340 0.5 (0.4718) 3.3 % 0.50 [ -0.42, 1.42 ]
Alderman 2006 (Cluster) (3) 24 24 0.154 (0.08921) 11.8 % 0.15 [ -0.02, 0.33 ]
Subtotal (95% CI) 434 425 32.1 % 0.11 [ -0.03, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.73, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
3 Low prevalence
Donnen 1998 100 98 -0.45 (0.1665) 9.5 % -0.45 [ -0.78, -0.12 ]
Kruger 1996 37 37 -0.38 (0.2265) 7.7 % -0.38 [ -0.82, 0.06 ]
Awasthi 2000 601 444 -0.05 (0.076) 12.1 % -0.05 [ -0.20, 0.10 ]
Awasthi 2001 (Cluster) (4) 63 61 0.17 (0.341) 5.1 % 0.17 [ -0.50, 0.84 ]
Awasthi 1995 (Cluster) (5) 25 25 0.98 (0.148) 10.1 % 0.98 [ 0.69, 1.27 ]
Subtotal (95% CI) 826 665 44.4 % 0.06 [ -0.46, 0.57 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 53.96, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI) 1416 1240 100.0 % 0.08 [ -0.11, 0.27 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 57.36, df = 10 (P<0.00001); I2 =83%
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Chi2 = 0.54, df = 2 (P = 0.76), I2 =0.0%
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(1) 2659 participants
(2) End value data
(3) 27995 participants
(4) 1672 participants
(5) 3712 participants
Analysis 4.2. Comparison 4 All children living in endemic area - Multiple dose, longest follow-up, Outcome
2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 4 All children living in endemic area - Multiple dose, longest follow-up
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Watkins 1996 116 2.45 (0.75) 111 2.39 (0.73) 67.5 % 0.06 [ -0.13, 0.25 ]
Subtotal (95% CI) 116 111 67.5 % 0.06 [ -0.13, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Moderate prevalence
Dossa 2001 37 6.5 (2.6) 28 6 (2.5) 1.6 % 0.50 [ -0.75, 1.75 ]
Dossa 2001 31 6.2 (1) 33 6.2 (1.5) 6.5 % 0.0 [ -0.62, 0.62 ]
Subtotal (95% CI) 68 61 8.1 % 0.10 [ -0.46, 0.66 ]
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
3 Low prevalence
Awasthi 1995 (Cluster) (1) 25 17.59 (4.5) 25 16.4 (4) 0.4 % 1.19 [ -1.17, 3.55 ]
Kruger 1996 37 5.62 (0.9) 37 5.54 (0.91) 14.7 % 0.08 [ -0.33, 0.49 ]
Donnen 1998 100 7.27 (3.56) 98 8.46 (4.18) 2.1 % -1.19 [ -2.27, -0.11 ]
Awasthi 2000 601 9.94 (4.9) 444 10.35 (5.1) 6.6 % -0.41 [ -1.03, 0.21 ]
Awasthi 2001 (Cluster) (2) 63 16.5 (6.51) 61 16.1 (6.48) 0.5 % 0.40 [ -1.89, 2.69 ]
Subtotal (95% CI) 826 665 24.4 % -0.14 [ -0.46, 0.18 ]
-4 -2 0 2 4
Favours control Favours deworming
(Continued . . . )
117Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school
performance (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(. . . Continued)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 6.88, df = 4 (P = 0.14); I2 =42%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 1010 837 100.0 % 0.02 [ -0.14, 0.17 ]
Heterogeneity: Chi2 = 8.54, df = 7 (P = 0.29); I2 =18%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 1.17, df = 2 (P = 0.56), I2 =0.0%
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(1) 3712 participants
(2) 1672 participants
Analysis 4.3. Comparison 4 All children living in endemic area - Multiple dose, longest follow-up, Outcome
3 Mid-upper arm circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 4 All children living in endemic area - Multiple dose, longest follow-up
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Watkins 1996 106 0.6 (0.51) 101 0.52 (0.5) 39.4 % 0.08 [ -0.06, 0.22 ]
Subtotal (95% CI) 106 101 39.4 % 0.08 [ -0.06, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
2 Moderate prevalence
Dossa 2001 37 0.1 (0.8) 28 0.1 (0.9) 16.7 % 0.0 [ -0.42, 0.42 ]
Dossa 2001 31 0.1 (0.7) 33 0 (0.8) 19.7 % 0.10 [ -0.27, 0.47 ]
Subtotal (95% CI) 68 61 36.3 % 0.06 [ -0.22, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
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(. . . Continued)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Low prevalence
Donnen 1998 100 0.62 (1) 98 0.97 (1.16) 24.3 % -0.35 [ -0.65, -0.05 ]
Subtotal (95% CI) 100 98 24.3 % -0.35 [ -0.65, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Total (95% CI) 274 260 100.0 % -0.03 [ -0.25, 0.18 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.68, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 6.56, df = 2 (P = 0.04), I2 =70%
-1 -0.5 0 0.5 1
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Analysis 4.4. Comparison 4 All children living in endemic area - Multiple dose, longest follow-up, Outcome
4 Triceps skin fold thickness (mm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 4 All children living in endemic area - Multiple dose, longest follow-up
Outcome: 4 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Moderate prevalence
Dossa 2001 31 0 (1.5) 33 -0.2 (1.6) 49.9 % 0.20 [ -0.56, 0.96 ]
Dossa 2001 38 -0.6 (1.3) 28 0.2 (1.7) 50.1 % -0.80 [ -1.55, -0.05 ]
Subtotal (95% CI) 69 61 100.0 % -0.30 [ -1.28, 0.68 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 3.36, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 All children living in endemic area - Multiple dose, longest follow-up, Outcome
5 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 4 All children living in endemic area - Multiple dose, longest follow-up
Outcome: 5 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Dossa 2001 38 0.8 (1.3) 32 0.5 (1.2) 1.0 % 0.30 [ -0.29, 0.89 ]
Dossa 2001 34 1.3 (1.5) 34 1.1 (1.2) 0.8 % 0.20 [ -0.45, 0.85 ]
Le Huong 2007 79 1.46 (0.888) 82 1.54 (0.833) 4.9 % -0.08 [ -0.35, 0.19 ]
Le Huong 2007 86 1.78 (0.9) 79 1.75 (0.755) 5.5 % 0.03 [ -0.22, 0.28 ]
Subtotal (95% CI) 237 227 12.3 % 0.02 [ -0.15, 0.19 ]
Heterogeneity: Chi2 = 1.72, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Low prevalence
Kruger 1996 37 0.24 (0.6) 37 0.26 (0.72) 3.8 % -0.02 [ -0.32, 0.28 ]
Awasthi 2000 (1) 601 9.67 (0.65) 444 9.67 (0.66) 54.2 % 0.0 [ -0.08, 0.08 ]
Goto 2009 (2) 134 9.59 (1.39) 135 9.69 (1.38) 3.2 % -0.10 [ -0.43, 0.23 ]
Kirwan 2010 (3) 158 10.04 (1.38) 162 10.03 (1.4) 3.8 % 0.01 [ -0.29, 0.31 ]
Ndibazza 2012 (4) 697 12.09 (1.19) 726 12.16 (1.2) 22.7 % -0.07 [ -0.19, 0.05 ]
Subtotal (95% CI) 1627 1504 87.7 % -0.02 [ -0.09, 0.04 ]
Heterogeneity: Chi2 = 1.12, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 1864 1731 100.0 % -0.02 [ -0.08, 0.04 ]
Heterogeneity: Chi2 = 3.05, df = 8 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 4.6. Comparison 4 All children living in endemic area - Multiple dose, longest follow-up, Outcome
6 School attendance (days present at school).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 4 All children living in endemic area - Multiple dose, longest follow-up
Outcome: 6 School attendance (days present at school)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 High prevalence
Miguel 2004 (Cluster) (1) 25 25 0.051 (0.027) 43.2 % 0.05 [ 0.00, 0.10 ]
Watkins 1996 123 120 -0.01 (0.015) 56.8 % -0.01 [ -0.04, 0.02 ]
Total (95% CI) 148 145 100.0 % 0.02 [ -0.04, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.90, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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(1) 20,000 participants, group 1 versus group 3 (2 year follow-up) from 3ie replication
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Analysis 5.1. Comparison 5 All children living in endemic area - Single dose (low risk of bias for allocation
concealment), Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 5 All children living in endemic area - Single dose (low risk of bias for allocation concealment)
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Sur 2005 (1) 342 12.6 (5.73) 340 12.1 (4.61) 3.7 % 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 342 340 3.7 % 0.50 [ -0.28, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 Low prevalence
Garg 2002 166 1.21 (0.77) 181 1.19 (0.67) 96.3 % 0.02 [ -0.13, 0.17 ]
Subtotal (95% CI) 166 181 96.3 % 0.02 [ -0.13, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Total (95% CI) 508 521 100.0 % 0.04 [ -0.11, 0.19 ]
Heterogeneity: Chi2 = 1.40, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =29%
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Analysis 5.2. Comparison 5 All children living in endemic area - Single dose (low risk of bias for allocation
concealment), Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 5 All children living in endemic area - Single dose (low risk of bias for allocation concealment)
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low prevalence
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 0.08 [ -0.21, 0.37 ]
-1 -0.5 0 0.5 1
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Analysis 5.3. Comparison 5 All children living in endemic area - Single dose (low risk of bias for allocation
concealment), Outcome 3 Mid-upper arm circumference (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 5 All children living in endemic area - Single dose (low risk of bias for allocation concealment)
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Nga 2009 (1) 122 15.5 (1.1) 118 15.4 (1.1) 54.1 % 0.10 [ -0.18, 0.38 ]
Nga 2009 (2) 120 15.6 (1.2) 122 15.3 (1.2) 45.9 % 0.30 [ 0.00, 0.60 ]
Subtotal (95% CI) 242 240 100.0 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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(1) End value data
(2) End value data
Analysis 5.4. Comparison 5 All children living in endemic area - Single dose (low risk of bias for allocation
concealment), Outcome 4 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 5 All children living in endemic area - Single dose (low risk of bias for allocation concealment)
Outcome: 4 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Nga 2009 (1) 118 12.22 (0.62) 114 12.12 (0.73) 46.4 % 0.10 [ -0.07, 0.27 ]
Nga 2009 (2) 117 11.99 (0.7) 118 12.01 (0.8) 38.3 % -0.02 [ -0.21, 0.17 ]
Subtotal (95% CI) 235 232 84.7 % 0.05 [ -0.08, 0.17 ]
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Low prevalence
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 15.3 % 0.06 [ -0.24, 0.36 ]
Subtotal (95% CI) 166 181 15.3 % 0.06 [ -0.24, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 401 413 100.0 % 0.05 [ -0.07, 0.17 ]
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 6.1. Comparison 6 All children living in endemic area - Multiple dose (low risk of bias for allocation
concealment), longest follow-up, Outcome 1 Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 6 All children living in endemic area - Multiple dose (low risk of bias for allocation concealment), longest follow-up
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 High prevalence
Hall 2006 (Cluster) 0 (0.071) 97.8 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 97.8 % 0.0 [ -0.14, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Moderate prevalence
Sur 2005 (1) 0.5 (0.4718) 2.2 % 0.50 [ -0.42, 1.42 ]
Subtotal (95% CI) 2.2 % 0.50 [ -0.42, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 100.0 % 0.01 [ -0.13, 0.15 ]
Heterogeneity: Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 1.10, df = 1 (P = 0.29), I2 =9%
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Analysis 6.2. Comparison 6 All children living in endemic area - Multiple dose (low risk of bias for allocation
concealment), longest follow-up, Outcome 2 Height (cm).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 6 All children living in endemic area - Multiple dose (low risk of bias for allocation concealment), longest follow-up
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low prevalence
Awasthi 2001 (Cluster) 63 16.5 (6.51) 61 16.1 (6.48) 0.40 [ -1.89, 2.69 ]
-4 -2 0 2 4
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Analysis 6.3. Comparison 6 All children living in endemic area - Multiple dose (low risk of bias for allocation
concealment), longest follow-up, Outcome 3 Haemoglobin (g/dL).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 6 All children living in endemic area - Multiple dose (low risk of bias for allocation concealment), longest follow-up
Outcome: 3 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Moderate prevalence
Le Huong 2007 79 1.46 (0.888) 82 1.54 (0.833) 47.4 % -0.08 [ -0.35, 0.19 ]
Le Huong 2007 86 1.78 (0.9) 79 1.75 (0.755) 52.6 % 0.03 [ -0.22, 0.28 ]
Subtotal (95% CI) 165 161 100.0 % -0.02 [ -0.21, 0.16 ]
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 All children living in endemic area - All multiple ordered by year, Outcome 1
Weight (kg).
Review: Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance
Comparison: 7 All children living in endemic area - All multiple ordered by year
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Awasthi 1995 (Cluster) 0.98 (0.148) 10.2 % 0.98 [ 0.69, 1.27 ]
Watkins 1996 0.13 (0.1071) 11.5 % 0.13 [ -0.08, 0.34 ]
Kruger 1996 -0.38 (0.22) 7.9 % -0.38 [ -0.81, 0.05 ]
Donnen 1998 -0.45 (0.229) 7.6 % -0.45 [ -0.90, 0.00 ]
Awasthi 2000 -0.05 (0.076) 12.4 % -0.05 [ -0.20, 0.10 ]
Dossa 2001 0 (0.26) 6.8 % 0.0 [ -0.51, 0.51 ]
Awasthi 2001 (Cluster) 0.17 (0.341) 5.0 % 0.17 [ -0.50, 0.84 ]
Dossa 2001 0 (0.13) 10.8 % 0.0 [ -0.25, 0.25 ]
Sur 2005 0.5 (0.46) 3.3 % 0.50 [ -0.40, 1.40 ]
Alderman 2006 (Cluster) 0.154 (0.08921) 12.0 % 0.15 [ -0.02, 0.33 ]
Hall 2006 (Cluster) 0 (0.071) 12.5 % 0.0 [ -0.14, 0.14 ]
Total (95% CI) 100.0 % 0.09 [ -0.10, 0.28 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 53.13, df = 10 (P<0.00001); I2 =81%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 helmint* helmint* helmint* helmint$ helmint*
2 Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
3 Necator americanus Necator americanus Necator americanus Necator americanus Necator americanus
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Table 1. Detailed search strategies (Continued)
4 Ascaris Ascaris Ascaris Ascaris Ascaris
5 Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
6 trichuris trichuris trichuris trichuris trichuris
7 Strongyloid* Strongyloid* Strongyloid* Strongyloid* Strongyloid*
8 albendazole hookworm* hookworm* hookworm$ 1-7/OR
9 mebendazole roundworm* roundworm* roundworm$ albendazole
10 piperazine pinworm* pinworm* pinworm$ mebendazole
11 levamisole whipworm* whipworm* whipworm$ piperazine
12 pyrantel 1-11/OR 1-11/OR 1-11/OR levamisole
13 tiabendazole albendazole albendazole albendazole pyrantel
14 - mebendazole mebendazole mebendazole tiabendazole
15 - piperazine piperazine piperazine 9-14/OR
16 - levamisole levamisole levamisole 8 and 15
17 - pyrantel pyrantel pyrantel Limit 16 to human
18 - tiabendazole tiabendazole tiabendazole -
19 - 13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
-
20 - 12 and 19 12 and 19 12 and 19 -
21 - - Limit 20 to human Limit 20 to human -
aCIDG Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011).
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Table 2. Community diagnosis categories and recommended treatment strategies
Community category (WHO
2002)
Prevalencea Percentageb School intervention
1. High prevalence or high in-
tensity
> 70% > 10% Targeted treatment of school-age children 2 to 3 times per year
2.Moderate prevalence and low
intensity
> 50% but < 70% < 10% Targeted treatment of school-age children once per year
3. Low prevalence and low in-
tensity
< 50% < 10% Selective treatment
Category (WHO 2006b) Prevalencea Action to be taken
High risk community > 50% Targeted treatment of pre-school and school-age children 2 or
3 times per year
Low risk community > 20% but < 50% Targeted treatment of pre-school and school-age children once
per year
aOf any worm infection.
bOf moderate to heavy infections.
Table 3. Accompanying health promotion activities
Accompanying intervention Details from trial Trials
To both intervention and control “The AWC workers, usually local women
(plus assistants), give pre-school education,
give nutritional supplements to malnourished
children, and record births and pre-school
deaths.”
Awasthi 2013 (Cluster)
“The parents of all children aged < 7 years
were offered a range of health services at child
health days, including vaccinations, vitaminA
supplements, growth monitoring and promo-
tion, and demonstrations of complementary
feeding.”
Alderman 2006 (Cluster)
“The primary job responsibilities of the AWW
[anganwadi worker] are to run a creche and
provide primary health care and supplemen-
tary nutrition for children < six years of age
and pregnant and lactating women.”
Awasthi 2001 (Cluster)
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Table 3. Accompanying health promotion activities (Continued)
All children received 10 mL of multivitamins
(over two days) as an incentive at each time
point. Each 5 mL of multivitamin contained:
Vitamin A 3000 IU, Vitamin B2 2.0 mg,
Nicotinamide 15.0 mg, Vitamin B1 1.5 mg,
Vitamin B6 2.0 mg, Vitamin D2 400 IU, D
panthenol 1.0 mg
Kirwan 2010
Children attended a mother and child health
clinic
Freij 1979a
Children in both groups received treatment
for other conditions in accordance with the
IMCI guidelines
Garg 2002
Children were followed up for routine immu-
nisations, and then quarterly, to age 5 years.
Children received BCG and oral polio immu-
nisations at birth, polio, diphtheria, pertus-
sis, tetanus, hepatitis B and Haemophilus in-
fluenzae type B immunisations at 6, 10 and 14
weeks, andmeasles immunisation at 9months
Ndibazza 2012
Three schools received fortified soup with 20
mg elemental iron per portion, and 100 mg
vitamin C per portion for 6 months
Kruger 1996
Only in the intervention group Treatment schools received worm prevention
education through regular public health lec-
tures, wall charts, and the training of teachers
in each treatment school onwormprevention.
Health education stressed the importance of
hand washing to avoid ingesting roundworm
and whipworm larvae, wearing shoes to avoid
hookworm infection, and not swimming in
infected fresh water to avoid schistosomiasis
Miguel 2004 (Cluster)
No additional intervention reported - 37 trials
Table 4. Data not included in meta-analysis
Infected children identified by screening - single dose
Nokes 1992
Albendazole
Growth measured but not reported: 9 weeks cited as too short a follow-
up period to demonstrate a change
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Table 4. Data not included in meta-analysis (Continued)
Tee 2013
Albendazole
No significant differences inmedian change inweight andweight-for-
height z-scores, and for mean change in weight-for-age, and height-
for-age z-scores at 12 months follow-up.
Weight: Median change in weight at follow-up in treatment group 2.6
(range 1.2 to 7.2) and control group 2.5 (range 1.2 to 6.6)
Height-for-age z-score: Mean change at follow-up in treatment group 1.1
(0.2) and in control group 1.1 (0.2)
Weight-for-age z-score: Median change at follow-up in treatment group -
1.0 (range 0.6 to 2.3) and in control group 0.8 (range 0.5 to 1.6)
Weight-for-height z-score: Mean change at follow-up in treatment group
0.5 (0.6) and in control group 0.1 (0.6)
Yap 2014
Albendazole
No significant differences in percentage stunted and sum of skinfolds
at 6 months follow-up.
Percentage stunted (≤ -2HAZ score):Mean at follow-up in treatment group
66% (mean change from baseline -7.0) and in control group 69% (mean
change from baseline -7.4)
Sum of skinfolds: Mean at follow-up in treatment group 12 mm (mean
change from baseline 1 mm) and in control group 12 mm (mean change
from baseline 1 mm)
Infected children identified by screening - multiple dose
Simeon 1995
Albendazole
No significant difference in any reported outcome for whole group.
Height-for-age z-score at baseline in treatment group -0.48 (0.95) and in
placebo group -0.39 (0.90). At follow-up in treatment group -0.48 (0.
97) and in placebo group -0.41 (0.89).
Body mass index (kg/m²) at baseline in treatment group 15.3 (1.3) and
in placebo group 15.5 (1.3). At follow-up in treatment group 15.6 (1.3)
and in placebo group 15.8 (1.4)
All children living in endemic area- single dose
Beach 1999
Albendazole
A nutritional benefit of treatment was not detectable after 4 months
for the entire trial population (853 participants, no figures provided)
.
Stratification by infection demonstrated small positive effects in the treat-
ment group for some anthropometric outcomes. In Ascaris-infected chil-
dren (51), height gain was 0.62 cm > placebo in the combination treat-
ment group (P = 0.01) at 4 months. In Trichuris-infected children (158)
, weight gain was 0.56 kg > placebo in the combination treatment group
(P = 0.01) at 4 months
Fox 2005
Albendazole
No results provided for whole trial population.
Results for height and weight only presented in the narrative for sub-
groups infected with hookworm and Ascaris: no significant anthropomet-
ric changes detected (no figures quoted). In those infected with Trichuris,
weight gain was greater in the albendazole group (difference compared
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Table 4. Data not included in meta-analysis (Continued)
to placebo 0.28 kg, P = 0.038). Adverse events: no serious adverse events
(albendazole 0/46 vs placebo 0/43). Myalgia and cough were reported
significantly more frequently in the placebo group compared to albenda-
zole
Greenberg 1981
Piperazine citrate
Treatment group tended to show worse nutrition than placebo.
Comparison showed no significant difference for all measured anthropo-
metric variables for the total group and for subgroups defined by severity
of infection (no figures provided)
Kloetzel 1982
Mebendazole
No significant difference was found between the groups.
Results reported as the proportion of treatment or control group that im-
proved, deteriorated, or experienced no change. Unclear which anthro-
pological measures were used in this categorization process. Proportions
in each category were not significantly different between trial arms (im-
proved: 51% inmebendazole group vs 49% in control; deteriorated: 35%
in mebendazole group vs 33% in control; no change: 14% in mebenda-
zole group vs 18% in control; no significance test results quoted)
Koroma 1996
Albendazole
Significant increases in weight-for-height, weight-for-age, and
height-for-age z-scores recorded in rural and urban treatment groups
at 6 months.
Mean increase in rural treatment group compared to placebo: weight-for-
height z-score 0.28 (SE 0.17) P < 0.05; weight-for-age z-score 1.04 (SE
0.03) P < 0.05; and height-for-age z-score 0.83 (SE 0.03) P < 0.001.
Mean increase in urban treatment group compared to placebo: weight-
for-height z-score 1.04 (SE 0.07) P < 0.05; weight-for-age z-score 1.02
(SE 0.09) P < 0.001; and height-for-age z-score 1.01 (SE 0.02) P <0.05
Michaelsen 1985
Tetra-chlorethylene
No significant difference in change in mean for haemoglobin.
(tetrachloroethylene 0.22 g/100 mL vs placebo 0.09 g/100 mL; quoted as
non-significant) or weight for height at 5months (tetrachloroethylene -1.
3%ofWHOreferencemean vs placebo -0.4%; quoted as non-significant)
Adverse events: 17% (19/119: results not given for separate trial arms) of
the children suffered adverse effects (nausea and ataxia) that began one
and a half hours after treatment. All symptoms disappeared within four
hours. Tetrachlorethylene is not in current use as a deworming drug
Nga 2009
Albendazole
No significant differences in weight-for-height, weight-for-age, and
height-for-age z-scores and skin fold thickness at 4 months.
There was no statistically significant effect of deworming on weight,
height, HAZ scores, WAZ scores, or WHZ scores. There were no statis-
tically significant differences in skin fold thickness after four months of
intervention
Wiria 2013 (Cluster)
Albendazole
No adverse events reported.
No significant difference in BMI at 21 months follow-up in children
aged 19 years and less.
Body mass index (kg/m2): median at follow-up in treatment group 21.56
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Table 4. Data not included in meta-analysis (Continued)
(IQR 19.44-24.12) and in placebo group 22.42 (IQR 19.68 - 25.56)
All children living in endemic area - multiple dose
Awasthi 1995 (Cluster)
Albendazole
During the trial there were 23 deaths, 13 were in the usual care arm
and 10 were in the treatment arm.
These data were not adjusted for cluster randomization.
Awasthi 2013 (Cluster)
Albendazole
Deworming showed no effect for death
MD in deaths per child-care centre at ages 1·0-6·0 was 0·16 (SE 0·11);
mortality ratio 0·95, 95% CI 0·89 to 1·02)
Goto 2009
Albendazole plus secnidazole
No significant differences in mean z-scores or prevalence of stunting,
underweight or wasting between the intervention groupswere found,
and the changes between intervals (eg between weeks 0 to 12, 0 to 24,
0 to 36, 12 to 24, etc.) did not differ significantly between groups.
Height-for-age z-score: at baseline in treatment group -1.08 (1.02) and in
control group -1.21 (1.0). At follow-up in treatment group -1.59 (0.93)
and in control group -1.70 (0.93).
Weight-for-age z-score: at baseline in treatment group -1.91 (1.15) and in
control group -1.85 (1.14). At follow-up in treatment group -2.62 (1.17)
and in control group -2.59 (1.17).
Weight-for-height z-score: at baseline in treatment group -1.25 (1.18) and
in control group -0.96 (1.17). At follow-up in treatment group -1.55 (1.
07) and in control group -1.83 (1.06)
Hadju 1997
Pyrantel pamoate
Albendazole
No significant differences detected between treatment groups onbasis
of multivariate analyses controlling for age, sex, and ‘times’.
Change inweight-for-age z-score: placebo0.02; pyrantel 1 x treatment 0.03;
pyrantel 2 x treatments 0.08; albendazole 1 x treatment -0.10; albendazole
2 x treatments 0.01.
Change in height-for-age z-score: placebo 0.01; pyrantel 1 x treatment 0.00;
pyrantel 2 x treatments 0.04; albendazole 1 x treatment -0.07; albendazole
2 x treatments 0.01.
Change in weight-for-height z-score: placebo 0.02; pyrantel 1 x treatment
0.08; pyrantel 2 x treatments 0.05; albendazole 1 x treatment -0.07;
albendazole 2 x treatments 0.03.
Change mid-arm circumference z-score: placebo -0.09; pyrantel 1 x treat-
ment -0.11; pyrantel 2 x treatments -0.11; albendazole 1 x treatment -0.
07; albendazole 2 x treatments -0.01
Hall 2006 (Cluster)
Albendazole
Trial authors reported no difference in final and change in height.
MUAC and subscapular skinfold thickness improved significantly in the
control group compared to the albendazole group (7.87 vs 7.61, P = 0.
005 and 1.22 vs 1.05, P = 0.005 respectively). These results do not appear
to have been adjusted for cluster randomization. The results that show
no effect, however, will not remain non-significant even after appropriate
adjustment, though the CIs may change
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Table 4. Data not included in meta-analysis (Continued)
Lai 1995
Mebendazole plus pyrantel
No difference in height or weight between treatment and control
group at the end of 2-year follow-up.SDsnot provided.Results stratified
for males and females:
Females: change in height in treatment arm 12.2 cm vs change in height
in placebo arm 12.4 cm; change in weight in treatment arm 5.6 kg vs
change in weight in placebo arm 5.6 kg.
Males: change in height in treatment arm 11.8 cm vs change in height in
placebo arm 11.4cm; change in weight in treatment arm 5.7 kg vs change
in weight in placebo arm 4.7 kg
Le Huong 2007
Mebendazole
No obvious trend in nutrition variable.
Anthropometric indices were calculated using WHO/NCHS reference
data. Being wasted, stunted and underweight was defined by z-scores ,<
- 2SD for weight-for-height, height-for-age and weight-for-age, respec-
tively.
Percentage underweight: At baseline Fe 41·9, Fe + MEB 51·9, MEB 50·6,
Placebo 45·1; after treatment Fe 33·7, Fe + MEB 46·8, MEB 38, Placebo
35·4.
Percentage stunted: At baseline Fe 30·2, Fe + MEB 31·6, MEB 41·8,
Placebo 31·7; after treatment Fe 29·1, Fe + MEB 27·8, MEB 29·1,
Placebo 29·3.
Percentage wasted:At baseline Fe 9·3, Fe +MEB 16·5, MEB 13·9, Placebo
12·2; after treatment Fe 5·8, Fe + MEB 17·7, MEB 13·9, Placebo 13·4
Miguel 2004 (Cluster)
Albendazole
No effect on nutrition or haemoglobin demonstrated
For haemoglobin a sample of around 4% (778/20,000) of the quasi-
randomized comparison of group 1 vs group 2 in 1998 was analysed
Height and weight data was collected on all individuals in standards 3-8
(9102/20000)
Difference in weight-for age z-score (treatment - control): 0.00 (SE 0.04)
Difference in height-for-age z-score end value (treatment - control): 0.09
(SE 0.05).
Difference in haemoglobin (g/L) (treatment - control): 1.6 (SE 1.4)
Ndibazza 2012
Albendazole
During the trial there were 16 deaths, 8 were in the placebo arm and
8 were in the treatment arm.
No significant differences in mean z-scores for weight-for-height,
weight-for-age, and height-for-age z-scores at 5 years of age.
Height-for-age z-score: at follow-up in treatment group -1.33 (1.34) and
in control group -1.27 (1.20)
Weight-for-age z-score: at follow-up in treatment group -0.88 (0.95) and
in control group -0.87 (0.91)
Weight-for-height z-score: at follow-up in treatment group -0.13 (1.28)
and in control group -0.17 (1.19)
Rousham 1994 (Cluster)
Mebendazole
ANOVAS of the change in z-scores revealed no significant improve-
ment with treatment.
Change in weight-for-age and weight-for-height z-scores were signifi-
cantly worse in the treatment group. Height-for-age z-score (mebenda-
134Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school
performance (Review)
Copyright © 2015 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 4. Data not included in meta-analysis (Continued)
zole 0.25 vs 0.17 in placebo group, P ’non-significant’), weight-for-age
z-score (mebendazole 0.03 vs 0.12 in placebo group, P < 0.05), weight-
for-height z-score (mebendazole -0.25 vs -0.05 in placebo group, P < 0.
001), and MUAC were presented (mebendazole 0.33 vs 0.23 in placebo
group, P ’non-significant’)
Stoltzfus 2001
Mebendazole
Mebendazole is reported as significantly reducing the prevalence
of mild wasting malnutrition in a subgroup of children aged < 30
months only
adjusted odds ratio for mebendazole 0.38 (95% CI 0.16 to 0.90) for
weight-for-height z-score < -1. Mebendazole is reported as significantly
reducing the prevalence of poor appetite across the whole group (adjusted
odds ratio for mebendazole 0.52 (95% CI 0.30 to 0.89) for weight-for-
height z-score < -1).Mebendazole hadno impact on iron indices. Adjusted
effect on motor scores had a tendency to favour mebendazole, but this
was not significant
Stoltzfus 1997 (Cluster)
Mebendazole
Weight gain: in a subgroup of under 10 year olds, the twice-yearly
treated group experienced significantly greater weight gain (kg) com-
pared to control (2.38 (SE 0.08) vs 2.11 (SE 0.08), P < 0.05).
In the thrice-yearly treatment group the difference was not significant (2.
31 (SE 0.08) vs 2.11 (SE 0.08), no P value stated).
Height gain: in under 10 year olds the thrice-yearly treated group expe-
rienced significantly greater height gain (cm) compared to control (4.59
(SE 0.07) vs 4.29 (SE 0.07), P < 0.01). In the twice-yearly treatment
group the difference in height gain was not significant (4.42 (SE 0.07) vs
4.29 (SE 0.07), no P value stated). There were no significant differences
found in the subgroup of children aged over 10 years.
Haemoglobin change: deworming had no effect on haemoglobin change
in an adjusted analysis presented for the whole trial group (g/L): control
11.3 (SE 1.7); twice-yearly treatment group 10.3 (SE 1.7); and thrice-
yearly group 12.7 (SE 1.7)
Willett 1979
Levamisole
No statistical difference in nutrition in terms of height and weight
differences between the 2 groups.
Growth rates presented are adjusted for a number of variables. Weight
gain (kg/year) in levamisole group 2.08 vs 1.92 in placebo group (P = 0.
06). Height gain (cm/year) in levamisole group 7.58 vs 7.73 in placebo
group (no significance quoted)
Table 5. Trials evaluating psychometric tests of cognition
Trial details Outcome measures Results
Infected children identified by screening - single dose
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Table 5. Trials evaluating psychometric tests of cognition (Continued)
Kvalsvig 1991a
Mebendazole vs placebo, 1 month
Card sorting task; cancellation task (num-
ber of letter ’s’ in text deleted in a time pe-
riod)
Changes in cognitive scores are not clearly
reported since “the dose of mebendazole
was inadequate to free children from infec-
tion”
Nokes 1992
Albendazole vs placebo
2.25 months
Digit span (forward and backward); arith-
metic and coding from Wechsler Intelli-
gence Scale for Children; fluency; listening
comprehension from the Clinical Evalua-
tion of Language functions; matching fa-
miliar figures test
Mean test scores pre- and post-intervention
presented with CIs
No comment made on significance of un-
adjusted data.
Results of multiple regression suggest a
greater improvement in treated children
in 3/10 tests (fluency, digit span forwards,
digit span backwards)
Infected children identified by screening - multiple dose
Simeon 1995
Albendazole vs placebo
6.5 months
1. Main trial (264 children)
Wide range achievement test: reading,
arithmetic, and spelling sub tests;
2. Subgroup 1 (189 children 189 infected
children from original population)
Digit span; verbal fluency test; visual
search; number choice; French vocabulary
learning;
3. Subgroup 2 (97 children from grade 5)
French learning; digit spans (forward and
backward); Corsi block span; verbal flu-
ency; picture search; silly sentences
1. Main trial: no difference in any
reported outcome measure;
2. Subgroup 1: no significant effect on
any of the outcome measures;
3. Subgroup 2: no significant
improvement with treatment in any of the
tests was found in multiple regression
modelling.
All children living in endemic area - single dose
Nga 2009
Albendazole
Cognitive performance was measured us-
ing Raven’s Colored Matrices and also a se-
ries of cognitive tests from Wechsler’s In-
telligence Scale for Children III: digit span
backward and forward, block design and
coding
Deworming had no significant effect on
any of the cognitive tests
Solon 2003
Albendazole vs placebo
16 weeks
Cognitive ability was measured using a
standardized written mental-abilities test
called the Primary Mental Abilities Test
for Filipino Children (PMAT-FC). The
test covers general knowledge and compre-
hension, verbal relationships, fundamen-
tal mathematical comprehension and skills,
numerical sequencing, and ability to per-
ceive and apply relationships based on
meaningless stimuli
Deworming had either no effect or a neg-
ative effect on mental ability scores. Data
was not reported
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Table 5. Trials evaluating psychometric tests of cognition (Continued)
All children living in endemic area - multiple dose
Awasthi 2000
Albendazole vs placebo, 2 years
1045 participants. Developmental status
(Denver Questionnaire)
No difference in development between
treatment groups in terms of proportion
with “normal” development
Miguel 2004 (Cluster)
Dewormingpackage including albendazole
vs placebo
1 year
30,000 participants. Cognitive tests in-
cluding picture search, Raven matrix, ver-
bal fluency, digit span, Spanish learning,
and a dynamic test using syllogisms mea-
sured for all three school groups in 2000
Outcome data not reported for cognitive
tests, though authors state: “Deworming
treatment effects are not significantly dif-
ferent than zero for any component of
the cognitive exam (results available on re-
quest)”
Ndibazza 2012
Albendazole vs placebo, post-treatment
870 participants. Block design, Picture vo-
cabulary scale, Sentence repetition, Verbal
fluency, Counting span, Running memory,
Picture search, Wisconsin card sort test,
Tap once tap twice task, Shapes task, Tower
of London
Deworming had no significant effect on
any of the cognitive tests
Stoltzfus 2001
Mebendazole vs placebo, 1 year
359 participants. Motor and language de-
velopment by parents reporting gross mo-
tor and language milestones using scoring
system developed specifically for the trial
Unadjusted data not reported.
Treatment had no significant effect on mo-
tor or language development
Watkins 1996
Albendazole vs placebo, 6 months
212participants. Interamerican vocabulary
test; Interamerican reading test; Peabody
picture vocabulary test
All outcome measures reported as unad-
justed scores.
No difference in any of the tests found be-
tween treatment groups
Table 6. Trials evaluating measures of physical well-being
Trial details Outcome measures Results
Infected children identified by screening - single dose
Yap 2014
Albendazole
VO2 max estimate (mL kg-1 min-1), 20 m
running laps completed grip strength (kg),
standing broad jump distance (cm). Mean
values reported
No effect was detected on any of the mea-
sures of physical well-being (99 in the al-
bendazole group and 95 in the control)
Stephenson 1989
Albendazole vs placebo, 6 months follow-
up
Harvard Step Test Deworming significantly improved chil-
dren’s physical well-being in a non-ran-
domly selected subgroup of children (33/
171)
Treatment group: mean = 80, SD = 5.51,
N = 18
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Table 6. Trials evaluating measures of physical well-being (Continued)
Placebo group: mean = 74, SD = 4.65, N
= 15
MD = 6.00, 95% CI 2.53 to 9.4
Stephenson 1993
Albendazole vs placebo, 8 months follow-
up
Harvard Step Test Deworming significantly improved chil-
dren’s physical well-being in a non-random
subgroup of children (54/328)
Treatment group: mean = 82, SD = 3.64,
N = 27
Placebo group: mean = 76, SD = 3.57, N
= 26
MD = 6.00, 95% CI 4.06 to 7.94
Table 7. Trials evaluating school attendance (days present at school)
Trial details Outcome measures Intervention Control Difference
Infected children identified by screening - multiple dose
Simeon 1995
Albendazole vs placebo
6.5 months
Mean % attendance
(class registers )
N = 264
Baseline
62.6 (SD 20.4)
Follow-up
67.3 (SD 18.4)
Baseline
66.3 (SD 20.8)
Follow-up
69.3 (SD 17.5)
2.0%
All children living in endemic area- multiple dose
Kruger 1996 Attendance at follow-up
only
(class registers)
N = 143
97.2% (iron group)
95.6%
98% (iron group)
95.2%
-0.8%
0.4%
Miguel 2004 (Cluster)
Group 1 vs 2+3 (1 year
follow-up)
School participation
N = 30,000
84.1% 73.1% (group 2)
76.6% (group 3)
9.3%
(SE 3.0%)
Miguel 2004 (Cluster)
Group 2 vs 3
(1 year follow-up)
School participation
N = 20,000
71.8% 66.4% 5.4%
(SE 2.7%)
Miguel 2004 (Cluster)
Group 1 vs 3
1999 (2 year follow-up)
School participation
N = 20,000
71.6% 66.4% 5.1%
(SE 2.7)
Watkins 1996
6 months
Attendance rates of chil-
dren actively attending
school.
N = 243
Baseline 92%,
SEM = 1
Follow-up 88%,
SEM = 1
Baseline 0.90,
SEM = 1
Follow-up 89%
SEM =1
-3%
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Table 8. School performance
Trial details Outcome measures Results
All children living in endemic area - multiple dose
Hall 2006 (Cluster)
Albendazole versus placebo, 2 years
2659 participants. Mathematics test score,
Vietnamese test score
No statistically significant differences in
test results at start or end of trial
Miguel 2004 (Cluster)
Dewormingpackage including albendazole
versus placebo
30,000 participants. Exam score perfor-
mance (measured by Internationaal Chris-
telijk Steunfonds Africa (ICS) adminis-
tered English, Mathematics and Science-
Agriculture exams) in pupils in grades 3 to
8
In the original trial and the pure replica-
tion, the trial authors reported no signifi-
cant difference, but data was not reported.
In the statistical replication, this was con-
firmed
A P P E N D I C E S
Appendix 1. Authors’ judgment on risk of bias
Potential bias Authors’ judgement
Random sequence generation (selection bias) High - not randomized or quasi-randomized
Unclear - states “randomized”, but does not report method
Low - describes method of randomization
Allocation concealment (selection bias) High - not concealed, open label trial for individually randomized, method of
concealment not adequate
Unclear - details of method not reported or insufficient details
Low - central allocation, sequentially numbered opaque sealed envelopes
Blinding (performance bias and detection bias) High - personnel, participants or outcome assessors not blinded
Unclear - no details reported, insufficient details reported
Low - personnel, participants and outcome assessors blinded
Incomplete outcome data (attrition bias) High - losses to follow-up not evenly distributed across intervention and control
group, high attrition rate (20% or more for the main outcome)
Unclear - no details reported, insufficient details reported
Low - no losses to follow-up, losses below 20% and evenly distributed across
groups, ITT analysis used
Note: for cluster-RCTs, the loss relates to the clusters
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(Continued)
Selective reporting (reporting bias) High - did not fully report measured or relevant outcomes
Unclear - not enough information reported to judge
Low - all stated outcomes reported
Other bias Low - no obvious other source of bias of concern to reviewers
High - major source of bias such as unexplained differences in baseline charac-
teristics
Appendix 2. Abridged table of characteristics
TrialID
Country
Who was
treated?
(Age)
How long
was the
follow-
up?
Trialde-
sign?
(No.
of partici-
pantsa)
Was
it a clus-
ter-RCT?
(No. of
clusters)
What in-
terven-
tion?
(Dose)
Co-inter-
ventions?b
What con-
trol?
How long
was
the treat-
ment?
Endemic
area?
(Commu-
nity cate-
gory num-
ber)
Alderman
2006
(Cluster)
Uganda
Chil-
dren (1 to
7 years)
3 years RCT (27,
995)
Yes (48) Albenda-
zole (400
mg)
Child
health
pack-
age - both
groups
No
treatment
Every 6
months
Yes (2)
Awasthi
1995
(Cluster)
India
Chil-
dren (1 to
4 years)
2 years Quasi-
RCT
(3712)
Yes (50) Albenda-
zole (400
mg)
None Placebo Every 6
months
Yes (3)
Awasthi
2000
India
Children
(1.5 to 3.5
years)
2 years Quasi-
RCT
(1045)
No Albenda-
zole (600
mg)
None Placebo Every 6
months
Yes (3)
Awasthi
2001
(Cluster)
India
Chil-
dren (1 to
4 years)
1.5 years RCT
(1672)
Yes (124) Albenda-
zole ± vita-
min A
(100,000
units)
Child
health
pack-
age - both
groups
Placebo +
vitamin A
Every 6
months
Yes (3)
Awasthi
2013
(Cluster)
India
Children
(≤ 5 years)
5 years RCT fac-
torial
(8338)
Yes (72) Albenda-
zole
(400 mg) ±
vitamin A
Child
health
pack-
age - both
groups
Usual care Every 6
months
Yes (3)
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(Continued)
Beach
1999
Haiti
Children
(grades 1
to 4)
4 months RCT (853) No Albenda-
zole (400
mg)
Ivermectin
(200
to 400 µg/
kg)
None Placebo +
vitamin C
(250 mg)
Single dose Yes (3)
Donnen
1998
Zaire
Children
(0 to 72
months)
1 year RCT (222) No Mebenda-
zole (500
mg)
None Placebo +
vitamin A
(60 mg)
No
treatment
Every 3
months
Yes (3)
Dossa
2001
Benin
Chil-
dren (3 to
5 years)
10 months RCT (65) No Albenda-
zole (200
mg) ± iron
None Placebo Repeated 1
month
later
Yes (2)
Fox 2005
Haiti
Chil-
dren (5 to
11 years)
6 months RCT (626) No Albenda-
zole
(400 mg) ±
vitamin C
(250 mg)
Diethyl-
carba-
mazine
(DEC, 6
mg/kg)
None Placebo Single dose Yes (2)
Freij
1979a
Ethiopia
Children
(1.5 to 5
years)
28 days Quasi-
RCT (13)
No Piperazine
(3 g)
Child
health
pack-
age - both
groups
Placebo Single dose In-
fected chil-
dren (un-
clear)
Freij
1979b
Ethiopia
Chil-
dren (1 to
5 years)
34 days Quasi-
RCT (44)
No Piperazine
(3 g x 2)
None Placebo Single dose In-
fected chil-
dren (3)
Garg 2002
Kenya
Chil-
dren (2 to
4 years)
6 months RCT (347) No Mebenda-
zole (500
mg)
Child
health
pack-
age - both
groups
Placebo Single dose Yes (2)
Goto 2009
Bangladesh
Chil-
dren (≤ 11
months)
36 weeks RCT (410) No Albenda-
zole (200
mg) ± sec-
None Placebo Every 12
weeks
Yes (2)
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nidazole
(0.5 mL/
kg, anti-
Giardia)
Greenberg
1981
Bangladesh
Children
(1.5 to 8
years)
11 months RCT (152) No Piperazine
citrate (80
mg/kg)
None Placebo Two doses
in 2 weeks
Yes (1)
Hadju
1996
Indonesia
Chil-
dren (6 to
10 years)
7 weeks RCT (64) No Pyrantel
pamoate
(10mg/kg)
None Placebo Single dose Yes (1)
Hadju
1997
Indonesia
Chil-
dren (± 8.3
years)
1 year RCT (330) No Albenda-
zole (400
mg)
Pyrantel
pamoate
(10mg/kg)
None Placebo Single dose
or every 6
months
Yes (1)
Hall 2006
(Cluster)
Vietnam
Children
(± 104.5
months)
2 years RCT (2,
659)
Yes (80) Albenda-
zole
(400 mg) ±
retinol
(200,000
IU)
None Placebo Every 6
months
Yes (1)
Kirwan
2010
Nigeria
Chil-
dren (1 to
5 years)
14 months RCT (320) No Albenda-
zole (200
to 400 mg)
Child
health
pack-
age - both
groups
Placebo Every 4
months
Yes (3)
Kloetzel
1982
Cameroon
Chil-
dren (1 to
8 years)
10 months RCT (337) No Mebenda-
zole (100
mg x3)
None Placebo 3doses in 3
days
Yes (1)
Koroma
1996
Sierra
Leone
Chil-
dren (6 to
10 years)
6 months RCT (187) No Albenda-
zole (400
mg)
None Placebo Single dose Yes (2)
Kruger
1996
South
Africa
Chil-
dren (6 to
8 years)
11 months RCT (74) No Albenda-
zole
(400 mg)
± soup for-
tified with
Child
health
pack-
age - both
groups
Placebo Re-
peated at 4
months
Yes (3)
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(Continued)
iron and
vitamin C
Kvalsvig
1991a
South
Africa
Children
(primary
school)
1 month RCT (un-
clear)
No Mebenda-
zole (500
mg)
None Placebo Single dose In-
fected chil-
dren (1)
Lai 1995
Malaysia
Children
(8 years)
2 years RCT (314) No Mebenda-
zole
(100 mg)
+ pyrantel
(200 mg)
None Placebo Every 3
months
Yes (1)
Le Huong
2007
Vietnam
Children 6 months RCT fac-
torial
(510)
No Mebenda-
zole (500
mg)
Iron-for-
tified noo-
dles
Placebo Twice
3 months
apart
Yes (2)
Michaelsen
1985
Botswana
Chil-
dren (5 to
14 years)
5 months RCT (121) No Tetra-
chloroethy-
lene (0.1
mL/kg)
None Placebo Single dose Yes (1)
Miguel
2004
(Cluster)
Kenya
Children
(8 years)
2 years RCT
(9102)
Yes (65) Albenda-
zole (400
to 600 mg)
Child
health
package -
only inter-
vention
group
No
treatment
Every 6
months
Yes (1)
Ndibazza
2012
Uganda
Chil-
dren (± 15
months)
Post-
treatment
RCT fac-
torial
(1423)
No Albenda-
zole (200
to 400 mg)
Child
health
pack-
age - both
groups
Placebo ?? Yes (3)
Nga 2009
Vietnam
Chil-
dren (6 to
8 years)
4 months RCT (510) No Albenda-
zole
(400 mg) ±
multi-
micronu-
trient forti-
fied biscuit
None Placebo Single dose Yes (2)
Nokes
1992
Jamaica
Chil-
dren (9 to
12 years)
9 weeks RCT (103) No Albenda-
zole (400
mg x3)
None Placebo Single dose In-
fected chil-
dren (1)
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(Continued)
Olds 1999
China,
Philip-
pines and
Kenya
Children
(school
children)
6 months RCT (103) No Albenda-
zole
(400 mg) ±
praziquan-
tel (40 mg/
kg)
None Placebo Single dose Yes (1)
Palupi
1997
Indonesia
Chil-
dren (2 to
5 years)
9 weeks RCT (191) No Albenda-
zole (400
mg)
Iron Iron (30
mg
weekly)
Single dose Yes (2)
Rousham
1994
(Cluster)
Bangladesh
Chil-
dren (2 to
6 years)
18 months RCT (1,
402)
Yes (13) Mebenda-
zole (500
mg)
Pyrantel
pamoate
(10mg/kg)
None Placebo Every 2
months
Yes (1)
Sarkar
2002
Bangladesh
Chil-
dren (2 to
12 years)
16 weeks RCT (81) No Pyrantel
pamoate
(11mg/kg)
None Placebo Single dose In-
fected chil-
dren (1)
Simeon
1995
Jamaica
Chil-
dren (6 to
12 years)
26 weeks RCT (392) No Albenda-
zole (800
mg)
None Placebo Repeated 3
to 6
months af-
ter
In-
fected chil-
dren (1)
Solon
2003
Philip-
pines
Children
(grades 1
to 6)
16 weeks RCT (851) No Albenda-
zole
(400 mg)
± multivi-
tamin and
iron
None Placebo Repeated 3
to 6
months af-
ter
Yes (2)
Stephen-
son
1989
Kenya
Children
(grades 1
to 2)
6 months RCT (150) No Albenda-
zole (400
mg)
None Placebo Single dose Yes (1)
Stephen-
son
1993
Kenya
Children
(grades 1
to 5)
8 months RCT (284) No Albenda-
zole (600
mg)
None Placebo Repeated 3
to 6
months af-
ter
Yes (1)
Stoltzfus
1997
(Cluster)
Tanzania,
Chil-
dren (± 10.
5 years)
12 months RCT
(3063)
Yes (12) Mebenda-
zole (500
mg, 2x or
None Placebo Every 4 or
6 months
Yes (1)
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(Continued)
Zanzibar 3x)
Stoltzfus
2001
Tanzania,
Zanzibar
Children
(6 to 59
months)
12 months RCT fac-
torial
(359)
No Mebenda-
zole (500
mg) ± iron
None Placebo Every 3
months
Yes (2)
Sur 2005
India
Chil-
dren (2 to
5 years)
12 months RCT (683) No Albenda-
zole
(400 mg) ±
vitamin B
None Placebo Every 6
months
Yes (2)
Tee 2013
Malaysia
Children 12 months RCT (33) No Albenda-
zole (400
mg x 2)
None Placebo Single dose Yes (NA)
Watkins
1996
Guatemala
Chil-
dren (7 to
12 years)
6 months RCT (226) No Albenda-
zole (400
mg)
None Placebo Repeated
at 12weeks
Yes (1)
Willett
1979
Tanzania
Children
(6 to 91
months)
12 months RCT (268) No Lev-
amisole (2.
5 mg/kg)
None Placebo Every 3
months
Yes (3)
Wiria
2013
(Cluster)
Indonesia
Children
and adults
≥ 2 years
21 months RCT (855) Yes (954) Albenda-
zole (400
mg x 3)
None Placebo Single dose Yes (1)
Yap 2014
Myanmar,
China
Chil-
dren (9 to
12 years)
6 months RCT (194) No Albenda-
zole (400
mg x 3)
None Placebo Single dose In-
fected chil-
dren (NA)
aNumber of participants analysed for primary outcome.
bFor details on “child health package” please see Table 3: Accompanying health promotion activities.
F E E D B A C K
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Ted Miguel and Michael Kremer, 11 January 2013
Summary
Dear Dr. Taylor-Robinson, Dr. Maayan, Dr. Soares-Weiser, Dr. Donegan, and Dr. Garner:
We are writing to clarify several points that you raise in your recent 2012 Cochrane review of deworming regarding our 2004 paper
“Worms: Identifying impacts on education and health in the presence of treatment externalities” in Econometrica.
In particular, we have four main concerns about the discussion of our piece in the recent review, and believe that they could change the
assessment of the quality of the evidence presented in our paper. We list these points here in the letter below, with a brief discussion of
each point. We then discuss several additional points in the attached document below, following this letter. We hope that these detailed
responses to your review will start a productive discussion about the interpretation of the evidence in the Miguel and Kremer (2004)
paper.
(All page numbers listed below refer to the July 2012 version of your review, with “assessed as up-to-date” as May 31, 2012.)
We recognize that writing a Cochrane review is a major undertaking, and we appreciate the time you have taken to read our paper, and
the dozens of other papers covered in the review. We hope that this note can serve as the starting point for discussion, both in writing
and via phone, if appropriate.
Our four points all relate to the claim made on page 6 of your review, and repeated throughout the review, about the Miguel and
Kremer (2004) paper:
“Miguel 2004 (Cluster) has a high risk of bias for sequence generation, allocation concealment, blinding, incomplete outcome data
and baseline imbalance.”
We have serious concerns about the claims you make about the risk of bias for baseline imbalance, incomplete outcome data, and
sequence generation. We discuss these in turn below.
Point (1): A leading issue is your current assessment of the quality of evidence on school attendance and participation, which is the
main outcome measure in the Miguel and Kremer (2004) trial. Several concerns are raised, including: a lack of baseline values for these
measures (leading to a risk of baseline imbalance), and statistically significant impacts for only one of the comparisons considered. The
quotes from your review are as follows:
[p. 21] “For school attendance (days present at school): (Miguel 2004 (Cluster) Table 6; Analysis 5.4) reported on end values for
attendance rates of children (1999, Group 1 versus Group 3), and found no significant effect (mean difference 5%, 95% CI -0.5 to
10.5). No baseline values were given so there is potential for any random differences between the groups to confound the end values.”
[p. 24] “Similarly, for school attendance, the GRADE quality of the evidence was very low. One quasi-randomized trial (Miguel 2004
(Cluster) reported an effect, which was apparent in only one of the two comparisons in up to a year of follow up, and not apparent in
the one comparison after one year. Miguel 2004 (Cluster) measured attendance outcomes directly, unlike the other two trials (Simeon
1995; Watkins 1996) which measured attendance using school registers, which may be inaccurate in some settings. However, in Miguel
2004 (Cluster), the values for school attendance were end values and not corrected for baseline. Thus random differences in baseline
attendance between the two groups could have confounded any result.”
We feel that these concerns are misplaced, and explain why here. We first discuss concerns about “baseline imbalance”.
First, we in fact do have baseline data on school participation (our preferred measure) for one of the comparisons that you focus on.
The authors of the Cochrane appear to have missed this data in our paper. In Table VIII, Panel A, there is a comparison of 1998 school
participation for both Group 2 and Group 3, when both were control schools. There is no statistically significant difference in school
participation across Group 2 and Group 3 in 1998, and if anything school participation is slightly lower in Group 2 (-0.037, s.e. 0.036).
This makes the difference between Group 2 and Group 3 in 1999 (0.055, s.e. 0.028), when Group 2 had become a treatment school,
even more impressive, since at baseline Group 2 had slightly lower school participation. We respectfully request that the authors of the
Cochrane review include this data as evidence of baseline balance in our key outcome measure, school participation, and that they edit
their claim that we do not have any such evidence.
It is interesting to note that, if we take the difference between Group 2 and Group 3 at baseline seriously, then the overall effect for
this “year 1” comparison is 3.7 + 5.5 = 9.2 percentage points. This is almost exactly the same as the 9.3 percentage point effect in
the other “year 1” comparison that the Cochrane authors focus on (Group 1 versus Groups 2 and 3 in 1998). Taken together, this is
quite striking evidence that the first year of deworming treatment significantly improves school participation. The Cochrane authors’
repeated concerns in their review about baseline balance being critical in randomized experiments suggests (to us) that they might
find it methodologically preferable to use a “difference-in-difference” design that explicitly controls for any baseline differences across
treatment groups, rather than the standard unbiased “endline” comparison across treatment groups. If this is in fact the case, then the
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relevant year 1 deworming treatment effect for the Group 2 versus Group 3 comparison (for which we have baseline data, as noted
above) is the 9.2 percentage point estimate, which we note is significant at 99% confidence.
Second, regarding baseline data on school attendance, we discuss that there is indeed evidence from school registers that recorded
attendance is indistinguishable in the three groups of schools in early 1998 (in Table I). While the register data has its weaknesses
- precisely the reason we developed the much more rigorous approach of unannounced school participation checks, combined with
tracking of school transfers and drop-outs - it is used in other trials, and in fact the Cochrane review considers school register data
sufficiently reliable to include a trial (Watkins 1996) that uses it in their meta-analysis of school attendance.
We are puzzled as to why the evidence in the Watkins (1996) trial is included at all in the Cochrane review if similar register data is
considered unreliable whenMiguel and Kremer (2004) use it. If school register data is considered (largely) unreliable, then theWatkins
(1996) article should be excluded from the review, in which case the “meta-analysis” of school attendance and participation impacts
will yield estimated effects that are much larger and statistically significant (since the Watkins impact estimates are close to zero). If the
register data is considered (largely) reliable, then the Watkins (1996) trial should be included in the review, but the baseline register
data in Miguel and Kremer (2004) should be considered as evidence that we do in fact have baseline balance on school participation.
But there is an inconsistency in how register data is considered across the two trials. This seemingly inconsistent approach taken by the
authors raises questions about the evenhandedness of the Cochrane review.
In fact, the appropriate use of school register data is more subtle than the Cochrane authors currently consider, since its use as baseline
data may in fact be appropriate even if it is inappropriate for use as outcome data. There are at least two reasons why. First, one of the
major weaknesses of the school register data used in Watkins (1996) is that it excludes any students who have dropped out, potentially
giving a misleading picture about school participation over time. However, this concern about drop-outs is irrelevant when we use
school register data at baseline, since the universe of students considered in the Miguel and Kremer (2004) article was restricted to
those currently enrolled in school in January 1998 (at the start of the school year), and thus the exclusion of drop-outs is not a concern.
Note that our use of the school register data at the start of the school year is a likely explanation for why the baseline average attendance
rates we obtain using this data are much higher than the average school participation rate that we estimate over the course of the entire
school year.
A second related issue is the quality of measured school attendance data conditional on student enrollment in school. Note that to the
extent that differences in attendance record-keeping prior to the introduction of the program are random across schools, they will not
bias estimates of treatment impact and any “noise” in these measures will be correctly captured by reported standard errors. However,
there are plausible concerns about the quality of school register data collected in treatment versus control schools in the context of an
experimental evaluation, with a leading concern being that school officials could erroneously inflate figures in the treatment group. Yet
once again these concerns are irrelevant in the Miguel and Kremer (2004) trial context since the baseline 1998 school register data that
we present (in Table I, Panel B) was collected before any interventions had even been carried out in the sample schools, once again
making the baseline school register data potentially more reliable than school register data used as an outcome.
While the data and measurement issues here are somewhat subtle, if anything they argue in favor of including the baseline school
register data in assessing the baseline balance in the Miguel and Kremer (2004) paper, while excluding the school register outcome data
in Watkins (1996) as potentially unreliable. Instead, the Cochrane authors completely dismiss the baseline register data in Miguel and
Kremer (2004) as unreliable evidence for baseline balance, while including the Watkins (1996) data in their meta-analysis of school
participation impacts, giving it equal weight with theMiguel and Kremer (2004) school participation impact evidence (which uses more
rigorous outcome data). Once again, the seemingly selective approach taken by the authors raises questions about the evenhandedness
of the Cochrane review.
An important final point has to do with the claim that there might have been “random differences” across groups. Given the randomized
design ofMiguel and Kremer (2004), there is no systematic difference to expect there to have been such random differences. The endline
comparison of outcomes across treatment groups yields unbiased treatment effect estimates. The remarkable balance across the three
groups in terms of dozens academic, nutritional, and socioeconomic outcomes at baseline (Table I) makes it even more unlikely that
there were large differences in school participation solely by chance. If the Cochrane authors would like to consider other characteristics
(other than school participation) to gauge the likelihood that Groups 1, 2 and 3 in our trial are in fact balanced at baseline they should
look at the whole range of outcomes presented in Table I of Miguel and Kremer (2004). The lack of significant baseline academic test
scores across Groups 1, 2 and 3 in our sample (Table 1, Panel C) is particularly good evidence that schooling outcomes were in fact
balanced at baseline, for instance. It is not clear to us why the Cochrane authors remain so concerned about baseline imbalance issues
given the experimental design (which leads to unbiased estimates) and the remarkable balance we observe along so many characteristics
in Table I of Miguel and Kremer (2004), and their review does not provide compelling justification for their concerns.
Moreover, in the standard statistical methods that we use, only those differences across groups that are too large to have been generated
“by chance” are considered statistically significant impacts. In other words, the standard errors generated in the analysis itself are precisely
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those that address the risk of imbalance “by chance” given our research design and sample size. Of course, random variation that is
orthogonal to treatment assignment does not alone generate bias.
Speculating about the possibility that there were simply positive impacts “by chance” in order to cast doubt on one set of results, but
not doing the same when there are zero estimated impacts, again raises questions about the evenhandedness of the Cochrane review.
(For instance, perhaps the “zero” impacts on Hb outcome measures in our sample were zero simply “by chance”, when the real point
estimates are in fact strongly positive, like the large school participation impacts we estimate. Yet this possibility is not mentioned in the
Cochrane review.) In our view, the Cochrane authors do not provide sufficient justification for their fears about imbalance “by chance”
in our sample, and we feel further concrete details about these concerns are needed to substantiate their assertions.
Taken together, the Cochrane review’s claim that there is a “high risk of bias for … baseline imbalance” (the claim made on p. 6 and p.
136, and throughout the review) appears highly misleading to us, given the: balance in school participation we observe between Group
2 and Group 3 in 1998; the balanced school attendance based on register data across Groups 1, 2 and 3 at baseline; the balance in other
measures of academic performance (including academic test scores) as well as multiple socioeconomic and nutritional characteristics
at baseline; and most importantly given the randomized experimental design, which implies that there is no systematic reason why the
three treatment groups would differ significantly along unobservable dimensions.
We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed “high
risk of bias for … baseline imbalance” in Miguel and Kremer (2004).
Point (2): There is also an important methodological point to make regarding how the authors of the Cochrane review assess the school
participation evidence. At several points they note that only some of the school participation comparisons are statistically significant
at 95% confidence. To be specific, the comparisons they focus on have the following estimated impacts and standard errors (from p.
130-131 of their review):
School participation outcomes measured £ 1 year:
9.3 percentage point gain (s.e. 3.1 percentage points)
5.5 percentage point gain (s.e. 2.8 percentage points) School participation outcomes measured > 1 year:
5.0 percentage point gain (s.e. 2.8 percentage points)
It is unclear to us why the reviewers separate out the three comparisons, rather than combining the groups in a single analysis using
standard analytical methods, as their principal assessment of the impact of deworming on school participation. They give no clear
methodological justification for this separation. Pooling data from three valid and unbiased “comparisons” still yields an unbiased
treatment effect estimate, but with much greater statistical precision, and is thus a methodologically preferable approach. At a minimum,
the Cochrane authors should discuss the pooled estimates (which are the focus of Miguel and Kremer 2004) in addition to the three
separate comparisons.
One simple approach to doing so that maintains the “comparisons” above, and at least goes part of the way towards using the full
sample, would be to pool 1998 and 1999 data for the Group 1 versus Group 3 comparison, since Group 1 is treatment during this
entire period and Group 3 is control for the entire period. The distinction between < 1 year and > 1 year outcomes seems rather artificial
to us, as discussed further below. It is unclear to us why the Cochrane authors never present this comparison of Group 1 versus Group
3 for 1998 and 1999 pooled together.
The preferred analysis in the Miguel and Kremer (2004) paper pools multiple years of data, and all groups, to arrive at the most
statistically precise estimated impact of deworming on schooling outcomes. This includes both school participation outcomes, as well
as academic test score outcomes (which the Cochrane authors currently exclude since in the paper we only present these “pooled”
test score results, rather than the simple differences across treatment groups). If the Cochrane authors would like to see the simple
differences across treatment groups for the academic test scores, we would be delighted to share the data with them. (To be clear, the
test score impact estimates in Miguel and Kremer (2004) come from a regression analysis that relies on the experimental comparison
between the treatment and control groups, and is not a retrospective analysis based on non-experimental data.)
In our view, the Cochrane authors do not provide adequate statistical justification for splitting results into the different “comparisons”,
or into “year 1” versus “year 2” impacts. “Pooling” these different comparisons, as we do in the Miguel and Kremer (2004) paper, is
standard with longitudinal (panel) data analysis with multi-year panels, and is appropriate for those that care about deworming impacts
at multiple time frames, ie at less than one year and at more than one year of treatment. Use of our full sample would immediately lead
to the conclusion that there are in fact positive impacts of deworming on school participation in our sample, with very large impact
magnitudes and high levels of statistical significance. This is the conclusion of theMiguel and Kremer (2004) paper, and a quick look at
the comparisons presented above also indicate that there are strong impacts: all three of the comparisons have large impact estimates and
all three are statistically significant at over 90% confidence, with one significant at over 99% confidence and another nearly significant
at 95% confidence (despite the data being split up into the three different comparisons). By treating each comparison independently
and in isolation, the authors are reaching inappropriate conclusions, in our view.
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To illustrate why the approach taken by the current version of the Cochrane review is inappropriate, imagine the simple thought
experiment of splitting up the data from Miguel and Kremer (2004) into “quarters” (three month intervals) rather than years of
treatment. There is no obvious a priori reason why this should not be as valid an alternative approach as the >1 year and <1 year
approach in the Cochrane review, as some other reviewers might instead have been interested in the impact of deworming treatment
over intervals shorter than one year. Then we would have 2 comparisons in quarter 1 of treatment (Group 1 versus Groups 2 and 3
in early 1998, and Group 2 versus Group 3 in early 1999), 2 comparisons in quarter 2 of treatment, 2 comparisons in quarter 3, 2
comparisons in quarter 4, and 1 comparison in each quarter from 5 through 8 (Group 1 versus Group 3 in 1999). This approach would
generate 12 valid “comparisons” of treatment and control schools over multiple time periods, but by slicing up the data ever more
finely and reducing the sample size considered in each comparison, it is almost certain that none of these comparisons would yield
statistically significant impacts of deworming on school participation at 95% confidence, even though the average estimated effect sizes
would remain just as large. This would clearly not be an attractive methodological approach. You could even imagine considering a
month by month treatment effect estimate, which would yield 36 different “comparisons”, all of which would be severely underpowered
statistically.
However, we view the Cochrane review’s slicing of our full dataset into three comparisons (two for year 1 treatment, and one for year
2), rather than conducting the analysis in the full dataset in much the same way. As we show in Miguel and Kremer (2004), when the
data from all valid comparisons is considered jointly, in order to maximize statistical precision using standard longitudinal (panel) data
regression methods, the estimated impacts are large and highly statistically significant. Just to be clear, we do not use any controversial
statistical methods, and our results do not rely on any non-experimental comparisons. The regression analyses in our paper rely entirely
on the variation in treatment status induced by the experimental design of the trial, and thus are just as appropriate analytically as the
simple “treatment minus control” differences that the Cochrane authors focus on. In our view, the most robust analytical approach
should use our full dataset, rather than the (in our view) more fragmented way of presenting the results in Table 6 of your review, which
leads to less statistical precision and no greater insight.
If the Cochrane authors feel that there is a strong a prior reason to focus on year 1 treatment results separately from year 2 treatment
results, then at a minimum they should consider both of the year 1 “comparisons” that they focus on jointly (ie Group 1 versus Groups
2 and 3 in 1998, and Group 2 versus Group 3 in 1999), in order to improve statistical precision and thus generate impact estimates
with tighter confidence intervals. If they wish to strictly employ the same exact “comparison” groups over time, then they should
at a minimum pool the 1998 and 1999 data and focus on the Group 1 versus Group 3 comparison. Doing either would yield an
unambiguous positive and statistically significant impact of deworming on school participation in our sample.
We respectfully request that the authors of the review consider these suggestions and reconsider their assessment regarding the claimed
lack of statistically significant school participation impacts in Miguel and Kremer (2004).
Point (3): The Cochrane review concludes that our trial has a “high risk of bias for … incomplete outcome data” (p. 90). We believe
this point is simply incorrect when applied to our school participation data, as we explain here. The review authors focus on the lack
of detail in Miguel and Kremer (2004) regarding the collection of Hb data, but then unfairly use this lack of clarity to downgrade the
reliability of all data in the trial, including the school participation data. The exact quote from the review is as follows:
[p. 15] However, results for health outcomes were presented for the 1998 comparison of Group 1 (25 schools) versus Group 2 (25
schools). Details of the outcomes we extracted and present are:
• Haemoglobin. This was measured in 4% of the randomized population (778/20,000). It was unclear how the sample were selected.
The Hb sample was a random (representative) sub-sample of the full sample, chosen by a computer random number generator.
Appendix Table AI of the Miguel and Kremer (2004) paper does discuss how the parasitological and Hb surveys were collected jointly
in early 1999. Table V mentions that the parasitological data in 1999 was collected for a random sub-sample. A random subset of those
individuals sampled for parasitological tests also had Hb data collected; this was not explicitly stated but should have been. The reason
for the relatively small sample for Hb testing was simply that a random (representative) sub-sample was selected for this testing. For
both Hb and parasitological tests, the time and expense of testing the entire sample of over 30,000 school children was prohibitive,
hence the decision to draw a representative sub-sample. Collection of this data for a representative sample should reduce concerns about
bias due to incomplete outcome data and selective attrition.
[p. 15] • Weight and height. This was measured in an unknown sample of the 20,000 children. No sampling method was given.
Section 3.1 of Miguel and Kremer (2004) does state explicitly that the anthropometric data was collected during pupil questionnaires
at school during 1998 and 1999. These were collected in standards (grades) 3-8, rather than in all grades, and for that reason there is
only data on a subset of the full sample. Height and weight data was collected on all individuals in standards 3-8.
We acknowledge that the discussion of sampling for hemoglobin outcomes was unclear in Miguel and Kremer (2004). However, the
fact that we only have Hb data for a random subset in no way affects the attrition rate for school participation data, which was collected
for the entire sample. There is no problem with attrition in the main outcome measure in the Miguel and Kremer (2004) trial, namely,
school participation. In fact the school participation data is unusually rigorous. We tracked individuals as they transferred across schools,
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or dropped out of schools, and collected school attendance on unannounced visit days to get a more representative picture of actual
school participation. This is in sharp contrast to most other trials.
For instance, Watkins (1996), which shows smaller school attendance impacts than Miguel and Kremer (2004), only considers school
attendance based on register data, among those attending school regularly, missing out on school drop-outs and transfers entirely. Yet
that trial surprisingly received equal weight with Miguel and Kremer (2004) in the meta-analysis of school attendance carried out in
this Cochrane review.
Taken together, the claim that there is a “high risk of bias for … incomplete outcome data” (the claim made on p. 6 and p. 136, and
throughout the review) appears incorrect to us, given the remarkably high quality of follow up data for school participation, which
serves as the main outcome of the trial, and the collection of a representative sub sample for both Hb and nutritional measures.
We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed “high
risk of bias for … incomplete outcome data” in Miguel and Kremer (2004), especially in regards to the school participation data.
(One small point: In the summary of findings table on page 5, it is stated that we only have school participation data for 50 clusters,
rather than 75 clusters. This is incorrect, since even using the Cochrane authors’ three “comparisons”, there are 75 distinct clusters that
contribute to the year 1 evidence for Group 1 versus Groups 2 and 3 in 1998, for instance.)
Point (4): The Cochrane review also considers the Miguel and Kremer (2004) trial to have “a high risk of bias for sequence generation”
[p. 6].
In particular, it discusses the quasi-random allocation of the 75 clusters:
[p. 14] “Eight trials were cluster randomized (Alderman 2006 (Cluster); Awasthi 2008 (Cluster); Awasthi 2001 (Cluster); DEVTA
(unpublished); Hall 2006 (Cluster); Rousham 1994 (Cluster); Stoltzfus 1997 (Cluster)), one was a trial with quasi-random allocation
of the 75 clusters (Miguel 2004 (Cluster))”.
It is never clearly specified why the randomization approach makes the trial “quasi-randomized”. It may be due to the use of an
alphabetical “list randomization” approach, rather than a computer random number generator, but if so, this is never laid out explicitly
by the Cochrane authors. The remarkable baseline balance on a wide range of characteristics (educational, nutritional, socioeconomic,
etc. shown in Table I of Miguel and Kremer 2004) across 75 clusters and over 30,000 individuals surely helps alleviate these concerns.
We would like to obtain more detailed information from the Cochrane authors on why the research design in Miguel and Kremer
(2004) is considered to have a “high risk of bias”. This is never explicitly discussed in the review.
We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed “high
risk of bias for … sequence generation” in Miguel and Kremer (2004).
We carefully read through the entire document and noted additional instances where we had questions and concerns below (following
this letter), and note the relevant page numbers in your review.
Finally, we also would like to briefly mention two working papers that we believe could usefully be incorporated into future versions
of the Cochrane review on deworming. One working paper (Baird et al.) trials long-term impacts of deworming treatment on labor
market outcomes. We are both co-authors on this paper. We are currently finishing the write up of this paper and hope to submit it to a
working paper series and a journal in 2013, and at that point we will share that paper with your group. That trial shows very large long-
run impacts of deworming treatment on labor market outcomes, up to ten years after the start of the primary school deworming project
that we trial. The second is a working paper by Dr. Owen Ozier of the World Bank, which examines long-run educational impacts on
individuals who were very young children at the start of the Kenya deworming project, and finds large positive test score effects. One
advantage of Ozier’s trial is his ability to compare outcomes across schools and across birth cohorts within those school communities,
allowing him to include “school fixed effects” that control for any baseline differences across schools. This methodological approach
addresses any lingering concerns about baseline “imbalance” across treatment groups.
We look forward to starting a discussion of these issues with your team, and we thank you for the time you have taken to consider
them. We realize that this is an extremely time-consuming process for your entire team, given the detailed reading you need to carry
out for literally dozens of trials, and we appreciate your willingness to consider these points.
Additional comments on the Cochrane review: (Cochrane text noted in italics, page numbers noted)
The Cochrane authors have the following discussion of the exam score data and school sample:
[p. 67] “Participants Number analysed for primary outcome: … Unclear for exam performance and cognitive tests Inclusion criteria:
none explicitly stated. “Nearly all rural primary schools” in Busia district, Kenya, involved in a NGO deworming programme were
studied, with a total enrolment of 30,000 pupils aged six to eighteen. Exclusion criteria: girls > 13 years old”.
The claim that there was no explicit inclusion criteria stated in the paper for the exam data appears inaccurate. Section 7.2 of Miguel
and Kremer (2004) discusses our attempts to test all students, including efforts to administer exams even to those students who had
since dropped out of school (see footnote 52).
In terms of the inclusion of schools in the sample, there were a total of 92 primary schools in the trial area of Budalangi and Funyula
divisions in January 1998. Seventy-five of these 92 schools were selected to participate in the deworming program, and they form the
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analysis sample here. The 17 schools excluded schools from the program (and thus the analysis) include: town schools that were quite
different from other local schools in terms of student socioeconomic background; single-sex schools; a few schools located on islands
in Lake Victoria (posing severe transportation difficulties); and those few schools that had in the past already received deworming and
other health treatments under an earlier small-scale ICS (NGO) program.
The Cochrane authors make the following point about worm infection rates, which relates to potential baseline imbalance across
treatment groups:
[p. 68] “Group 1 schools have an overall prevalence of 38% heavy/moderate worm infection in 1998, compared to the initial survey
in control schools in 1999, where it was 52%.”
This is a misleading comparison. The comparison of Group 1 worm infection in 1998 versus Group 2 worm infection in 1999 is
simply inappropriate, given the well-known variability across seasons and years in worm infection rates (as a function of local weather,
precipitation, temperature, etc.). There is abundant health and nutritional data from pupil surveys for Groups 2 and 3 at baseline in
1998, and they indicate that these groups appear very similar to Group 1 at baseline (see Table I of Miguel and Kremer 2004) but no
parasitological data was collected for Groups 2 and 3 in 1998, nor for Group 3 in 1999, since it was considered unethical to collected
detailed worm infection data in a group that was not scheduled to receive deworming treatment in that year. Once again, standard
errors for the comparison of outcomes among different treatment groups take into account the possibility of random differences at
baseline, and thus statistical significance levels already reflect the possibility that there is some random baseline variation across schools,
but this variation alone of course does not cause bias.
The Cochrane authors have the following discussion of our health data:
[p. 68] “However, in a personal correspondence the authors state that there is no health data for Group 3 schools for 1999.”
This claim is not entirely accurate, and must be the result of a misunderstanding. There is abundant health and nutritional data from
pupil surveys for Group 3 in 1999, but no parasitological data was collected for Group 3 in 1999, since it was considered unethical to
collected detailed worm infection data in a group that was not scheduled to receive deworming treatment in that year.
[p. 68] 27/75 schools were involved in other NGO projects which consisted of financial assistance for textbook purchase and classroom
construction, and teacher performance incentives. The distribution of these other interventions is not clear, but the authors state that
these schools were stratified according to involvement in these other programmes.
[p. 70] The intervention was a package including deworming drugs for soil transmitted helminths, praziquantel to treat schistosomiasis
in schools with > 30% prevalence, and health promotion interventions. In addition 27/75 schools were involved in other NGO projects
which consisted of financial assistance for textbook purchase and classroom construction, and teacher performance incentives. The
distribution of the latter interventions is not clear. These co-interventions confound the potential effects of deworming drugs to treat
STHs. However, the authors kindly provided a re-analysis of their data, with the praziquantel treated schools removed from the analysis.
This represents as subgroup analysis of the original quasi-randomized comparison“.
Given that these other interventions had no measurable impacts on educational outcomes (as reported in several other articles), and
that they are balanced across our treatment groups, these prior interventions are not a major concern for the analysis.
Sincerely,
Ted Miguel and Michael Kremer
I agree with the conflict of interest statement below:
I certify that we have no affiliations with or involvement in any organization or entity with a financial interest in the subject
matter of our feedback.
Reply
We appreciate these helpful and detailed comments. We have checked through these carefully, and responded to the key points below.
Risk of bias assessment contested (point 1).
Miguel and Kremer were concerned that we had been unduly harsh on assessing the risk of bias of their trial in several points in their
comments. We have reassessed this in the light of their comments and the recent replication, which is helpful as it clarifies more details
on the methods.
Baseline imbalance: We agree and now move the risk of bias in relation to imbalance at baseline to ”low“. The remaining criteria of the
risk of bias remain unaltered.
Incomplete data: Thank you for your additional information about the methods. This is also contained in the replication analysis, and
this has been adjusted to low.
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Quality of the evidence in relation to schooling and advocacy of combining results (point 2).
Miguel and Kremer were concerned that the quality of the evidence on school attendance was ranked as ”very low“. We thank them for
their concern and have revaluated the reasons for downgrading, taking into account the pure and the statistical replication. It remains
ranked as very low with full justification given in the ’Summary of findings’ table footnotes.
Miguel and Kremer also advocate combining results for school participations from the three school participation results from quasi-
randomized comparisons. Just to recap, for year 1 follow-up, there are results from:
Group 1 vs Groups 2+3;
Group 2 vs Group 3.
And at two years of follow-up, results from Group 1 vs Group 3.
We have not combined the estimates from the quasi-randomized comparisons in meta-analysis because they are not independent.
However the separate estimates are all documented in the review.
Due to the trial design the pooled estimate that Miguel and Kremer prefer contains a non-randomized before and after comparison, as
clarified in the replication trials.
The second point the authors raise in the paragraph ”However, we view the Cochrane’s slicing…“.We have addressed this by combining
the multiple dose trials in one analysis, using the longest follow-up time point. Justification for this is provided in the review text. This
is a helpful comment and has helped with shortening the review.
Losses to follow-up on haemoglobin and school attendance (point 3).
Thanks for these clarifications about the sampling for height, weight, and Hb. These are noted in the review.
For school attendance, there is downgrading as stated in the table so that the GRADE assessment of the quality is very low, for risk of
bias, imprecision, and indirectness. The missing data and many of the methodological issues debated here are now made much clearer
in the replication trials. The other information that is highly relevant is the health promotion co-intervention.
The GRADE table is agreed by all authors after considerable discussion. It is also checked by two other editors. This is based on
information in the original trial reports and now, with your trial, the two papers concerning the replication.
Risk of bias on sequence generation; and additional papers (point 4).
Thank you for this information.
This is a quasi-randomized method of allocation, as described in the Cochrane Handbook for Systematic Reviews of Interventions, and as
clarified in the replication trials.
Thanks for these additional papers you mention. They were considered by the authorship team and do not meet the inclusion criteria
for the review.
Contributors
David Taylor-Robinson, Paul Garner, Karla Soares-Weiser, Sarah Donegan.
Harold Alderman, 14 January 2013
Summary
Shortly after my paper on deworming in Uganda was published in the BMJ, I had an exchange of correspondence with Dr. Garner
regarding the standard errors reported in one table. After that exchange I shared the following letter with the BMJ and with him in
April 2007:
Dear Editor,
Prof. Paul Garner has kindly pointed out that, in an article published in the BMJ, my coauthors and I inadvertently failed to adjust
standard errors in one of the tables for cluster based sampling. While table 2 of that paper reports means for growth in grams of 2413
[CI=2373 - 2454] and 2259 [CI=2216 - 2301] for the treatment and control groups respectively, once the design effect is taken into
consideration the confidence intervals should, in fact, be [CI=2295 - 2533] and [CI=2121 - 2396].
The conclusions of the trial, however, are unaffected as they are based on the multivariate regressions reported in table 3 for which the
standard errors had been corrected for cluster based sampling. For example, the confidence interval for the finding that the children
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who attended child health days every six months where deworming medicine was provide had a significantly greater weight gain than
similar children who attended child health days at which albendazole was not provided is unaffected; the CI for the difference in weight
gain remains [59g - 262 g].”
Recently the BMJ has invited me to submit a letter addressing the earlier comments as well as more recent variations of that theme. I
believe that it is sufficient to indicate that the results presented in the multivariate analysis remain the basis for the conclusion of the
trial. Given the heterogeneity of ages in the trial population and the fact that the velocity of weight gain is dependent on age, table
2 was presented for background only while the primary analysis was presented in table 3. The results in this table control for these
covariates as well as the duration of time between visits or the total time a child participated in the child health days organized for his
or her community. These results provide more precise estimates.
Harold Alderman
International food Policy Research Institute
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my
feedback.
Reply
Thank you for this information which is duly noted.
Contributors
David Taylor-Robinson, Paul Garner, Sarah Donegan.
WH A T ’ S N E W
Last assessed as up-to-date: 14 April 2015.
Date Event Description
27 July 2015 Amended We added an external source of support, the Evidence and Programme Guidance Unit, Department of
Nutrition for Health andDevelopment,World HealthOrganization (WHO), to the Acknowledgements
and Sources of support sections.
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 2, 1998
Date Event Description
8 July 2015 New citation required but conclusions have not
changed
A new search was conducted and new trials added. We
also responded to feedback
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(Continued)
26 February 2015 New search has been performed 1. We added four new trials: two in the category
children infected and two in an endemic area.
2. The results from the Awasthi 2013 (Cluster)
(DEVTA) trial were added.
3. We used the replication (Aiken 2015) to correct
the errors in the primary publication by Miguel 2004
(Cluster)); and used the statistical replication (Davey
2015) to inform risk of bias and interpretation.
4. We took account of comments and criticisms
from Miguel and Kremer in the analysis. This
included a proposal to use single set of follow-up
outcomes. After performing new analyses in this
review, we found that there was no evidence that the
intervention effect varied with length of follow-up,
and therefore consolidated the analysis of (ie < 1 year
and > 1 year) in the previous Cochrane Review
(Taylor-Robinson 2012) into one set.
5. We changed the classification of Stephenson
1989 and Stephenson 1993. Previously these trials
were in the “all children in an endemic area” category,
whereas now they are classified in the “children with
infection”. This decision was based on reviewing the
trials with parasitologists and examining the
prevalence and intensity of the infection where clearly
the whole community was heavily infected.
6. We noticed that the trial Adams 1994 was
actually a sub-trial of Stephenson 1993 and therefore
merged with Stephenson 1993 (the full citation to
Adams 1994 can be found in Stephenson 1993). The
total number of trials in the review has changed
accordingly. The data previously contributed to the
review by Adams 1994 has been removed, since more
complete outcome data for the whole Stephenson
1993 trial is reported in the other articles.
7. We adjusted the ’Summary of findings’ tables,
review text, and conclusions in the light of these
changes.
10 October 2012 New citation required but conclusions have not
changed
We updated the ’Summary of findings’ tables, updated
the abstract, and made minor corrections
10 October 2012 New search has been performed In September 2012, we identified a minor data entry
error with a haemoglobin value, which we corrected
We also received feedback on the GRADE assessments.
This led to changes in the assessment of the quality of
the evidence for several outcomes. Most changes were
towards higher quality evidence.We refined the table by
adding additional footnotes to clarify the classification.
The specific changes were:
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(Continued)
• For single dose weight screened, GRADE moved
from moderate to low;
• For single dose haemoglobin GRADE moved
from low to moderate, after data entry corrected; and
for formal tests, GRADE moved from very low to low;
• For multiple dose (< 1 year), formal tests and
schooling moved from very low to low, following
upgrading of study quality;
• For multiple doses (> 1 year), weight and
haemoglobin moved from very low to low, following
upgrading of study quality; and cognition moved
from very low to low.
We adjusted the wording in the abstract to take these
changes into account
31 May 2012 New search has been performed Substantive update:
1. We added a logic framework to the background.
2. We replaced Awasthi 1995 (unpublished data)
with the published data (Awasthi 1995 (Cluster)). We
received clarification on methods and results from
Miguel and Kremer and included this study in the
review (Miguel 2004 (Cluster)). Also, we tried to
include the Awasthi 2013 (Cluster) completed in
2006 but were unable to as it remains unpublished as
of May 2012.
3. We added haemoglobin as a primary outcome
and we added all trials measuring haemoglobin. We
merged end values and change values to simplify the
review. We reanalysed the school attendance data. In
addition, we brought the sensitivity analysis in line
with current best practice (by only including trials
with evidence of allocation concealment).
4. We added ’Summary of findings’ tables. We
adjusted the wording in line with our policy of using
standard words to correspond to quality of the
evidence.
5. In the light of these changes, we rewrote the
review entirely.
31 May 2012 New citation required but conclusions have not
changed
We updated the review and added new studies.
7 May 2008 Amended There are two alterations to the review:
1. We have corrected an error in the discussion.
The sentence that read “There was a weight gain of 2.
413 kg in the treatment parishes and 2.474 kg in the
control parishes at an unspecified follow-up point.”
now reads “There was a weight gain of 2.413 kg in the
treatment parishes and 2.259 kg in the control
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(Continued)
parishes at an unspecified follow-up point.”
2. We have detailed our correspondence to date
with Michael Kremer and Edward Miguel in the
discussion.
12 August 2007 New citation required and conclusions have changed 2007, Issue 4 (substantive update): author team
changed; we modified the review title from the original
title of “Anthelmintic drugs for treating worms in chil-
dren: effects on growth and cognitive performance”; we
updated methods, reapplied the inclusion criteria, re-
peated data extraction, added new trials, and included
additional analyses as recommended by policy special-
ists
31 March 2000 New citation required and conclusions have changed 2000, Issue 2 (substantive update): we added new trials
and updated the review
C O N T R I B U T I O N S O F A U T H O R S
DTR wrote the protocol, applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and wrote the first draft
of the review. KSW and NM applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and drafted the results
of the update. SD assessed risk of bias and extracted data for a subset of the trials, and contributed to the analysis and the writing of
the review. PG provided advice at all stages of the review production, applied inclusion criteria, assessed quality, quality assured data
extraction, helped construct the comparisons, and helped write the review.
D E C L A R A T I O N S O F I N T E R E S T
This Cochrane Review is supported by a DFID grant aimed at ensuring the best possible systematic reviews, particularly Cochrane
Reviews, are completed on topics relevant to the poor, particularly women, in low- and middle-income countries. DFID does not
participate in the selection of topics, in the conduct of the review, or in the interpretation of findings. The grant provides partial salary
support for PG, SD, and the funds for the contract with Enhance Reviews Ltd.
PG receives additional salary support from the COUNTDOWN Research Consortium, which is funded by the DFID. COUNT-
DOWN is committed to trials and development of mass treatment programmes related to NTDs.
S O U R C E S O F S U P P O R T
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Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
• Evidence and Programme Guidance Unit, Department of Nutrition for Health and Development, WHO, Switzerland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Not applicable.
N O T E S
Not applicable.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anthelmintics [∗pharmacology; therapeutic use]; Child Development [drug effects]; Cognition [∗drug effects]; Growth [drug effects];
Helminthiasis [complications; ∗drug therapy]; Intestinal Diseases, Parasitic [complications; ∗drug therapy]; Nutritional Status [∗drug
effects]; Randomized Controlled Trials as Topic; Soil [∗parasitology]; Weight Gain [drug effects]
MeSH check words
Adolescent; Child; Child, Preschool; Humans
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